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ABSTRACT
Obesity and insulin resistance are central components of metabolic syndrome (MetS),
which is a risk factor for type 2 diabetes (T2DM) and cardiovascular diseases. The
genes encoding uncoupling proteins (UCP), -adrenergic receptors (BAR) and leptin
receptor (LEPR) are involved in energy expenditure and lipid and glucose metabolism
and long-term weight regulation, and can thus be regarded as candidate genes of
obesity. The present study was undertaken to investigate the association of gene variants
in the UCP1, UCP2, UCP3, B2AR, B3AR, and LEPR genes with body weight and the
incidence of T2DM in the Finnish Diabetes Prevention Study. In addition, new putative
candidate genes were explored by microarray analysis of the transcriptome of adipose
tissue in response to weight reduction in individuals presenting features of MetS.
   The combination of the Gln27Gln genotype in the B2AR gene and the Arg64 allele in
the B3AR gene was associated with the risk of T2DM. The G(-3826)G genotype in the
UCP1 gene associated with higher weight during the follow-up. Lys109Lys, Gln223Gln
genotypes and 3’UTR Ins allele in the LEPR gene were associated with T2DM risk,
while the 3’UTR Del/Del genotype associated with higher weight during the follow-up.
Four variants in UCP3 associated with total and LDL-cholesterol concentrations, and
four variants in the UCP2-UCP3 gene region associated with measures of abdominal
obesity. Furthermore, a risk haplotype for waist-to-hip ratio and for serum total and
LDL-cholesterol concentration was found in UCP2-UCP3 gene region. Long-term
moderate weight reduction in subjects with features of MetS resulted in downregulation
of gene expression in adipose tissue, where specifically the expression of genes
involved in extracellular matrix and cell death was reduced. One of the genes exhibiting
the most remarkable change was tenomodulin, which is an interesting novel candidate
gene to be investigated in detail.
   In conclusion, genetic variation in B2AR, B3AR, and LEPR may indicate a risk of
T2DM, whereas genetic variation in UCP1 and LEPR may modify the risk of obesity.
Variation in UCP2-UCP3 gene region is associated with lipid levels and abdominal
obesity, which are features of MetS. Moderate weight reduction involves alterations in
the extracellular matrix of adipose tissue, as well as in death of adipocytes.
National Library of Medicine Classification: QS 532.5.A3, QU 120, QU 477, QU 500,
QU 75, QU 95, WK 810, WK 820
Medical Subject Headings: Adipose Tissue; Blood Glucose/metabolism; Body
Weight/genetics; Cholesterol, LDL; Diabetes Mellitus, Type 2; Finland/epidemiology;
Gene Expression Regulation; Genetic Variation; Genotype; Lipids/metabolism;
Metabolic Syndrome X; Obesity; Receptors, Adrenergic, beta; Receptors, Leptin; Risk
Factors; Subcutaneous Fat, Abdominal
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1. INTRODUCTION
Obesity is a severe health problem in today’s society, where energy intake too easily
exceeds the needs of energy expenditure due to the ready availability of energy-dense
food supplies and sedentary lifestyles. In particular, the central type of obesity and
ectopic fat deposition in insulin-sensitive tissues (muscle, liver and pancreas), has been
shown to associate with metabolic aberrations, such as insulin resistance. Obesity and
insulin resistance are central components of metabolic syndrome, which is a disorder
where several disadvantageous metabolic characteristics cluster, and predispose to type
2 diabetes and cardiovascular diseases. Most risk factors of type 2 diabetes, such as
overweight, abdominal obesity, sedentary habits, and unhealthy diet, can be modified by
lifestyle changes, whereas the contributions of age, race, genetic factors, and low birth
weight as risk factors cannot be altered (1).
   The metabolic abnormalities in obesity derive from multiple environmental and
genetic factors, several of which are already known. The vast majority of obesity cases
are polygenic, where a multitude of genes interact with each other and with
environmental factors to induce the disorder. Each of these relatively common genetic
variants has only a small or modest effect on the predisposition, though in extremely
rare cases of monogenic obesity only a single gene variation is responsible for the
disorder. Association studies, linkage studies and genome-wide association studies have
been used as tools to find new and to study the existing candidate genes of obesity.
Many candidate genes of obesity can be regarded also as candidate genes for diabetes
due to the partly overlapping etiology.
   This series of studies deals with two lifestyle intervention cohorts, in an attempt to
study the association of known candidate genes with type 2 diabetes in Finnish Diabetes
Prevention Study, and to search for new candidate genes in a weight reduction study
Genobin, where the effect of weight reduction on gene expression profiles of adipose
tissue was explored by microarray technology. Candidate genes used in the association
studies include the uncoupling proteins 1-3, 2- and 3-adrenergic receptors and the
leptin receptor, which are involved in energy expenditure and lipid and glucose
metabolism (uncoupling proteins and adrenergic receptors), or long-term weight
regulation (leptin receptor).
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2. REVIEW OF LITERATURE
2.1. Obesity
2.1.1. Definition and prevalence
Obesity can be defined as an excess of body fat. A surrogate marker for body fat content
is the body mass index (BMI), which is determined by weight (kg) divided by height
squared (m2) (Table 1). In terms of percent of total body fat, which can be measured in
several ways e.g. by skin-fold thicknesses, bioelectrical impedance or underwater
weighing, obesity can be defined as 25% in men and 35% in women (2).
   Total body adipose tissue (AT) is situated in two major compartments: subcutaneous
AT (SAT) and internal AT (2, 3). Internal AT is further divided into visceral (VAT) and
nonvisceral components, where VAT refers to the intrathoracic and intra-
abdominopelvic compartments (4). The most practical way to estimate central obesity in
clinical practice is to measure waist circumference (WC), because WC strongly
correlates with the amount of abdominal VAT accumulation (5) and an excess of
abdominal fat is most tightly associated with the metabolic risk factors, cardiovascular
disease (CVD) and especially to type 2 diabetes (T2DM) (6, 7). Abdominal obesity is
defined as WC  102/88 cm (men/women) in the United States, (2) and as WC  100/90
cm (men/women) in Finland (8). The guidelines from International Diabetes Federation
(year 2007) suggest that Europid individuals with WC  94/80 cm (men/women) may
be at a higher risk for impaired glucose tolerance (IGT) and T2DM, and they need to
have their level of risk further investigated (9).
Table 1. The classification of overweight and obesity according to the body mass index (BMI).
BMI (kg/m2) Classification Risk of co-morbidities
< 18.5 Underweight Low
18.5-25 Normal range Average
> 25 Overweight, obesity
25-30 Pre-obese Increased
30-35 Obesity class I Moderate
35-40 Obesity class II Severe
> 40 Obesity class III, morbid obesity Very severe
Adopted from World Health Organisation: Technical Reports Series 2000 (10)
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   International data indicate that the obesity epidemic is a serious global health
problem. In 2003-2004, 32% of adults in USA were obese and 66% were overweight or
obese (11). During the last decades, the prevalence of obesity doubled in adults in the
United States (11) and in Finland (12). In Finland, 20/19% (men/women) were obese
and 68/52% (men/women) were overweight or obese in the year 1997 (8), whereas
22/21% (men/women) were obese in 2002 (13). The prevalence has increased especially
in individuals with low socio-economic status (13). According to the definition of
obesity and depending on the age of the child, up to 10–20% of school age children in
Finland are overweight (12, 14). An overweight child carries a high risk to become an
overweight adult and to be at risk of associated health problems (14).
2.1.2. Multifactorial etiology
Obesity has always existed in human populations, but until recently it has been
comparatively rare (15). In only a few decades, the industrialised world has changed
from a calorie-poor to a calorie-rich environment. Obviously, the recent unlimited
availability of low-cost, calorie-dense food, along with increasing sedentary lifestyles,
has played a major role in the adult obesity pandemic (15). Obesity results from the
interaction of many factors, including genetic, metabolic, behavioural, and
environmental influences (16) (Figure 1). The rapidity by which obesity is increasing
suggests that behavioural and environmental influences, rather than genetic changes,
have fuelled the epidemic.
   Despite popular stereotypes portraying obesity as a problem of gluttonous behaviour
and poor willpower, there is a considerable body of evidence that genetic factors play an
important role in determining body weight (17). Family clustering of obesity is known
to exist. The correlation of BMI is much higher between monozygotic than dizygotic
twins (0.74 versus 0.32, respectively), whereas it is 0.24 for siblings and 0.19 for
parents and offspring (18). The BMI of adopted children correlates with that of their
biological parents (19). These and other data suggest an estimated heritability of 50% to
90% (17). Even though the susceptibility to obesity is determined to a significant extent
by genetic factors, a favourable “obesigenic” environment is necessary for its
phenotypic expression (20).
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Figure 1. Factors influencing the development of obesity.
   In the 1960s, Neel proposed the ‘thrifty gene’ hypothesis, whereby genes that
predispose to obesity would have had a selective advantage in populations that
frequently experienced starvation (21). People who possess these genes in today’s
obesigenic environment might be those that ‘overreact’ - not just becoming slightly
overweight, but extremely obese, such as the high-risk groups of Pima Indians and
Pacific Islanders. This has led to a second hypothesis, which states that only those with
fewer risk alleles of obesity susceptibility genes (the former non-survivors) are now
able to resist our obesigenic environment and remain at a normal weight without
conscious effort (20).
   The present work deals with the genetic basis of common obesity and gene-lifestyle
interactions, and therefore, other aspects such as socio-economic, cultural and
behavioural factors possibly leading to obesity will not be reviewed here.
2.1.3. Adipose tissue
AT is a heterogeneous tissue containing different cell types, including mature
adipocytes, preadipocytes, endothelial cells, vascular smooth muscle cells, leukocytes,
monocytes and macrophages (22). The functions of adipocytes can be grouped generally
Environmental
factors
OBESITY
Metabolic         Appetite             Diet                   Physical
    rate             and satiety      composition            activity
Glucose and insulin            Lipid                   Inflammatory
      metabolism               metabolism                    factors            Adipokines
Genetic factors INTER-
ACTION
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into three partially overlapping categories: i) lipid metabolism, ii) glucose metabolism
and iii) endocrine functions; such as modulating the immune response, appetite and
energy balance, blood pressure (BP) control, haemostasis, angiogenesis, bone mass, and
thyroid and reproductive function. (23-25). Adipocyte differentiation (adipogenesis)
derives from multipotent mesenchymal cells, which become committed to the
adipoblast lineage (26). Expansion of fat stores requires new blood vessels (27), which
appears to be regulated in part by factors produced within AT, such as leptin and matrix
metalloproteinases (28).
Adipose tissue as an energy storage
AT is the largest energy reservoir in the body. The major function of adipocytes is to
store triglycerides (TG) in lipid droplets in periods of energy excess (lipogenesis) and to
mobilise this energy reserve during times of deprivation (lipolysis). When energy intake
chronically exceeds energy expenditure (EE), the resulting imbalance causes an
expansion of adipocytes (20), whereas situations of negative energy balance involve
loss of adipocyte TG stores and apoptosis (28).
   The short-term control of lipogenic and lipolytic processes is modulated by hormonal
signals, whereas the long-term changes are accomplished by altering the size of
adipocytes (29). The number of adipocytes is set during childhood and adolescence and
stays relatively constant throughout adulthood, although there is constant and continual
turnover (30). In obese individuals, turnover is higher compared to their leaner
counterparts; approximately 10% of adipocytes are renewed annually at all adult ages
and levels of BMI (30). The number of adipocytes has been shown to be a major
determinant for the fat mass in adults (30).
   Lipolytic regulation is complex due to the heterogeneity of fat depots, gender
differences, and the diversity of hormones (catecholamines, insulin, thyroid, growth,
and sex hormones) and other factors (dieting, exercise, age) governing this process (31).
The lipolytic pathway acts through a stimulatory guanosine triphosphate (GTP) -binding
protein (Gs) and the antilipolytic pathway through inhibitory GTP-binding protein (Gi)
(32, 33). Activation of -adrenergic receptors (BAR) 1-3 leads to enhanced release of
fatty acids (FA), whereas 2-AR activation leads to a decrease in lipolytic activity (34).
In human white fat cells, 2-AR (B2AR) is the dominating lipolytic receptor (35).
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Adipose tissue as secretory organ
An active role for the adipocyte in energy metabolism was demonstrated with the
discovery of leptin (36), a secretory product that originates almost exclusively from the
adipocyte and serves a hormonal function in mediating satiety by activating receptors
situated in the hypothalamus. It is now recognised that AT produces multiple bioactive
peptides, termed ‘adipokines’, which act locally and distally via autocrine, paracrine and
endocrine mechanisms (37) (Table 2). The adipokine signals are integrated in a network
with other tissues and organs such as the liver, skeletal muscle, adrenal cortex, brain,
and the sympathetic nervous system (25). Many of these adipokines are classical
cytokines such as interleukin-6 (IL-6) or tumour necrosis factor-  (TNF-), and others
including leptin, are structurally related to cytokines (27). Excess adiposity is associated
with increased serum IL-6, TNF- and C-reactive protein (CRP) concentrations and
obesity is also characterized as low-grade inflammation state (38).
Table 2. The most common adipokines and their main effects.
Adipokine Function/Effect
Leptin Food intake, reproduction, angiogenesis, immunity
Adiponectin Insulin sensitizer, anti-inflammatory
Resistin Inflammation, IR
Angiotensinogen Electrolyte homeostasis, BP
Tumour necrosis factor- Inflammation, atherosclerosis, IR
Interleukin-6 Inflammation, atherosclerosis, IR
Adipsin Stimulates TG storage, inhibits lipolysis
Acylation stimulating protein Influences the rate of TG synthesis
Fasting-induced adipose factor Lipid metabolism, angiogenesis
Plasminogen activator inhibitor 1 Vascular homeostasis, blood clotting
Tissue factor Major cellular initiator of the coagulation cascade
Monocyte chemoattractant protein1 Inflammation, cell adhesion
Transforming growth factor- Cell adhesion and migration, growth and differentiation
Visfatin IR, proinflammatory
Vaspin IR
Retinol binding protein 4 Lipid metabolism
C-reactive protein Inflammation, atherosclerosis, IR
Apelin IR
Hepcidin Inflammation, iron homeostasis
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Adipophilin Lipid accumulation, atherosclerosis
Lipocalin 2 (39) IR
IR, insulin resistance; BP, blood pressure; TG, triglyceride. Modified from Ahima et al. 2006 (40), Ronti
et al. 2006 (25), Frhbeck et al. 2001 (29), and Lago et al. 2007 (41).
Adipose tissue depots
AT differs in its adipogenic potential and lipolytic response depending on its regional
distribution (26). There is strong evidence that an excess of VAT is more strongly
related to metabolic risk factors than its counterparts in other fat compartments (42, 43).
SAT nonetheless is a much larger (~80% of total body fat) compartment than VAT
(10% of total body fat) (44). The former is usually divided into gluteofemoral and
truncal SAT, of which the truncal fat is more strongly related to metabolic risk factors
than gluteofemoral fat, and it may have a greater impact on risk factors than VAT
because of its greater mass (2).
   In addition to depot-specific differences, a further distinction must be made between
brown and white adipocytes. Brown adipocytes are found only in mammals, and differ
from white adipocytes in that they express uncoupling protein 1 (UCP1) gene.
Morphologically, brown adipocytes are multilocular, contain less overall lipid and are
particularly rich in mitochondria (24). Recent results indicate that brown adipose tissue
(BAT) is present and active in human adults (45-48).
2.1.4. Comorbidities
Although affected individuals often focus on the social stigma of obesity, this condition
is much more than a cosmetic problem; it is strongly associated with a reduction in life
expectancy of ~8 y, as well as with an increased risk of several serious diseases (Table
3), including T2DM, coronary heart disease (CHD) and certain cancers such as breast
and colon cancers (49). Numerous large-scale studies in humans have shown that
overall mortality rises steadily as a function of increasing body weight (17). Even small
increases in weight across a population can have a devastating impact on public health.
Close to 300 000 deaths each year in the United States are believed to be attributable to
obesity, making obesity the second leading cause of preventable death in that country
(50). It has been reasonably argued that obesity is beginning to overtake infectious
diseases and undernutrition as the most significant contributor to illness in global terms
(51).
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Table 3. Relative risk for health problems associated with obesity (BMI>30 vs. BMI<25).
Greatly increased Moderately increased Slightly increased
Relative risk >> 3 2 < relative risk < 3 1 < relative risk < 2
T2DM CHD Cancer (breast, endometrial, colon)
Breathlessness Osteoarthritis (knees) Fetal defects associated with maternal obesity
Dyslipidaemia Hypertension Impaired fertility
Gallbladder disease Hyperuricaemia and gout Increased anaesthetic risk
Insulin resistance Low back pain due to obesity
Sleep apnea Polycystic ovary syndrome
Reproductive hormone abnormalities
T2DM, Type 2 diabetes mellitus; CHD, coronary heart disease.
Adopted from World Health Organisation: Technical Reports Series 2000 (10).
   Each disease whose risk is increased by being overweight can be classified into one of
two pathophysiological categories (52). The first category of disabilities arises from the
increased AT mass itself. These include the embarrassment of obesity and the
behavioural responses it produces, osteoarthritis, and sleep apnea. The second category
is risks that result from the metabolic changes associated with excess AT. These include
T2DM, gallbladder disease, hypertension, CVD, and some forms of cancer.
   Some individuals are more predisposed than others to obesity-associated diseases, but
presently it is difficult to identify the ‘at risk’ individuals who would benefit the most
from individualised monitoring and care (15, 53). Physiologically, metabolically
deleterious forms of obesity associate with a preferential accumulation of centrally
located fat (43) and with ectopic fat deposition in insulin-sensitive tissues, such as
muscle, liver and pancreas. This aberrant fat content strongly correlates with severe
generalised insulin resistance (IR) and the development of a chronic inflammatory state,
partly due to the infiltration of the AT by macrophages (15, 53). It should also be noted
that different subtypes of obesity exist. For example, one can identify two types, 1)
metabolically healthy, but obese, and 2) metabolically obese, but normal weight
individuals (54). Even though they have normal BMI, in some individuals (prevalence
around 15%) the fat mass and plasma TG as well as VAT and liver fat content can be
high, predisposing to T2DM, metabolic syndrome (MetS), and CVD (54).
2.1.5. Metabolic syndrome
The MetS (syndrome X, the insulin resistance syndrome) is a common metabolic
disorder that results from increasing prevalence of obesity (53). The constellation of
23
metabolic abnormalities includes glucose intolerance, IR, central obesity,
dyslipidaemia, and hypertension (Table 4) (53). These conditions co-occur in an
individual more often than might be expected by chance. MetS is associated with
increased risk of CVD, T2DM, and also susceptibility to polycystic ovary syndrome,
fatty liver, cholesterol gallstones, asthma, sleep disturbances, and some forms of cancer
(55).
Table 4. Comparison of definitions of the MetS.
WHO, 1998 (56) EGIR, 1999 (57) ATPIII, 2001 (58) IDF, 2005 (59)
T2DM or IFG or IGT or IR IR-hyperinsulinaemia Central obesitya
Plus 2 of following Plus 2 of following 3 of following Plus any 2
BMI >30 or
WHR >0.9/0.85 (M/F)
WC 94/80 cm (M/F) WC >102/88 cm (M/F)
TG 1.7 mmol/l or HDL-C
<0.9/1.0 mmol/l (M/F)
TG >2.0 mmol/l or
HDL-C <1.0 mmol/l
TG 1.7 mmol/l TG >1.7 mmol/l
HDL-C <1.0/1.3
mmol/l (M/F)
HDL-C <1.0/1.3
mmol/l (M/F)
BP >140/90 mm Hg BP 140/90 mm Hg
and/or medication
BP 135/85 mm Hg
or medication
BP 130/85 mm Hg
or medication
Albumin excretion
>20µg/min
FPG 6.1 mmol/l FPG 6.1 mmol/l FPG 5.6 mmol/l or
T2DM diagnosis
a Ethnicity specific waist circumference as  the measure of central obesity
WHO, World Health Organization; EGIR, European group for the study of insulin resistance; ATPIII,
Adult Treatment Panel III; IDF, International Diabetes Federation; IFG, impaired fasting glucose; IGT,
impaired glucose tolerance; IR, insulin resistance; BMI, body mass index; WHR, waist-to-hip ratio; WC,
waist circumference; M, male; F, female; TG, triglycerides; HDL-C, high density lipoprotein cholesterol;
BP, blood pressure; FPG, fasting plasma glucose.
   There are several definitions for MetS, which agree in their essential components but
differ in the detail and criteria (Table 4) (53, 55, 57-60). Furthermore, there has been a
debate about the very existence of MetS as a single entity, since metabolic and
cardiovascular abnormalities which are extremely common in elderly people do not
appear to cluster together under a single common factor (61). Regardless of the
diagnostic criteria used, there is full agreement that beneficial lifestyle changes, with the
emphasis on weight reduction, constitute the first-line therapy for MetS (62). In patients
in whom lifestyle changes fail to reverse metabolic risk factors, consideration should be
given for treating the specific abnormalities in these risk factors with drugs in
combination with lifestyle modification (55).
   The role of AT is crucial in the pathophysiology of MetS (63). VAT is more active in
terms of accepting and releasing free fatty acids (FFA) in a metabolically restricted
circulation. The liver processes the blood from this area and thus the rest of the body is
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partly protected from an excessive exposure to FFA. As long as massive energy storage
takes place in SAT, the buffering capacity of VAT is preserved, but when the storage
capacity of the SAT becomes exhausted, the visceral area is forced to take over and its
buffering capacity is then blunted (63). When AT capacity is overwhelmed by buffering
demands, an increase in TG rich particles occurs, and new surrogate storage depots are
used for the excess of fat, e.g. the liver (64) and to a lesser extent skeletal muscle. Fatty
liver disease further leads to steatohepatitis as the generic response of an overloaded
system. The functional capacity of the AT varies among subjects explaining the
incomplete overlapping between the MetS and obesity (63).
2.2. Type 2 diabetes (T2DM)
2.2.1. Definition and prevalence
T2DM is a complex disease characterised by elevated levels of serum glucose, caused
mainly by impairment in both insulin secretion and insulin functional pathways. T2DM
accounts for ~90-95% of all those with diabetes (65). The epidemic of T2DM observed
in recent years is a clear indication of the importance of environmental factors in
diabetes onset; in particular, obesity and physical inactivity are well-established risk
factors. Currently, T2DM can be divided into several subcategories, with grouping by
mode of inheritance and by major pathway affected. This includes a collection of
monogenic disorders that can be subdivided into maturity-onset diabetes of the young,
syndromes of IR, and mitochondrial diabetes (66).
   American Diabetes Association has defined criteria for the diagnosis of diabetes (65)
as follows:
fasting plasma glucose (FPG) < 5.6 mmol/l = normal fasting glucose
FPG 5.6-6.9 mmol/l = impaired fasting glucose (IFG)
FPG  7.0 mmol/l = provisional diagnosis of diabetes
(must be confirmed by second test).
With oral glucose tolerance test (OGTT) the following criteria are used:
2-h postload glucose < 7.8 mmol/l = normal glucose tolerance (NGT)
2-h postload glucose 7.8-11.1 mmol/l = IGT
2-h postload glucose  11.1 mmol/l = provisional diagnosis of diabetes
(must be confirmed by second test).
Patients with IFG and/or IGT are now referred to as having ‘pre-diabetes’ indicating the
relatively high risk for the development of diabetes (65, 67).
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   The prevalence of diabetes in all age-groups worldwide was estimated to be 2.8% in
2000 and is projected to be 4.4% in 2030 (most of which will be T2DM) (68). The total
number of people with diabetes is projected to rise from 171 million in 2000 to 366
million in 2030, with India, China and USA being the top three countries estimated to
have the highest numbers of people with diabetes (68). Extreme examples of high
prevalence are encountered in the Nauru Islanders of the tropical Pacific (41%), Pima
Indians in Arizona (50%) and urban Wanigela people in Papua New Guinea (37%) (69).
It has been evaluated that diabetes is likely to be the fifth leading cause of death
worldwide, similar in magnitude (5.2% of all deaths) to the numbers reported for
victims of HIV/AIDS (70).
2.2.2. Pathophysiology of T2DM
The pathogenesis of T2DM is complex and in most cases clearly requires defects in
both pancreatic -cell function and tissue insulin sensitivity (71). A degree of
hyperglycaemia sufficient to cause pathological and functional changes in various target
tissues, without clear clinical symptoms, may be present for a long period of time before
diabetes is actually diagnosed (65, 67). During this asymptomatic period, it is possible
to demonstrate an abnormality in glucose metabolism by measurement of plasma
glucose in the fasting state or after a challenge with an oral glucose load (72). The
chronic hyperglycaemia in diabetes leads to long-term damage, dysfunction, and failure
of several organs, especially the eyes, kidneys, nerves, heart, and blood vessels (65).
The major cause (75-80%) of death among individuals with diabetes is CVD (9).
   T2DM is said to be a “2-hit” disease in which IR is accompanied by -cell defects
preventing the compensatory upregulation of insulin secretion (73). The genetic and
molecular bases for the reduction in insulin sensitivity and -cell function are not fully
understood, but it seems that body fat distribution and especially visceral fat are major
determinants of IR while reductions in -cell mass contribute to -cell dysfunction (74).
It has become apparent that insulin sensitivity is influenced by a number of different
factors such as genetic factors (75), age (76), acute exercise (77), physical fitness (78),
diet (79), medications (80), obesity (81), and body fat distribution (82-85). Once
hyperglycaemia exists, -cell dysfunction is clearly present in subjects with T2DM (71).
One way to quantify this change is to measure the decrease in the insulin response to
intravenous glucose (74).
   Normally, -cell size stays relatively constant and, as such, -cell mass is maintained
at an optimal level through most of adulthood (86). However, -cells adapt to obesity
and IR by increasing their mass. The onset of T2DM is accompanied by a progressive
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decrease in -cell mass (87), which is due to the marked increase in -cell apoptosis
(88-90). As a result, the body can no longer adapt to any increases in metabolic load.
Several mechanisms can trigger the increase in -cell apoptosis, such as the
development of endoplasmic reticulum stress (91), chronic hyperglycaemia, chronic
hyperlipidaemia, oxidative stress (92), and cytokines (86). Pancreatic  -cell
dysfunction is genetically determined and appears early in the course of the disease
(93).
2.2.3. Pathways from obesity to T2DM
Obesity increases the risk of diabetes to a much greater extent than it increases the risk
of other diseases, independently of age, race and physical activity (94). The relationship
between obesity and diabetes displays such an interdependence that the term 'diabesity'
has been coined (95). It is estimated that about 60-90% of all patients with T2DM are or
have been obese, though only 10% of obese individuals are diabetic (96).
   In the obesity-diabetes relationship, two factors are recognised to be the major
components: insulin deficiency and IR. Chronic hyperglycaemia, by means of the
glucotoxicity phenomenon, impairs insulin sensitivity, while sustained
hyperinsulinaemia inhibits both insulin secretion and insulin action. (96). Based on
Randle’s hypothesis from 1960s (97), the dominant factor in obesity is the permanent
elevation of plasma FFA and consequently the predominant utilisation of lipids by the
muscle leading to a diminution of glucose uptake and, therefore, IR (96, 97) (Figure 2).
The partial reversibility of the evolution of obesity towards diabetes is well
demonstrated by lifestyle changes and multidisciplinary weight loss programmes (98-
100).
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Figure 2. Potential mechanisms of obesity-induced insulin resistance (IR). Elevated rate of fat
breakdown and excessive food intake lead to increased release of circulating free fatty acids
(FFAs). These have a detrimental action on the uptake of glucose by skeletal muscle, production
of glucose by the liver, and systemic dyslipidaemia. Initially, the -cells of the pancreas
compensate for these processes by producing more insulin. However, with time, there is a
failure of the -cells to continue to secrete huge amounts of insulin leading to the development
of hyperglycaemia, impaired glucose tolerance (IGT), and hence T2DM. K+ channel is an
essential part of insulin signalling, and it can be disturbed by FFA. FFAs also enhance
expression of uncoupling protein 2 (UCP2), which diminishes ATP production necessary for
insulin secretion. FFAs can also induce -cell apoptosis via endoplasmic stress response. Leptin
has been shown to have anti-apoptotic effects in -cells, which may also be diminished in the
leptin-resistant state. Modified from Hajer et al. 2008 (101).
   As well as FFA, AT in obese individuals also releases increased amounts of glycerol,
hormones, proinflammatory cytokines and other factors that are involved in the
development of insulin secretion defects and IR (102). In addition to adipocyte-derived
factors, increased release of TNF-, IL-6, monocyte chemoattractant protein and
additional products of macrophages and other cells that populate AT might also have a
role in the development of insulin secretion defects and IR (102).
   The distribution of body fat in itself is a critical determinant of insulin sensitivity.
Whereas simple obesity is typically associated with IR, insulin sensitivity also varies
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markedly in lean individuals because of differences in body fat distribution. Lean
individuals with a more peripheral (subcutaneous) distribution of fat are more insulin
sensitive than lean subjects with centrally (abdominal and chest areas) distributed fat
(102).
2.2.4. Lifestyle changes in the prevention of T2DM
Modest weight loss has been shown to have a beneficial effect on cardiovascular risk
factors such as hypertension, hyperlipidaemia, and T2DM, and to reduce clustering of
these risk factors (103). Recent lifestyle intervention studies in individuals with IGT
suggest that even modest beneficial changes in lifestyle can prevent or delay the
appearance of T2DM (Table 5).
Table 5. Lifestyle intervention studies in the prevention of diabetes.
Study Intervention n Relative risk reduction (%) Duration (years)
Malmö 1991 (104) Lifestyle 415 63 6
Da Qing 1997 (100) Lifestyle a 577 31 (1), 46 (2), 42 (3) a 6
DPS 2001 (98) Lifestyle b 522 58 3
DPP 2002 (99) Lifestyle c
Metformin
1079
1073
58
31
3
3
Japanese 2005 (105) Lifestyle d 458 67 4
IDPP 2006 (106) Lifestyle e
Metformin
Lifestyle +
Metformin
133
133
129
29
26
28
3
3
3
a Treatment groups: 1)diet only, 2)exercise only, and 3)diet plus exercise
b See the text
c Goals: 7% weight loss, 150 min of physical activity per week
d Goal: BMI<24 kg/m2 for the standard intervention group, <22 kg/m2 for the intensive intervention group
e Healthy diet (reduction in total energy, fat and sugar intake, and increase in fibre intake), and 30 min
physical activity per day
DPS, Finnish Diabetes Prevention Study; DPP, Diabetes Prevention Program; IDPP, Indian Diabetes
Prevention Programme. Modified from Laakso and Uusitupa 2007 (1), and Alberti et al. 2007 (9).
Malmö Study
   The Malmö study included 181 Swedish men with IGT and 41 with T2DM (104),
who aimed to change their dietary habits and level of physical activity. Over six years,
their body weight decreased by 2.0-3.3 kg, whereas body weight increased by 0.2-2.0
kg in control subjects (n=193). The incidence of T2DM was 11% in the IGT group and
29% in the control subjects, showing a reduction of 63% during the mean follow-up of
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six years. The findings of a 12-year follow-up (107) suggest that a long-term
intervention programme, with an emphasis on lifestyle changes, including dietary
counselling and physical exercise, will reduce mortality in subjects with IGT.
Da Qing IGT and Diabetes Study
   In the Chinese Da Qing IGT and Diabetes Study, 577 individuals with IGT were
randomised either to one of three active treatment groups or to control group (100).
During six years the body weight decreased by 1.9 kg in the combined intervention
group, whereas body weight decreased by 0.9 kg in control subjects. During the follow-
up, the cumulative incidence of diabetes was 44% in the diet group, 41% in the exercise
group, and 46% in the diet-plus-exercise group, compared with 68% in the control
group, indicating 43% lower incidence in the combined intervention group, compared
with the control group. The benefits of the intervention were still apparent 14 years after
the 6 year active period (108).
Finnish Diabetes Prevention Study
   In the Finnish Diabetes Prevention Study (DPS), 522 middle-aged, overweight
subjects with IGT were randomly assigned to either the intervention group or the
control group (109). The subjects in the intervention group were given detailed advice
about how to achieve the goals of the intervention, whereas the subjects in the control
group were given general oral and written information about diet and exercise, but no
specific individualised programmes were offered. An oral glucose-tolerance test was
performed annually, and the diagnosis of diabetes was confirmed by a second test.
   Weight loss during the first year was 4.2 kg in the intervention group and 0.8 kg in the
control group, while the loss by the end of year 2 was 3.5 kg and 0.8 kg for the
intervention and control groups, respectively. Weight loss was also associated with a
significant reduction in the WC and with an improvement in plasma TGs as well as
decreases in systolic and diastolic BP (sBP, dBP), emphasising the multitude of effects
of a modest weight loss. In a subgroup of DPS (n=52), changes in insulin sensitivity and
insulin secretion were studied by means of a frequently sampled intravenous glucose
tolerance test (FSIGT) (110). A strong correlation between the 4-year changes in insulin
sensitivity (Si) and weight was observed for both intervention and control groups. In the
entire study group, Si improved by 64% in the highest tertile of weight loss but
deteriorated by 24% in those who gained weight (lowest tertile) (110).
   During the mean follow-up of 3.2 years, the cumulative incidence of diabetes was
11% in the intervention group and 23% in the control group (98). Thus, the risk of
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diabetes was reduced by 58% in the intervention group. Recently, an extended follow-
up of 7 years on DPS was reported (111) showing sustained lifestyle changes and a
reduction in diabetes incidence even after the individual lifestyle counselling had been
terminated three years previously. During the total follow-up of 7 years, the cumulative
incidence of T2DM was 23% in the intervention group and 38% in the control group,
indicating 43% reduction in relative risk.
US Diabetes Prevention Program
   In the US Diabetes Prevention Program (DPP) (99) 3234 overweight adults of diverse
ethnic backgrounds were randomly assigned to metformin (a biguanide-type
antihyperglycaemic agent), lifestyle intervention or placebo group. The average weight
loss was 2.1, 5.6, and 0.1 kg in the metformin, lifestyle intervention, and placebo
groups, respectively. During the average follow-up of 2.8 years, the cumulative
incidence of diabetes was 22%, 14%, and 29% in the metformin, lifestyle intervention,
and placebo groups, respectively, showing 58% and 31% reduction in the incidence of
T2DM for the lifestyle intervention and metformin groups, respectively, when
compared to the placebo group.
Japanese Study
   The Japanese trial consisted of an intensive intervention group (n=102) and a standard
intervention group (n=356), including men with IGT (105). Body weight decreased by
2.2 kg in the intensive intervention group and by 0.4 kg in the standard intervention
group. The cumulative 4-year incidence of diabetes was 3% in the intensive intervention
group and 9% in the standard intervention group and, indicating 67% reduction in the
risk of T2DM.
Indian Diabetes Prevention Programme
   In the Indian Diabetes Prevention Programme (IDPP) (106) 531 subjects with IGT
were randomised into four groups: lifestyle modification (LSM), metformin (MET),
LMS+MET, and control group. No significant changes in body weight were seen during
the intervention. The 3-year cumulative incidences of T2DM were 39%, 41%, 40%, and
55% in the LSM, MET, LMS+MET, and control groups, respectively. The relative risk
reduction was 29% with LSM, 26% with MET, and 28% with LSM+MET, as compared
with the control group.
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2.3. Genetics of obesity
2.3.1. Methods of genetic studies
Two main approaches have been used to identify the genes underlying polygenic
diseases such as obesity: candidate-gene and whole-genome approaches (112, 113).
Candidate genes include the functional and positional candidates. Functional candidates
are genes that are selected since they have some plausible role in obesity and/or IR
based on their known or presumed biological role in energy homeostasis, whereas
positional candidate genes are identified because they lie within genomic regions that
have been shown to be genetically important in linkage or association studies.
Polymorphic markers, single nucleotide polymorphisms (SNPs), or deletion/insertion
polymorphisms (Del/Ins) within the gene of interest are genotyped among the studied
population, and possible associations with traits of interest, or differences in genotype
frequencies between affected vs. non-affected individuals are then studied.
   Whole-genome approaches cover genome-wide linkage studies and genome-wide
association studies (GWAS). Linkage studies involve typing of families using
polymorphic markers that are positioned across the whole genome at a density of ~10-
20 cM (~10-20 Mb), followed by calculating the degree of linkage of the marker to a
disease trait (113, 114). Finally, positional candidate genes can then be identified by
fine-mapping the regions around the peaks of linkage. This approach does not rely on
any pre-existing knowledge of the genes that underlie the trait being studied, and it has
been successful in identifying single-gene forms of obesity (115).
   The novel technique GWAS (114) has been made possible by the International
HapMap (haplotype map of the human genome) resource (116), the availability of dense
genotyping chips (Affymetrix and Illumina), and large and well-characterized clinical
samples (117). Large-scale SNP-discovery projects are currently providing the
necessary SNP information to online resources such as the dbSNP database. In GWAS,
approximately 300 000-500 000 SNPs are typically analysed in ~1000-2000 cases and
~1000-5000 control subjects (118).
2.3.2. Common obesity is a polygenic disease
   The 1990s brought the positional identification of a series of murine obesity genes
including leptin and its receptor, carboxypeptidase E and agouti, and also the critical
regulatory role of melanocortin 4 receptor (MC4R) was established (119). These
discoveries were followed by the finding of mutations in homologous genes causing
morbid human obesity presenting in childhood. Human Obesity Gene Map 2005 (120)
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(http://obesitygene.pbrc.edu) lists 11 genes as single-gene mutations with an obesity
phenotype and of these MC4R deficiency represents the most common monogenic
obesity disorder that has been identified so far. It is present in 1-6% of obese individuals
of different ethnic groups, with a higher prevalence in cases with increased severity and
earlier age of onset (113).
   In summary, the known monogenic forms of obesity are very rare in the general
population, accounting for <1% of cases (115). The role of genetic factors in most
human obesities (‘common obesity’) is complex, being determined by the interaction of
several genes (polygenic), each of which may have relatively small effects, i.e., they are
‘susceptibility’ genes and function in interaction with each other as well as with
environmental factors such as nutrients, physical activity and smoking (112).
   The Human Obesity Gene Map 2005 (120) incorporates published results up to the
end of October 2005. According to this update, 176 human obesity cases due to single-
gene mutations in 11 different genes have been reported and 50 loci related to
Mendelian syndromes relevant to human obesity have been mapped to a genomic
region. The number of human obesity quantitative trait loci derived from genome scans
continues to grow, and is now 253 for obesity-related phenotypes from 61 genome-wide
scans (120). However, a recent meta-analysis of linkage studies failed to find strong
positive loci for BMI (115). Association studies have found 426 positive associations
with 127 candidate genes, of which 22 genes are each supported by at least five positive
studies, and 12 genes supported by at least ten studies (Table 6). The obesity gene map
shows putative loci on all chromosomes except Y (120).
Table 6. Genes showing associations with obesity-related phenotypes in 10 replicative
association studies.
Gene Gene name Location Phenotypes studied
ADIPOQ Adiponectin 3q27 BMI, obesity, weight, WHR, VAT, WC
B2AR 2-adrenergic receptor 5q31-q32 BMI, obesity, weight, fat mass, fat %, WHR,
leptin, VAT and SAT, adipocyte size, lipolysis
B3AR 3-adrenergic receptor 8p12-p11.2 BMI, obesity, weight, fat mass, fat %, WHR,
VAT and SAT
GNB3 G-protein, polypeptide 3 12p13.31 BMI, obesity, weight, fat mass, fat %, lipolysis,
waist and hip circumference
LEP Leptin 7q31.3 BMI, obesity, weight, leptin
LEPR Leptin receptor 1p31 BMI, obesity, weight, fat mass, fat %, leptin,
abdominal fat, lean mass, adipocyte size,
24h EE, WC
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NR3C1 Nuclear receptor subfamily
3, group C, member 1
5q31 BMI, obesity, weight, WHR, leptin, VAT,
lean mass
PPARG Peroxisome proliferative
activated receptor 
3p25 BMI, obesity, weight, fat mass, fat %, WHR,
leptin, VAT and SAT, lean mass
HTR2C Serotonin receptor 2c Xq24 BMI, obesity, weight
UCP1 Uncoupling protein 1 4q28-q31 BMI, obesity, weight, fat %, WHR, RMR,
meal-induced thermogenesis
UCP2 Uncoupling protein 2 11q13.3 BMI, obesity, weight, fat mass, fat %,
glucose/lipid oxidation, 24h EE, RQ, REE,
24h SMR, skinfold thickness
UCP3 Uncoupling protein 3 11q13 BMI, weight, fat mass, fat %, WHR, leptin,
lean mass, caloric intake, RQ, REE, RMR,
skinfold thickness
BMI, body mass index; WHR, waist-to-hip ratio; VAT, visceral adipose tissue; WC, waist circumference;
SAT, subcutaneous adipose tissue; EE, energy expenditure; RMR, resting metabolic rate; RQ, respiratory
quotient; REE, resting EE; SMR, sleeping metabolic rate. Modified from Rankinen et al. 2006 (120), and
Bell et al. 2005 (113).
   Recent studies using the GWAS approach have identified SNPs in the fat mass and
obesity associated gene (FTO) (121-124) associated with obesity in several populations.
FTO was originally found as a T2DM susceptibility gene but was then shown to
predispose to T2DM through an effect on BMI (122). Very recently, reports from an
Indian population have shown that the T2DM predisposing effect of FTO might also be
independent of the effect of BMI (125). As a gene of unknown function in an unknown
pathway, FTO provides an example of how GWAS can point to previously unsuspected
candidate genes (121). In addition to BMI, FTO is also associated with hip
circumference and weight (121), in children, adults, and elderly, with no difference
between males and females (122). The at-risk haplotype yielded a proportion of
attributable risk of 20-22% for common obesity (122, 123).
2.4. Genetics of T2DM
Multiple lines of evidence support the view that a genetic component plays an important
role in the pathogenesis of T2DM (66). This can be seen in i) the spectrum of T2DM
prevalence in different ethnic groups, ii) familial aggregation studies and iii) twin
studies, and iv) the heritability of intermediate phenotypes (126). The complex genetic
pattern of T2DM, including the variable age of onset, reduced penetrance, locus and
allelic heterogeneity, and the likelihood of phenocopies (multiple different genetic and
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nongenetic causes), as well as the likelihood that many genes interacting with the
environment contribute to T2DM have confounded the search for T2DM susceptibility
loci (126).
   Over the last decade 27 genome-wide linkage scans and a huge number of candidate
gene studies have been published in multiple ethnic groups in an attempt to discover
genes having an impact on the T2DM risk (66). Despite the differences, eight
susceptibility regions show at least some evidence for replication and appear likely to
harbor one or more susceptibility genes, namely chromosomes 1q, 2q, 3q, 8p, 11q, 12,
18p and 20 (126). Some of the genes possibly corresponding for the high lod scores in
these susceptibility loci have been identified, such as calpain 10 (chr. 2q) (127), protein
tyrosine phosphatase 1B and heteronuclear factor 4A (chr. 20) (128-130), liver pyruvate
kinase and calsequestrin 1 (chr. 1q) (131, 132), and adiponectin (chr. 3q) (133-135).
Despite the initial identification through a linkage signal, which would be expected to
select relatively strong effects, each of these variants above has only a modest
individual effect. Thus, it is believed that i) the effects of individual variants are likely
to be small; ii) multiple variants probably contribute to replicated linkage signals; and
iii) most variants are noncoding and regulatory rather than altering the protein structure
(126).
   Very large number of studies has been conducted on candidate genes identified
through physiological pathways, and for some genes, reasonable replication has been
achieved. In each case, similar to the situation of those genes identified through linkage,
the effect of these variants is relatively small, with odds ratio (OR) <1.4 (126). In these
functional candidate gene studies, the variants are more often in a coding region of the
gene. The most consistent findings as a T2DM risk variant have been the P12 allele in
the peroxisome proliferative activated receptor 2 (PPAR2) gene (136-138) and the
K23 allele in the Kir6.2, a subunit of the -cell ATP-sensitive K-channel (KCNJ11)
(139-142). Promising findings have also been made with G971R variant in the insulin
receptor substrate (IRS-1) gene, G482S variant in the PPAR coactivator-1 gene, and
K121Q variant in the plasma cell glycoprotein 1 gene (126). Most recently, a novel
T2DM susceptibility gene, transcription factor 7 like 2 gene (TCF7L2, chr. 10q), which
has displayed impressive associations (the strongest known OR of 1.7) in several
populations, was found (143, 144).
   In 2007, five GWAS provided new insights into T2DM etiology, with six new gene
regions identified (117, 144-148). These five studies had several features in common: i)
relatively large sample size (in combination >18000 individuals), ii) all participants
were of Northern European ancestry, and iii) extensive follow-up case-control studies
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(118). These novel, confirmed genetic regions altering the risk of T2DM include:
haematopoietically expressed homeobox- insulin-degrading enzyme (HHEX-IDE),
solute carrier family 30 member 8 (SLC30A8), CDK5 regulatory subunit associated
protein 1-like 1 (CDKAL1), cyclin-dependent kinase inhibitor 2A (CDKN2), insulin-like
growth factor 2 mRNA-binding protein 2 (IGF2BP2) and FTO genes, of which FTO
was shown to mediate its effects through a primary effect on adiposity (118).
2.5. Candidate genes of the present study
The present series of studies is part of a series of genetic association studies conducted
on obesity and diabetes candidate genes in different populations. Traditionally, genes
that play a role in EE, lipid turnover, insulin signalling, adipogenesis and molecules
secreted by AT have been the focus of the research group’s efforts. As soon as follow-
up data on DPS was available, it was possible to investigate genetic association in this
study longitudinally. So far over 40 genes with one or more variants have been
examined in DPS (149), with positive associations between obesity and/or diabetes
related traits and gene variants in PPAR2 (150), 2B-adrenergic receptor (151), SUR1,
Kir6.2 (142), TNF, IL-6 (152), IGF-1R, IRS-1, IRS-2 (153), hepatic lipase (154),
SLC2A2 (155), TCF7L2 (156), adiponectin receptor 1 (157), ghrelin (158, 159), ghrelin
receptor (160), tenomodulin (161, 162), and FTO (163) genes.
The selection of genes for the present studies was based partly (B3AR, UCP1) on
previous findings of the research group (164-166). The supplementation with B2AR,
UCP2 and UCP3 to these was a natural choice, since these genes all deal with energy
metabolism, and belong to the same superfamilies of G protein-coupled receptors
(BARs) and anion carrier proteins (UCPs). The leptin receptor (LEPR) gene was added
to this series of studies due to increasing interest and evidence of its importance as a
genetic modifier of obesity and T2DM risk.
2.5.1. 2-adrenergic receptor (B2AR)
Catecholamines are important regulators of fat cell lipolysis in human white AT (WAT)
(32, 33). Noradrenaline (NA) and adrenaline regulate lipolysis through lipolytic -
adrenergic receptors 1-3 and antilipolytic 2-adrenergic receptors (32, 33).
   BARs are members of G protein-coupled receptor (GPCR) superfamily, which
includes nearly 2000 members classified into over 100 subfamilies (167). All GPCRs
have an extracellular N-terminal segment, seven transmembrane (TM) domains, which
form the TM core, three exoloops, three cytoloops, and a C-terminal segment (167).
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B2ARs are widely distributed and, as part of the sympathetic nervous system, they play
important roles in regulating cardiac, vascular, pulmonary, metabolic, central nervous
system (CNS), and reproductive functions (168).
   Despite the variety of functions involving B2AR, knockout (KO) mice are normal and
fertile, but they become hypertensive in response to adrenaline infusion or to the
cardiovascular stress induced by exercise (168). Studies with B1/B2AR double KO mice
suggest that in the mouse, BAR stimulation of cardiac inotropy and chronotropy is
mediated almost exclusively by the B1AR, whereas vascular relaxation and metabolic
rate are controlled by all three BARs (169).
   The B2AR gene was cloned in 1986 (170), and it was localised to chromosome 5q31-
q32 (171). The gene is intronless (172), and it encodes a protein of 413 amino acids (aa)
(171). Receptor transcripts have a 5’-leader region harboring an open reading frame that
encodes a 19-aa peptide (172), which has been shown to inhibit translation of B2AR
mRNA thus regulating cellular expression of the receptor (173). This peptide, termed as
5’-leader cistron (5’LC), harbors a variant Arg19Cys, which increases expression of
B2AR (174). Recently, crystal structure of the human B2AR has been resolved and this
represented a major achievement in view of its low natural abundance, inherent
structural flexibility, and instability in detergent solutions (175, 176). Previously,
knowledge on the GPCR structure was based on data obtained with rhodopsin (177).
   Several variants within the coding block of B2AR have been identified: Arg16Gly,
Gln27Glu, Val34Met, and Thr164Ile. In studies utilizing site-directed mutagenesis and
recombinant expression, amino acid changes at positions 16, 27, and 164 have been
found to alter receptor function (178, 179). The Ile164 displays altered coupling to
adenylyl cyclase (178), the Gly16 displays enhanced agonist-promoted downregulation,
and the Glu27 form is resistant to downregulation (179). Thus, Gly16 and Glu27 may
have opposite effects on agonist-mediated desensitization of the B2AR (180). Gln27Glu
variant has been found to be associated with increased body weight (181-185),
hypertriglyceridaemia (186, 187) and susceptibility to T2DM (185, 188). Gln27Glu
variant may have different impact on obesity according to gender (184) and physical
activity (189). Positive associations of different B2AR variants with obesity/diabetes
related traits are listed in the Table 7, whereas the negative studies (187, 190-196) are
not included.
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Table 7. Positive associations of B2AR gene variants with obesity and diabetes related traits.
Ref Subjects
(number/ethnicity)
SNP Risk
allele
Association
(181) 140 women
Swedish Caucasian
Arg16Gly
Gln27Glu
Arg
Glu
Lower receptor agonist sensitivity
Higher risk of obesity, higher fat mass,
and larger fat cells
(192) 1152
French Caucasian
Gln27Glu Gln Higher weight, BMI, and WHR
among physically inactive men
Interaction with physical activity
(183) 278 men
Japanese
Gln27Glu Glu Higher frequency among obese
(184) 138 men, 109 women
Swedish Caucasian
Gln27Glu Gln
Glu
Higher frequency among obese men
Higher frequency among obese women
(185) 104 T2DM, 26 obese
NGT, 478 lean NGT
Japanese
Gln27Glu
Arg16Gly
Glu
Arg
Higher risk of obesity and T2DM
Higher risk of obesity in women
(197) 124 obese, 450 lean
Japanese
5’LC-
Cys19Arg
Arg Higher BMI and TG
Higher frequency among T2DM
(n=113)
(182) 180 men
Swedish Caucasoid
Gln27Glu Glu Higher BMI, cholesterol, TG, and
VLDL levels
(198) 119 obese, 717 lean
French Caucasoid
Arg16Gly
Gln27Glu
Arg
Gln
Additive effect with Gln27 on adiposity
Higher risk of obesity (men)
(199) 743
French-Canadian
Arg16Gly
Gln27Glu
Arg
Glu
Higher frequency among obese,
higher total and LDL-cholesterol
Higher total and LDL-cholesterol
Combination with Arg16Gly results
in higher abdominal SAT
(188) 461 T2DM, 593 NGT
Swedish Caucasoid
Gln27Glu Gln Higher frequency among T2DM
Higher insulin and FFA
(200) 12 male twin pairs Gln27Glu Gln Higher weight and SAT gain, increase
in insulin-AUC, and plasma leptin
during overfeeding
(186) 251 men
Japanese
Arg16Gly
Gln27Glu
Gly
Glu
Lower HDL-cholesterol
Higher TG, higher prevalence of fatty
liver
(201) 604
Caucasoid
Arg16Gly Arg Higher BMI
Interaction with physical activity on
FFA levels
(202) 112 obese, 127 lean
Spanish Caucasoid
Gln27Glu Glu Higher risk of obesity (men, n=40),
specially among those with low HDL-
cholesterol
(203) 15 obese women
Spanish Caucasoid
Gln27Glu Glu Lower lipolysis and fat oxidation
promoted by exercise
(204) 130 T2DM, 130 NGT
Asian
Arg16Gly Arg Higher risk of diabetes
Earlier onset of diabetes
(205) 205 black, 415 white Arg16Gly Risk allele is modified by interaction
with B3AR Trp64Arg on fat reduction
after endurance training (black)
(206) 159 obese, 154 lean
Caucasoid
Gln27Glu Glu Interaction with carbohydrate intake
on the risk of obesity
(207) 666
Caucasoid
Gln27Glu Glu Higher BMI among obese men (n=79)
Higher 2h glucose
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(208) 260 black, 482 white Arg16Gly
Gln27Glu
Arg
Gly
Gln
Higher fat accumulation (n=39)
Lower reduction in BMI and fat mass
during endurance training
Higher fat accumulation (n=58)
(209) 1576
several ethnicities
Arg16Gly
Gln27Glu
Gly
Arg
Gln
Higher sBP, risk of hypertension
Higher BMI, higher risk of obesity
Higher risk of obesity
(210) 47 T2DM
Japanese
Arg16Gly Gly Higher fasting insulin and HOMA-IR
(211) 834 white
345 African American
Arg16Gly Gly Interaction with B1AR Arg389Gly on
increase in BMI over years (in men)
(212) 160 men
Japanese
Arg16Gly
Gln27Glu
Gly
Glu
Higher frequency of weight gain
and BP elevation, higher plasma NA
Higher frequency of BP elevation
 in combination with B3AR Trp64Arg
Higher plasma NA
(213) 329 adolescents
Asian
G(1053)C C Higher BMI, interaction with B3AR
Trp64Arg on BMI
(214) 155 men
Japanese
Arg16Gly Gly Higher HOMA-IR, fasting insulin,
NA, body fat mass, and BP
(215) 154 obese men
Japanese
Arg16Gly Gly Higher frequency among subjects with
rebound weight gain (n=36)
Higher NA, leptin, fat mass, and BMI
(216) 642
Caucasoid
5’LC-
Cys19Arg
Arg16Gly
Gln27Glu
Cys
Arg
Gln
Higher TG and LDL-cholesterol
Higher TG and LDL-cholesterol
Higher TG and LDL-cholesterol
(217) 123 obese, 206 lean men
Japanese
Arg16Gly
Gln27Glu
Gly
Glu
Higher frequency among obese
Higher fat mass, WHR, and leptin
Higher frequency among obese
Higher fat mass, WHR, and leptin
(218) 55 obese men
Japanese
Arg16Gly Gly Higher weight gain and BP elevation
Higher fat mass, WHR, and leptin
(219) 342 T2DM, 305 NGT
Italian Caucasoid
Arg16Gly
Gln27Glu
Arg
Gln
Combination with UCP3 C(-55)T
results in higher prevalence of T2DM
Higher risk of diabetes
(220) 149 obese hypertensive,
139 lean hypertensive,
149 control
Chinese
Gln27Glu Glu Higher frequency among obese
hypertensive
Ref, reference; SNP, single nucleotide polymorphism; BMI, body mass index; WHR, waist-to-hip ratio;
T2DM, Type 2 diabetes mellitus; NGT, normal glucose tolerance; TG, triglyceride; VLDL, very low
density lipoprotein; LDL, low density lipoprotein; SAT, subcutaneous adipose tissue; FFA, free fatty
acid; AUC, area under curve; HDL, high density lipoprotein; BP, blood pressure; sBP, systolic BP;
HOMA-IR, homeostasis model assessment for insulin resistance; NA, noradrenaline. The risk allele in
‘association’-column is written in bold.
2.5.2. 3-adrenergic receptor (B3AR)
In mature brown adipocytes, NA interacts with all three types of adrenergic receptors: ,
1, and 2; these receptor types are associated with activation of different signalling
pathways, the most significant of which is the pathway for –adrenergic stimulation of
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thermogenesis (221). B3AR increases thermogenesis through the action of UCP1 in
brown fat cells and stimulates the mobilisation of lipids from the white fat cells (35).
Whereas B1AR and B2AR subtypes are most active in WAT lipolysis, B3AR is less
active, particularly in the SAT where it can activate lipolysis only to a minor extent
(222). However, in VAT, the B3AR has a strong lipolytic action, and it has been
suggested that this is of importance for some of the metabolic aberrations seen in obese
subjects (222).
   Mice lacking B3AR display a modest increase in body fat, indicating that B3AR plays
a role in energy balance (223). B1AR but not B2AR mRNA levels are upregulated in
WAT and BAT of B3AR-deficient mice, implying that B3AR mediates physiologically
relevant signalling and that cross-talk exists between B3AR and B1AR gene expression
(223). Mice that lack all three known BARs had a reduced metabolic rate and became
slightly obese on a Chow diet (224). On a high-fat diet, they developed massive obesity
that was entirely due to a failure to express diet-induced thermogenesis (224). Their
BAT was unresponsive to both physiological (cold exposure) and pharmacological (-
agonist) stimulation (225). In AT of obese (fa/fa) Zucker rats, the amount of B3AR was
reduced by 71% as compared with lean control animals (226).
   B3AR was cloned in 1989, and shown to be expressed mostly in BAT and WAT, but
also in ileum, liver, soleus muscle (227), and pancreatic -cells (228). The B3AR gene is
located in chromosome 8p12-p11.2 (229), consisting of two exons and a single intron
which encode a protein of 408 aa (230).
   In 1995, a Trp64Arg variant, situated in the first intracellular loop of the receptor, was
identified and reported to be associated with increased body weight, clinical features of
IR, and early development of T2DM (231-233). This variant has been shown to have
functional significance; the Arg64 variant causes a10-fold decreased receptor
responsiveness to activation by a B3AR agonist compared with the Trp allele (234).
Reduced receptor function may lead to decreased lipid mobilisation from the fat depots
and/or decreased thermogenesis in BAT, thus predisposing to obesity. Individuals
homozygous for the Arg64 allele secrete significantly less insulin in response to a
glucose infusion, have higher fasting glucose levels, and have lower glucose
effectiveness (Sg), compared with those homozygous for the Trp allele (235).
Transfection studies with rat -cells have shown that cells transfected with the Arg64
variant secrete less insulin, both spontaneously and after exposure to human B3AR
agonist, and their glucose responsiveness is significantly reduced (228). These findings
may help explain the earlier onset of T2DM observed in several populations of
individuals with the Arg allele.
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   The coexistence of common variants in the B3AR (Trp64Arg) and B2AR (Gln27Glu)
genes has been reported to be associated with T2DM (188), and the interaction with
B2AR Arg16Gly variant has contributed to the changes in fat mass and abdominal
obesity (205). However, the results of meta-analyses have been contradictory in
defining the association between Trp64Arg variant and BMI, i.e. two studies finding the
variant carriers to exhibit higher BMI than normal homozygous subjects (236, 237), one
study finding the association only in East Asians but not in Europeans (238), and one
study finding no association (239). One meta-analysis suggested that Trp64Arg variant
has moderate effects on IR in Asian populations and in obese and diabetic subgroups
(240). Positive associations of B3AR Trp64Arg variant with obesity/diabetes related
traits are listed in the Table 8, whereas the negative studies (190, 196, 214, 241-248) are
not included.
Table 8. Positive associations of Trp64Arg variant in B3AR gene with obesity and diabetes
related traits.
Ref Subjects
(number/ethnicity)
Risk
allele
Association
(233) 390 T2DM, 252 NGT
Pima Indian
Arg Lower age at onset of T2DM
(231) 185 obese, 94 lean
French Caucasoid
Arg Higher weight gain during adult life
(232) 128 T2DM, 207 NGT
Finnish Caucasoid
Arg Lower age at onset of T2DM
Higher WHR, insulin response in OGTT, dBP,
and lower rate of glucose disposal (in NGT)
(249) 159 T2DM, 191 NGT
Japanese
Arg Higher BMI, fasting and 2h insulin in OGTT (in NGT)
(250) 254 obese, 151 lean
Finnish Caucasoid
Arg Earlier onset of obesity
(251) 238 obese, 91 lean
French Caucasoid
Arg Higher weight gain,
additive effect with UCP1 A(-3826)G
(252) 131 obese, 256 lean,
women
Japanese
Arg Greater VAT area, higher body fat, sBP, glucose,
insulin, cholesterol, and TG levels
Lower HDL-cholesterol
(253) 25 T2DM, 36 NGT
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Mexican American
Arg Lower age at onset of T2DM
Higher 2h insulin in OGTT
(164) 170 obese
Finnish Caucasoid
Arg Combination with UCP1 A(-3826)G results in lowered
BMR
(254) 45 sib-pairs
Mexican American
Arg Higher BMI, fat mass, and WC
(255) 27 obese women
Caucasoid
Arg Lower exogenous glucose infusion in clamp study
Lower total glucose disposal in clamp study
(256) 77 obese women
Finnish Caucasoid
Arg Combination with UCP1 A(-3826)G results in
lower weight reduction during VLCD,
and increased weight during maintenance period
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(234) 208
Swedish Caucasoid
Arg Higher BMI, lower sensitivity for receptor agonist
in VAT adipocytes
(166) 70 T2DM, 123 NGT
Finnish Caucasoid
Arg Combination with UCP1 A(-3826)G
results in higher weight gain
(235) 62
several ethnicities
Arg Lower insulin secretion and glucose effectiveness
Higher fasting glucose
(199) 743
French Canadian
Arg Higher total and SAT abdominal fat area in men
Interaction with 2-AR 6.7/6.3kb on
total and SAT abdominal fat area in men
(257) 24 obese women
Caucasoid
Arg Lower reduction of VAT during weight reduction
(258) 909 women
Caucasoid
Arg Interaction with 2b-AR Glu12/Glu9 on
fat mass and percent fat
(188) 461 T2DM, 593 NGT
Swedish Caucasoid
Arg Higher 2h glucose and FFA
(259) 453
Mexican American
Arg Interaction with PPAR2 Pro12Ala on
higher BMI, insulin, and leptin levels
(260) 476
Japanese-American
Arg Higher WHR, insulin, and HOMA-IR
(among obese men)
(205) 205 black, 415 white Trp,
Arg
Risk allele is modified by interaction with B2AR
Arg16Gly on fat reduction after endurance training
(in black)
(261) 62
several ethnicities
Arg Lower RMR and higher thermic effect of feeding
(262) 105 obese children
Japanese
Arg Higher BMI and lower HDL-cholesterol,
apoA-I, and apoA-II levels (in boys)
(263) 76 women
Japanese
Arg Lower weight reduction
(264) 224 obese
Asian
Arg Combination with UCP3 C(-55)T resulted in lower
reduction in VAT, and glucose and FFA levels
(265) 296 neonates
Chinese
Arg Higher insulin and insulin-to-glucose ratios among
small for gestational age babies (n=76)
(266) 332
Caucasoid
Arg Higher leptin level among women (n=172)
(211) 340 African
American,
813 white
Arg Interaction with B1AR Arg389Gly on higher
increase in BMI among women (n=658)
(267) 295 obese, 147 lean
children
Hungarian
Arg Higher weight, body fat, sBP, and insulin levels
(212) 160 men
Japanese
Trp Higher frequency of BP elevation
(213) 329 adolescents
Asian
Arg Higher BMI, body fat, and plasma leptin
Interaction with B2AR G(1053)C on BMI
(268) 295 men
Japanese
Arg Interaction with high energy intake
on higher risk of obesity
(218) 55 obese men
Japanese
Arg Higher weight gain, BP elevation, fat mass,
WHR, and plasma NA level
(220) 149 obese hypertensive,
139 lean hypertensive,
149 control, Chinese
Arg Higher frequency among obese hypertensive
vs. other groups (in men)
Ref, reference; T2DM, Type 2 diabetes mellitus; NGT, normal glucose tolerance; WHR, waist-to-hip
ratio; OGTT, oral glucose tolerance test; dBP, diastolic blood pressure; BMI, body mass index; VAT,
visceral adipose tissue; sBP, systolic blood pressure; TG, triglyceride; HDL, high density lipoprotein;
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BMR, basal metabolic rate; WC, waist circumference; VLCD, very low calorie diet; SAT, subcutaneous
adipose tissue; FFA, free fatty acid; HOMA-IR, homeostasis model assessment for insulin resistance;
RMR, resting metabolic rate; apoA, apolipoprotein A; NA, noradrenaline. The risk allele in ‘association’-
column is written in bold.
2.5.3. Uncoupling protein 1 (UCP1)
The uncoupling proteins 1, 2, and 3 (UCP1-3) are members of the superfamily of anion
carrier proteins situated in the inner membrane of mitochondria (269). UCP1 is a
dimeric protein, the three-dimensional structure of which is not known. It is believed to
consist of six -helices connected by loops with the third matrix side loop containing
the purine nucleotide-binding domain (270). Both the N- and C-terminal amino acids
face the intramembrane space (270).
   Brown adipocytes possess abundant mitochondria with densely packed cristae, and
they are unique in expressing UCP1, ‘thermogenin’, which functions to uncouple
mitochondrial respiration in the inner mitochondrial membrane (271). Mitochondrial
adenosine triphosphate (ATP) synthesis from adenosine diphosphate (ADP), driven by
electron flow from reduced substrate (mainly NADH) to oxygen, defines oxidative
phosphorylation (272). Oxidation is coupled by the electron transport chain to pumping
of protons from the mitochondrial matrix, generating a proton motive force (or
electrochemical potential difference) for protons across the inner membrane of the
mitochondria. This force drives the protons back into the matrix through an ATP
synthase, which couples proton transport across the membrane to phosphorylation of
ADP (272). UCP1 is able to dissipate the proton gradient, thereby uncoupling fuel
oxidation from the availability of ADP. Thus, the physiological consequence of UCP1
activity is unrestrained oxidation of fuels with the sole byproduct being the generation
of heat (271). Mild uncoupling of respiration can also prevent the accumulation of
oxygen radicals generated by mitochondria, and control the NAD+/NADH ratio and
thereby regulate ketogenesis, lipogenesis and amino acid synthesis, which are
dependent on the levels of these cofactors (272).
   UCP1 expression is increased by cold acclimation and overfeeding, and reduced in
fasting and genetic obesity (273). UCP1 is activated by FFA and inhibited by purine
nucleotides (274). In response to a cold environment, NA released by sympathetic
nerves stimulates both lipolysis – thus increasing the intracellular FFA availability –
and the transcription of the UCP1 gene (Figure 3) (274). The ability of NA to stimulate
lipolysis and thermogenesis in adipocytes is controlled largely by B3AR (275).
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Figure 3. The role of UCP1 in thermogenesis of brown adipose tissue. In response to several
stimuli, the catecholamines released by the sympathetic system increase the intracellular
concentration of cAMP and, as a result, the lipolytic activity is enhanced, resulting in an
increase in the intracellular FFA concentration, which activates both UCP1 gene transcription
and UCP1 activity. Activation of UCP1 reduces the proton gradient generated by the respiratory
chain and decreases the membrane potential, which in turn accelerates respiration. Increased
respiration and shunting of ATP synthesis induce thermogenesis. AC, adenylate cyclase; B3AR,
3-adrenergic receptor; cAMP, cyclic adenosine monophosphate; CNS, central nervous system;
FFA, free fatty acid; Gs, stimulatory guanosine triphosphate binding protein; HSL, hormone
sensitive lipase; NA, noradrenaline; PKA, protein kinase A; TG, triglyceride; UCP1, uncoupling
protein 1. Modified from Yasuda et al. 2006 (276), Argiles et al. 2002 (274), and Pecqueur et al.
2001 (277).
   Transgenic mice with genetic ablation of BAT develop obesity, and as obesity
progresses, also hyperphagia develops (278). When fed with a Western diet, they
develop also morbid metabolic complications, such as IR, hyperglycaemia, and
hyperlipidaemia (279). BAT phenotype of the adipose organ in rodents is important for
the prevention of obesity and diabetes (280).
   Human UCP1 was cloned in 1988 (281). The UCP1 gene is located on chromosome
4q28-q31, having six exons all of which are translated, encoding a protein of 305 aa
(282).
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   There are many common exonic variants (Arg40Trp, Ala64Thr, Val137Met,
Met229Leu, Lys257Asn), which have not been associated with obesity (270). However,
the A(-3826)G variant in the 5’UTR close to an enhancer region, has been found to be
associated with obesity and metabolic disorders (166, 256, 283). The simultaneous
existence of the variants in the B3AR (Trp64Arg) and UCP1 (A(-3826)G) genes are
known to have an additive effect on low basal metabolic rate (BMR) (164) and weight
gain (166, 251, 256). Positive associations of UCP1 variants with obesity/diabetes
related traits are listed in the Table 9, whereas the negative studies (245, 284, 285) are
not included.
Table 9. Positive associations of UCP1 gene variants with obesity and diabetes related traits.
Ref Subjects
(number/ethnicity)
SNP Risk
allele
Association
(251) 238 obese, 91 lean
French Caucasoid
A(-3826)G G High weight gain during adult life,
additive effect with B3AR Trp64Arg
(286) 153 obese
Caucasoid
A(-3826)G G Lower UCP1 mRNA in VAT
(164) 170 obese
Finnish Caucasoid
A(-3826)G G Combination with B3AR Trp64Arg
resulted in lower BMR
(256) 77 obese women
Finnish Caucasoid
A(-3826)G G Combination with B3AR Trp64Arg
resulted in lower weight reduction during
VLCD and faster weight gain after it
(166) 70 T2DM, 123 NGT
Finnish Caucasoid
A(-3826)G G Combination with B3AR Trp64Arg
resulted in higher weight gain
(283) 526 obese women
Australian Caucasoid
A(-3826)G G Higher BMI
(287) 12 male twin pairs A(-3826)G G Worse recovery from overfeeding
(285) 25 T2DM, 25 NGT
Japanese
A(-112)C
Met229Leu
C
Leu
Higher frequency among diabetic subjects
Higher frequency among diabetic subjects
(288) 118 obese
Polish Caucasoid
A(-3826)G G Higher TG and FFA levels,
Lower HDL-cholesterol level
(266) 332
Spanish Caucasoid
A(-3826)G G Higher weight among women
(289) 93 T2DM
Japanese
A(-112)C C Higher HOMA-IR and hepatic lipid
content
(290) 295 T2DM, 113
offspring, 120 NGT
Czech Caucasoid
A(-3826)G G Higher BMI among offspring of T2DM
Ref, reference; SNP, single nucleotide polymorphism; VAT, visceral adipose tissue; BMR, basal
metabolic rate; VLCD, very low calorie diet; T2DM, Type 2 diabetes mellitus; NGT, normal glucose
tolerance; BMI, body mass index; TG, triglyceride; FFA, free fatty acid; HDL, high density lipoprotein;
HOMA-IR, homeostasis model assessment for insulin resistance. The risk allele in ‘association’-column
is written in bold.
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2.5.4. Uncoupling protein 2 (UCP2)
UCP2 is widely distributed with the greatest amounts found in spleen, thymus,
pancreatic -cells, heart, lung, WAT, BAT, stomach, testis, and macrophages, and lesser
amounts found in brain, kidney, liver, and muscle (269, 291). UCP2 is a key component
of -cell glucose sensing, since it seems to regulate glucose stimulated insulin secretion
(GSIS) (270, 292). It has been suggested that increased UCP2 expression might lead to
a reduced risk of obesity, but increased risk of diabetes; thus, UCP2 has been called the
‘adiposity angel and diabetes devil’ (Figure 4) (293). Furthermore, UCP2 regulates FFA
metabolism in multiple tissues, and negatively modulates the production of reactive
oxygen species (ROS) (270, 292).
Mice lacking UCP2 following targeted gene disruption are viable and appear normal
(294). No differences in body weight were seen compared to wild-type littermates.
UCP3 mRNA levels were unchanged, whereas UCP1 mRNA in WAT was increased
(294). Immunological studies showed that ROS production in macrophages was higher
than in the wild-type mice, and that UCP2 is active in the limitation of ROS and in
antioxidant defence (294).
   Overexpression of UCP2 in rat pancreatic islets resulted in severe blunting of GSIS
(295), whereas glucose-stimulated mitochondrial membrane hyperpolarization and the
ATP content of islets were reduced, suggesting that the low ATP level led to reduced
glucose-induced depolarization, thereby causing reduced insulin secretion (296).
Studies on mice revealed that UCP2 deficiency  resulted in higher islet ATP levels and
increased GSIS (297). UCP2 was markedly upregulated in islets of ob/ob mice, a model
of obesity-induced diabetes, whereas ob/ob mice lacking UCP2 had restored first-phase
insulin secretion, increased serum insulin levels, and greatly decreased levels of
glycaemia (297). It was concluded that UCP2 is a critical link between obesity, -cell
dysfunction and T2DM (297). Furthermore, short-term inhibition of UCP2 expression
ameliorated the hyperglycaemic syndrome in two distinct animal models of obesity and
diabetes by modifying both insulin secretion and insulin signal transduction in AT
(298).
   Endogenously produced mitochondrial superoxide activates the UCP2-mediated
proton leak, thus lowering ATP levels and impairing GSIS (299). Furthermore,
hyperglycaemia- and obesity-induced loss of glucose responsiveness is prevented by a
reduction in mitochondrial superoxide production or gene KO of UCP2 (299).
Therefore, one of the key missing elements in hyperglycaemia-induced -cell
dysfunction could be the activation of UCP2 by superoxide (299). It is believed that the
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physiological role of UCP2 is to prevent excessive superoxide generation through a
feedback loop (300).
Figure 4. UCP2 expression increases with high fat feeding and/or in response to obesity and
insulin resistance (IR). Effects of the increased expression of UCP2 are different in adipocytes
and skeletal muscle vs. pancreatic -cells. FFA, free fatty acid; ROS, reactive oxygen species.
Modified from O’Rahilly 2001 (293) and Langin 2001 (301).
   UCP2 and UCP3 were identified in 1997 by reverse cloning, i.e. by
‘mining’databases of expressed sequence tags or searching sequences for similarity to
UCP1 in complementary DNA (cDNA) libraries (302, 303). UCP2 and UCP3 have
59% and 57% identity, respectively, with UCP1, and 73% identity with each other
(269). The transcription initiation of UCP2 is placed only 7 kb downstream of the
UCP3 stop codon in the chromosome 11q13 (304). There are 8 exons in UCP2 gene, of
which 1 and 2 are untranslated (304).
   Three common variants exist in the UCP2 gene, one situated in the promoter region
(G(-866)A), one is a missense variant in exon 4 (Ala55Val), and one is located in the
untranslated exon 8 (3’UTR 45 bp Del/Ins). It has been shown that the functional G(-
866)A variant, situated in a multifunctional cis regulatory site, acts as a binding site for
a pancreatic transcription factor PAX6 (305). This variant has been associated with
increased AT mRNA expression and obesity (306), -cell function and diabetes (305),
insulin secretion (307), energy metabolism (308), and CHD (309). In a recent meta-
analysis of genome-wide linkage studies, suggestive evidence for chromosome 11q13.3-
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22.3 was observed for BMI-defined obesity (115). Positive associations of different
UCP2 variants with obesity/diabetes related traits are listed in the Table 10, whereas the
negative studies (310-313) are not included.
Table 10. Positive associations of UCP2 gene variants with obesity and diabetes related traits.
Ref Subjects
(number/ethnicity)
Variant Risk
allele
Association
(314) 82
790
Pima Indian
Ala55Val
Del/Ins
Ala+Val
Del+Ins
Lower SMR than in heterozygotes
Lower SMR than in heterozygotes
Lower 24h EE than in heterozygotes
Higher BMI than in heterozygotes
(older subgroup)
(315) 596 South Indian
83 British Caucasoid
Del/Ins Ins Higher BMI in women
(287) 12 male twin pairs Ala55Val
Del/Ins
Val
Del
Poorer recovery from overfeeding, high RQ
Greater increase in TSH response to TRH
Poorer recovery from overfeeding
Higher weight increase after overfeeding
(306) 340 obese, 256 lean,
791 control
Caucasoid
G(-866)A G Higher BMI, lower UCP2 mRNA
expression in AT
(305) 201 obese T2DM,
391 obese
Caucasoid
G(-866)A A Lower disposition index
Higher risk of diabetes
Higher activation of the promoter in -cell
(307) 301
Italian Caucasoid
G(-866)A A Lower glucose stimulated insulin secretion
(Studied also in human islets, n=10)
(309) 465 T2DM men
2695 men
British Caucasoid
G(-866)A A Lower antioxidant status
Higher oxidative stress (patients with CHD)
Higher CHD risk
(308) 296 obese, 568 lean,
children
Caucasoid
G(-866)A A Lower lipid oxidation, higher carbohydrate
oxidation  (obese subgroup, n=147)
(316) 681 T2DM
Caucasoid
G(-866)A A Higher levels of TG, cholesterol, LDL-
cholesterol
(317) 483 T2DM, 181
offsprings, 565 NGT
100 morbidly obese
Italian Caucasoid
G(-866)A A Lower insulin sensitivity, studied by clamp
Higher frequency among T2DM women
UCP2 mRNA correlates with IR in SAT
(318) 283 T2DM, 388 NGT
125 NGT
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several ethnicities
G(-866)A
Ala55Val
Del/Ins
Haplotype
A
GVI/AVD
Lower UCP2 mRNA in SAT (n=36)
Higher BMI, TG, and insulin levels
(319) 157 obese, 150 lean
Spanish Caucasoid
Del/Ins Ins Higher risk of obesity
(320) 504 T2DM, 133 NGT
Asian
Ala55Val Ala+Val Higher risk of T2DM in combination with
PPAR C(161)T than in Ala55Val heteroz.
(321) 413 T2DM, 172 NGT
Japanese
G(-866)A A Higher promoter activity in -cell line
Earlier need for insulin therapy
Higher frequency of insulin treatment
(322) 746 T2DM, 327 NGT
Italian Caucasoid
G(-866)A G Higher risk of T2DM
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(323) 565 T2DM, 299 NGT
Pima Indian
G(-866)A
Del/Ins
G
Del
Lower 24h metabolic rate (n=185)
Lower 24h metabolic rate (n=185)
(324) 2936 men
Caucasoid
G(-866)A A Higher risk of T2DM, especially in obese
Additive effect with UCP3 C(-55)T
(325) 658 women
Asian
G(-866)A
Ala55Val
A
Val
Lower HDL-cholesterol
Lower HDL-cholesterol
(326) 458 obese women
Asian
G(-866)A
Ala55Val
A
Val
Lower VLCD-induced BMI reduction
Lower VLCD-induced BMI reduction
(327) 150
Caucasoid
Ala55Val Val Lower circulating leptin level
(328) 3457 T2DM,
French Caucasoid
G(-866)A G Higher risk of CHD
Ref, reference; SMR, sleeping metabolic rate; EE, energy expenditure; BMI, body mass index; RQ,
respiratory quotient; TSH, thyroid stimulating hormone; TRH; thyrotropin-releasing hormone; AT,
adipose tissue; T2DM, Type 2 diabetes mellitus; CHD, coronary heart disease; TG, triglyceride; LDL,
low density lipoprotein; NGT, normal glucose tolerance; IR, insulin resistance; SAT, subcutaneous
adipose tissue; HDL, high density lipoprotein; VLCD, very low calorie diet. The risk allele in
‘association’-column is written in bold.
2.5.5. Uncoupling protein 3 (UCP3)
Both UCP3 mRNA and protein are found only in skeletal muscle, and to a lesser extent
in heart (269). UCP3 mRNA is also found in BAT, but there is controversial data about
whether or not the protein has been identified in BAT (269). The functions proposed for
UCP3 include regulation of redox state, regulation of FA and glucose metabolism and
control of ROS formation (274, 329, 330). The abundant and relatively selective
expression of UCP3 in skeletal muscle suggests that it may be a mediator of adaptive
thermogenesis in humans (331).
   UCP3 expression has been shown to increase in human skeletal muscle during fasting,
a state characterised by a marked increase in circulating plasma FA concentrations and
FA oxidation rates, suggesting a role for this gene in the regulation of FA homeostasis
(332). Acute exercise induces upregulation of UCP3 mRNA and protein levels, whereas
endurance training results in the downregulation of UCP3 (333, 334). When oxidative
capacity is high, such as in physically well trained subjects, FAs can easily be oxidised
and therefore are not likely to accumulate inside the mitochondria, and only a little
amount of UCP3 is needed to export FA anions from the mitochondrial matrix (335).
   The UCP3 protein content has been shown to be 50% lower in T2DM patients
compared with healthy control subjects, evidence of a role for UCP3 in T2DM,
consistently with mouse studies (336). Also ageing, which is characterised by
mitochondrial dysfunction, is accompanied by a reduction in UCP3 levels (335). UCP3
expression varies two- to three-fold and may be a determinant of the variability in rates
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of EE and the degree of obesity. Indeed, BMI has been shown to be negatively
correlated with the expression levels in Pima Indians (337).
   UCP3 KO mice appear to be healthy animals (338). However, the respiration
activities in skeletal muscle mitochondria are abnormal. Mitochondria are more
coupled, meaning that UCP3 has a proton transport activity and consequently functions
as a genuine UCP. At the cellular level, skeletal muscle UCP3 KO increased the rate of
ATP synthesis 4-fold (339). Moreover, mitochondria lacking UCP3 also produced more
ROS, which might enhance oxidative damage to lipids, proteins, and DNA, thus
accelerating the ageing process (338). Studies on transgenic mice strongly suggest that
enhancement of UCP3 expression is a promising approach for the treatment of obesity,
since overexpression of human UCP3 in mouse skeletal muscle results in hyperphagia
and leanness (340). These mice also exhibit lower FPG and insulin levels and an
increased glucose clearance rate, and a striking reduction in AT mass (340).
   The human UCP3 gene maps to the distal segment of 11q13, adjacent to the region
housing UCP2 (331). Given the close proximity and the high degree of similarity
between UCP2 and UCP3 (~70% at the nucleotide level), it is likely that one UCP gene
arose from the other via a duplication event (331). The UCP3 gene contains 7 exons,
multiple transcription initiation sites, and it gives rise to two main alternative
transcripts, the shorter one having a polyadenylation site in exon 6, which terminates
approximately 50% of the transcripts (270). Therefore, human UCP3 exists as long
(UCP3L, 312 aa) and short (UCP3S, 275 aa) forms (331).
   Although a number of amino acid substitutions have been reported, most are rare, like
Val9Met, Arg70Trp, Val102Ile, Arg143X, Arg282Cys, Arg308Trp, and a mutation at the
junction of exon 6 and intron 6, allowing only the UCP3 short form to be translated
from the allele (exon 6 ivs + 1G/A, GAIVS6) (270). In addition, many silent or intronic
variants exist. A promoter region variant -55 C/T is potentially interesting because it is
situated only 6 bp apart from the TATA box and 4 bp from a DR1 site, which is a part
of a retinoic acid response element (341). The -55 T allele associates with higher UCP3
expression (341), which has been positively correlated with SMR and 24 h EE (337). In
French subjects, the -55 T/T genotype was associated with higher BMI (342), but lower
risk of T2DM (343). Positive associations of different UCP3 variants with
obesity/diabetes related traits are listed in the Table 11, whereas the negative studies
(344) are not included.
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Table 11. Positive associations of UCP3 gene variants with obesity and diabetes related traits.
Ref Subjects
(number/ethnicity)
SNP Risk
allele
Association
(341) 67
Pima Indian
C(-55)T C Lower UCP3 mRNA in
skeletal muscle (n=18)
(343) 232 obese, 49 T2DM,
894 control
171 T2DM, 124 NGT
French Caucasoid
C(-55)T C
T
C
Higher frequency among T2DM
Higher cholesterol, LDL-cholesterol,
and apolipoprotein (control group)
Higher frequency among T2DM
(342) 401 obese, 231 lean
French Caucasoid
C(-55)T T Higher BMI
(345) 710 South Indian
450 Caucasoid
C(-55)T T Higher WHR in females
(346) 419
Caucasoid
C(-55)T C Higher BMI
(347) 734
Caucasoid
GAIVS6 240 bp
allele
Higher BMI, fat mass, % body fat,
and leptin
(264) 224 obese
Asian
C(-55)T T Lower reduction in VAT after weight
reduction, in combination with B3AR
Trp64Arg
Lower reduction of glucose and FFA
(348) 162
Caucasoid
C(-55)T T Higher WHR
(349) 345 men, 377 women
Hispanic and non-
Hispanic white
Tyr210Tyr (C/T)
Tyr99Tyr (T/C)
C(-55)T
T
C
T
Lower fat and lean mass despite of
higher dietary intake (women)
Higher dietary intake and lean mass
(women)
Higher dietary intake and lean mass
(women)
(350) 1873
Caucasoid
C(-55)T
Tyr99Tyr
Tyr210Tyr
C Higher BMI
(219) 342 T2DM, 305 NGT
Italian Caucasoid
C(-55)T T Combination with B2AR Arg16Gly
results in higher prevalence of T2DM
in older age
(351) 214 obese, 246 lean,
women
Asian
+521G/C
+1063G/A
Tyr210Tyr
Haplotype
C
A
C
CGTACC
Lower weight reduction after VLCD
Lower weight reduction after VLCD
Lower weight reduction after VLCD
Higher weight, WHR, and BMI at
baseline
Higher weight reduction after VLCD
(324) 2936 men
Caucasoid
C(-55)T T Higher risk of diabetes, especially in
the obese
Additive effect with UCP2 G(-866)A
(352) 225 obese
Spanish Caucasoid
C(-55)T T Higher CRP
(325) 658 women
Asian
Tyr210Tyr T Lower HDL-cholesterol
(326) 458 obese women
Asian
+521G/C
+1063G/A
Tyr210Tyr
C
G
C
Lower BMI and fat mass reduction
Lower BMI and fat mass reduction
Lower BMI and fat mass reduction
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Haplotype Haplotype with UCP2 associates
with lower BMI and fat mass
reduction after VLCD
(353) 282
Japanese
C(-55)T C Lower HDL-cholesterol
Higher BMI
Ref, reference; SNP, single nucleotide polymorphism; T2DM, Type 2 diabetes mellitus; NGT, normal
glucose tolerance; LDL, low density lipoprotein; BMI, body mass index; WHR, waist-to-hip ratio; VAT,
visceral adipose tissue; FFA, free fatty acid; VLCD, very low calorie diet; CRP, C-reactive protein; HDL,
high density lipoprotein. The risk allele in ‘association’-column is written in bold.
2.5.6. Leptin receptor (LEPR)
Finding of leptin
The “obese” locus was first described 6 decades ago (354) and was later shown by
positional cloning to be the LEP gene that encodes a secreted protein, leptin (36). Mice
and humans homozygous for a leptin gene mutation (Lep ob/ob) develop hyperphagia,
early-onset obesity, severe IR, steatosis, hypothalamic hypogonadism, deficits of the
thyroid and growth hormone axes, and immunosuppression (40, 355). Circulating
concentrations of leptin reflect fat cell stores – increasing with overfeeding and
decreasing with starvation. Leptin administration to obese leptin-deficient animals has
reversed their hyperphagia, hypothermia, decreased locomotor activity, and all
neuroendocrine and immunological abnormalities (356). Leptin therapy also
dramatically reduced body weight (mostly fat mass) in four children (357-359) and
three adults (360) with leptin deficiency. Leptin is expressed mainly in WAT
adipocytes, though low levels are produced in the stomach, mammary gland, placenta,
and skeletal muscle (40).
Leptin acts through leptin receptor
The diverse nature of leptin is supported by the universal distribution of LEPR. LEPR
was cloned in 1995 (361). It was identified to be the same gene which was mutated in
diabetic db/db mouse (362), which had earlier been shown to have a similar phenotype
to ob/ob mouse, but to be resistant to leptin treatment (363). Also the leptin resistant
Zucker fatty rat (fa/fa) carries a mutation in the LEPR gene (364). LEPR localises to
chromosome 1p31 (365), and the long form has 18 exons (366). LEPR is a single-
transmembrane-domain receptor, which displays a structural similarity to the class I
cytokine receptor family (367).
   The LEPR is produced in several alternatively spliced forms, designated LEPRa –
LEPRf, that share the common extracellular domain (>800 aa) and the transmembrane
domain (34 aa), and have a variable intracellular domain, characteristic of each of the
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isoforms (367). “Short forms” of LEPR may have roles in binding (LEPRe), transport
(LEPRa), and clearance (LEPRc and LEPRd) of leptin (368), whereas only LEPRb, the
“long form” (1162 aa), encodes all protein motifs capable of activating the janus kinase
– signal transduction and transcription (JAK-STAT) pathway, which in turn stimulates
transcription of target genes (369).
Figure 5. Leptin participates in long-term weight regulation. It is secreted from adipose tissue,
circulating at levels that are proportional to body adipose stores, and exerts its effects through
the leptin receptor, inhibiting (-) the NPY/AGRP neurons and stimulating (+) the POMC/CART
neurons in hypothalamus arcuate nuclei. Activation of the NPY/AGRP has an orexigenic effect,
promoting food intake, whereas the POMC/CART neurons have the opposite anorexigenic
effect. ARC, arcuate nucleus; AGRP, Agouti-related protein; CART, cocaine and amphetamine
regulated transcript; LEPR, leptin receptor; MC4R, melanocortin 4 receptor; NPY, neuropeptide
Y; POMC, proopiomelanocortin. Modified from Bell et al. 2005 (113) and Crowley 2008 (370).
   Within the CNS, the hypothalamus is the main site of leptin action with respect to
controlling food intake and EE (371). High levels of the LEPRb are expressed in several
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hypothalamic nuclei including the arcuate nucleus, where two neuronal subtypes are
critical targets: i) an orexigenic pathway comprising neuropeptide-Y and agouti-related
protein -containing neurones and ii) an anorexigenic pathway consisting of
proopiomelanocortin and cocaine- and amphetamine-regulated transcript -containing
neurones (Figure 5). These neurones subsequently innervate various second order
neurone centres where further integration of satiety/adiposity signalling occurs (371).
   Leptin resistance is common in obesity, and the mechanisms responsible for this
phenomenon may include defects of the leptin receptor, leptin transport, genes involved
in leptin signal transduction, or defective transport of leptin across the blood-brain
barrier (369). At the level of pancreatic -cell, leptin resistance may contribute to
dysregulation of the adipo-insular axis and promote the development of
hyperinsulinaemia and manifest as T2DM in overweight patients (372).
Genetic variation in leptin receptor
Mutations in LEPR are rare; in a recent study, 300 subjects with hyperphagia and severe
early-onset obesity were sequenced for LEPR mutations, and only 8 nonsense or
missense mutations were found, each resulting in impaired receptor signalling (373).
However, the LEPR gene is highly polymorphic, and associates with obesity traits in
several studies.
   A common CTTTA-pentanucleotide Del/Ins variant of the 3’-UTR part of the LEPR
gene is believed to generate an A+U-rich sequence, that should be able to form a stem-
loop structure, which may affect mRNA stability in the cell (374). The Del/Ins variant
has been found to be associated with serum insulin levels (374, 375), serum high
density lipoprotein (HDL)-cholesterol and apolipoprotein A (apoA) -I levels (376), and
susceptibility to T2DM (375).
   A Lys109Arg variant in exon 4 in the extracellular domain of the LEPR has been
associated with glucose homeostasis (377) and insulin response (378), whereas the
Gln223Arg variant, situated in exon 6 in the extracellular domain of the LEPR, has been
found to be associated with glucose and insulin homeostasis (378-380), EE (381), body
weight, and fat mass (382-386). However, few studies (387-391), one meta-analysis
(392) and a pooling analysis of raw data (393) did not find any association of
Lys109Arg or Gln223Arg with BMI or WC. Positive associations of different LEPR
variants with obesity/ diabetes related traits are listed in the Table 12.
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Table 12. Positive associations of LEPR gene variants with obesity and diabetes related traits.
Ref Subjects
(number/ethnicity)
Variant Risk
allele
Association
(388) 10 obese, 10 lean
Pima Indian
A(-36)T (intron 16)
A(+37)C (intron 19)
Pro1019Pro (A/G)
T
C
G
Higher % body fat
Higher % body fat
Higher % body fat
(374) 249 obese, 138 lean
Finnish Caucasoid
3’UTR del/ins Del Higher serum insulin (n=120)
(394) 12 male twin pairs Gln223Arg Gln Metabolic abnormalities in
response to long-term overfeeding
(382) 319 black,
522 Caucasoid
Gln223Arg Arg Higher adiposity values in
Caucasian males
(375) 41 T2DM, 81 NGT,
men
Caucasoid
3’UTR del/ins Del Higher serum insulin
Higher risk of diabetes
(385) 29 obese, 89 lean
Greek
Gln223Arg Arg Higher BMI and % body fat
(384) 280 obese women
Caucasoid
Lys109Arg
Gln223Arg
Lys656Asn
Lys
Gln
Asn
Higher leptin levels
Higher abdominal fat
Higher hip circumference and SAT
(378) 89 IGT, 269 NGT
obese women
Caucasoid
Lys109Arg
Gln223Arg
Lys656Asn
Arg
Lys
Gln
Lys
Higher glu-AUC (pre-MP, IGT)
Higher insulin (post-MP, IGT)
Higher insulin (post-MP, IGT)
Higher glu, glu-AUC (pre-MP,IGT)
(386) 220 women
Caucasoid
Gln223Arg Gln Higher BMI
(395) 192 women Lys656Asn Lys Lower fat oxidation rate
Higher glucose oxidation rate
(383) 336
Brazilian  Caucasoid
Gln223Arg Arg Higher BMI among non-smokers
(381) 452
Pima Indian
Gln223Arg Arg Lower 24h EE and physical activity
Higher adipocyte cell size
(396) 259 weight gainers,
277 stable weight
Dutch Caucasoid
Lys109Arg
Gln223Arg
Arg
Arg
Higher leptin among weight gainers
Higher leptin among weight gainers
(377) 143 black, 397 white Lys109Arg Lys Regular exercise improves glucose
homeostasis in Arg allele carriers (in
whites)
(379) 36 T2DM, 99 IFG,
377 NGT, men
Japanese
Arg223Gln
Pro1019Pro (A/G)
Gln
A
Higher insulin and HOMA-IR for
subjects with Arg/Gln or Gln/Gln +
A/A combination (in NGT)
(397) 1873
Caucasoid
Lys109Arg
Lys656Asn
Pro1019Pro
Haplotype
Lys
GCA
Higher lean and fat mass
Association with lean and fat mass
(380) 67
Caucasoid
Gln223Arg Arg Reduction in insulin sensitivity
and glucose clearance
(376) 221 men
Japanese
3’UTR del/ins Ins Lower HDL-cholesterol and apoA-I
levels
(398) 770 IGT
Multicentre study
3’UTR del/ins Del Lower weight and WC reduction
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(399) 775 T2DM, 688 NGT
Asian
Lys109Arg Lys Higher BMI
Ref, reference; T2DM, Type 2 diabetes mellitus; NGT, normal glucose tolerance; BMI, body mass index;
SAT, subcutaneous adipose tissue; IGT, impaired glucose tolerance; glu, glucose; AUC, area under curve;
MP, menopausal; EE, energy expenditure; IFG, impaired fasting glucose; HOMA-IR, homeostasis model
assessment for insulin resistance; HDL, high density lipoprotein; apoA, apolipoprotein A; WC, waist
circumference.
2.6. Transcriptomics of adipose tissue
DNA microarrays provide information on mRNA expression from thousands of genes
in tissues of interest simultaneously (113). The collection of genes that are expressed or
transcribed from genomic DNA, the transcriptome, is a major determinant of cellular
phenotype and function of each tissue (400). Differences in gene expression are
responsible for morphological and phenotypic differences, and cellular responses to
environmentary stimuli (400). The enormous quantity of data generated from each
experiment can be analysed to search pathways or gene clusters that respond to
experimentary conditions (401).
   The effect of agouti (Ay) and obese (Lepob) mutation on the gene expression profile of
AT has been studied using microarrays (402). Over one thousand transcripts were
significantly correlated with body mass, with a large proportion of these genes encoding
proteins which are characteristic of macrophages. The results suggested, and
histological data from both mice and humans confirmed, that the macrophage content of
AT correlated with BMI and adipocyte size (402). More recently, in abdominal SAT
from Pima Indians, most inflammation-related genes were upregulated in adipocytes of
obese subjects, emphasizing the active role of mature adipocytes in obesity-related
inflammation (403).
   In a comparison of omental AT gene expression of obese and lean subjects, 89 genes
were upregulated and 64 genes were downregulated in obese patients (404). The
downregulated genes were mostly lipolysis inducer genes and growth factor genes,
whereas the upregulated genes encoded mitogen-activated protein kinases, perhaps
pointing to an attempt to restrain adipocyte proliferation and differentiation.
Downregulation of genes normally associated with adipocyte differentiation was also
shown in mice (405, 406), suggesting that the adipocytes are engaged in a
dedifferentiation process that could be a consequence of their enlargement induced by
obesity.
   Effects of short-term weight reduction on AT gene expression profile have been
studied in humans. In one study, the effects of different hypocaloric diets on SAT gene
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expression were studied in obese women (407), revealing that weight loss of 7.5%
increased the expression of 52 genes whereas expression of 44 genes was decreased.
Most changes after a 10 week diet were modest (<25% of baseline), but all genes
regulating the formation of polyunsaturated FAs from acetyl-CoA and malonyl-CoA
were markedly down-regulated (30-60% decrease) (407). Weight reduction has been
shown to regulate the expression of inflammation-related genes in SAT of obese
subjects. Consumption of a VLCD for 28 days was shown to improve the inflammatory
profile by decreasing the levels of proinflammatory factors and increasing those of anti-
inflammatory molecules in SAT (408). The genes were mostly expressed in the
stromavascular fraction, which is known to contain macrophages. Long-term caloric
restriction in mice resulted in 345 differentially expressed genes (409, 410). Down-
regulated genes were classified as being involved in the cytoskeleton, extracellular
matrix (ECM), inflammation, or angiogenesis. Dietary restriction has been shown to
extend the life span and retard many age-related changes in laboratory rodents. A
comparison of altered genes showed that certain functions, such as metabolism, energy
metabolism, stress and immune response, cell growth, and transcription regulation were
shared across species (411).
   Genomic examination of AT has provided a wealth of information about changes in
gene expression in obesity and diabetes. It has been hypothesised that lack of lipogenic
adipocytes, whether due to extreme leanness (lipodystrophy) (412) or extreme obesity
(ob/ob mice), promotes diabetes due to an increase in the lipogenic burden experienced
by tissues other than adipose tissue. If the liver is capable of handling the burden,
normoglycaemic obesity is achieved; otherwise diabetes will be the consequence (401).
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3. AIMS OF THE STUDY
The present study was undertaken to investigate the association of selected candidate
genes with body weight and body weight changes and the incidence of diabetes in the
Finnish Diabetes Prevention Study (DPS). In addition, new putative candidate genes
were sought by examining the transcriptome of WAT in response to a weight reduction
intervention (Genobin) study. The specific aims of this study were:
1. To study the association of genetic variation in the B2AR, B3AR, and UCP1
genes with the incidence of T2DM and body weight (Study I)
2. To evaluate the association of genetic variation in the LEPR gene with the
incidence of T2DM and body weight (Study II)
3. To examine the association of genetic variation in the UCP2 and UCP3 genes
with the incidence of T2DM, body weight and serum cholesterol levels (Study
III)
4. To determine the effect of weight loss on the gene expression profile of AT in
subjects with features of MetS (Study IV)
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4. SUBJECTS AND METHODS
4.1. Subjects and study designs
4.1.1. The Finnish Diabetes Prevention Study (Studies I-III)
DPS is a randomised, controlled, multicenter study carried out in Finland in 1993-2000
(98, 109, 413). The study subjects were recruited through various methods with a
special emphasis on the high-risk groups such as obese subjects and first-degree
relatives of T2DM patients (109). The main inclusion criteria were as follows: BMI >25
kg/m2, age 40 to 64 years, IGT based on the mean values of two OGTT measurements.
Altogether 522 individuals with IGT were randomised into either a control group or an
intensive, individualised diet and exercise intervention group in five outpatient clinics
(Helsinki, Kuopio, Oulu, Tampere, and Turku). Randomisation to the intervention and
control groups was stratified according to the clinic, sex, and the mean plasma glucose
concentration two hours after an oral glucose load (7.8-9.4 or 9.5-11.0 mmol/l).
Baseline characteristics of the study subjects are presented in Table 13. The subjects
were excluded if they had a previous diagnosis of diabetes other than gestational
diabetes. Other exclusion criteria were vigourous exercise, active glucose-lowering
treatment other than routine dietary and health advice, and chronic diseases (413).
   The individuals in the intervention group received detailed and individually tailored
counselling on lifestyle, diet and exercise. The goals were (98):
-reduction in weight of 5%
-reduction in total intake of fat to <30% of daily energy intake
-reduction in the intake of saturated fat to <10% of daily energy intake
-increment in fibre intake at least to 15 grams per 1000 kcal
-moderate exercise for at least 30 minutes per day
   Each individual in the intervention group had seven individual sessions with a clinical
nutritionist during the first year of the study and then one session every three months.
The intervention group also received individual guidance on increasing the level of
physical activity. The control group received general advice about healthy food and the
importance of weight reduction and increased physical activity (98). The primary
outcome measure was the development of diabetes, and all the study subjects had an
OGTT at each annual visit. If the first OGTT showed diabetic values, the diagnosis was
confirmed by another OGTT done at least 1 week after the first one (413). The subject
continued in the study if his/her second OGTT showed non-diabetic values. A medical
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history was taken and a physical examination done at baseline and at each annual
follow-up visit.
4.1.2. The Genobin Study (Study IV)
Originally, 75 overweight or obese (BMI 28-40 kg/m2) subjects aged 40 to 70 years
were recruited to the study from the Kuopio area in 2004. Volunteers were recruited by
newspaper announcements and by inquiries made to subjects who had previously
participated in other studies arranged by the Department of Clinical Nutrition and the
Research Institute of Exercise Medicine. The subjects had IFG (FPG 5.6-7.0 mmol/l) or
IGT (2-h plasma glucose 7.8-11.0 mmol/l) and at least two other features of MetS
according to the ATPIII criteria (58) as modified by American Heart Association (414):
WC >102/88 cm (males/females), fasting serum TG concentration 1.7 mmol/l, fasting
serum HDL-cholesterol <1.0/1.3 mmol/l (males/females), BP 130/80 mm Hg.
   Subjects were randomised into one of the following groups: a weight reduction (WR)
group (n=28), aerobic exercise training group (n=15), resistance exercise training group
(n=14) or a control group (n=18). Subjects were matched for age, gender and the status
of glucose metabolism. In addition, 11 normal-weight subjects (mean age 48±9 years,
mean BMI 23.7±1.9 kg/m2) were recruited. For Study IV, only the WR group and the
control group were included. Baseline characteristics of the study subjects are presented
in Table 13.
   At screening, the health status and the medical history of the subjects were examined
by interview, and the liver, kidney and thyroid function were examined. OGTT, FSIGT,
AT biopsy, BP measurement, anthropometric measurements, and biochemical
measurements for serum total and lipoprotein lipids, serum FFA, and leptin were done
at baseline and after the intervention period. The biochemical, anthropometric and BP
measurements were performed also at the 12 weeks’ time point.
   The duration of the study varied between 32 and 38 weeks, the mean duration being
33.3 ± 1.1 weeks. The WR group had a 12-week intensive WR period. The aim for the
weeks 12-33 was to maintain the achieved weight loss. A clinical nutritionist provided
individual instructions to decrease the energy intake level based on an interview and 4-
day food records kept by the subjects at baseline. The subjects kept 4-day food records
twice during the intensive period and two times during weeks 20 to 33. Subjects were
asked to maintain their habitual level of physical exercise. Physical activity was
monitored by a questionnaire at the beginning and for weeks 12 and 33 of the study.
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   The control group subjects were advised to continue their normal lifestyle during the
study. They were given general advice for recommended diet and regular physical
activity according to current recommendations.
Table 13. Baseline characteristics of the subjects in Studies I-III and in Study IV.
DPS Genobin
Intervention
group
Control group Weight
reduction
group
Control group
N 265 257 28 18
Gender (M/F) 91/174 81/176 12/16 8/10
Age (years) 55±7 55±7 59±7 61±7
Weight (kg) 86.7±14.0 85.5±14.4 92.8±15.1 87.9±8.3
BMI (kg/m2) 31.3±4.6 31.0±4.5 32.9±3.2 32.4±2.5
Waist circumference (cm) 102±11 101±11 108±9 105±7
Fasting plasma glucose
 (mmol/l)
6.1±0.8 6.2±0.7 6.4±0.5 6.5±0.4
2-h plasma glucose
 (mmol/l)
8.9±1.5 8.9±1.5 6.9±2.0 8.0±2.4
Serum cholesterol
 (mmol/l)
5.6±1.0 5.6±0.9 5.2±1.0 5.5±1.1
Serum LDL-cholesterol
(mmol/l)
3.6±0.8 3.6±0.8 3.4±0.9 3.6±0.9
Serum HDL-cholesterol
 (mmol/l)
1.2±0.3 1.2±0.3 1.2±0.2 1.3±0.2
Serum triglycerides
 (mmol/l)
1.7±0.8 1.7±0.8 1.5±0.6 1.8±0.6
Blood pressure (mm Hg)
          Systolic 140±18 136±17 * 137±17 137±12
          Diastolic 86±9 86±10 90±10 87±10
Data are mean ± SD. * P=0.03 for the comparison with the intervention group by two-tailed t-test. DPS,
Finnish Diabetes Prevention Study; M, male; F, female; BMI, body mass index; LDL, low density
lipoprotein; HDL, high density lipoprotein. Modified from Tuomilehto et al. 2001 (98), Lindström et al.
2003 (415), and Kolehmainen et al. 2007 (416).
4.2. Methods
4.2.1. Anthropometric measurements
Weight and height were measured in light clothing, and BMI was calculated as kg/m2.
Waist and hip circumference were measured as described (109), and WHR (not
included in Study IV) was calculated. In Studies I-III also the sagittal and transverse
diameters were measured as described (109). The long-term weight change was
calculated as: [(weightend of follow-up – weightbaseline)/ weightbaseline] x 100%. In Study IV,
the body composition was analysed by bioelectrical impedance (STA/BIA Body
Composition Analyser, Akern Bioresearch Srl, Firenze, Italy).
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4.2.2. Glucose tolerance tests
A 2-h OGTT was performed after consumption of 75 g of glucose. Samples for glucose
and insulin were taken at fasting and 120 min. The FSIGT in study IV was performed
by administrating 300 mg/kg body weight glucose as 50% solution through a catheter
inserted into an antecubital vein. During the first 10 minutes, blood samples were drawn
every two minutes and immediately before (19 min) the 20 min insulin bolus (0.03 U/kg
body weight). Plasma glucose and serum insulin concentrations were followed for 180
min, with altogether 25 blood samples being collected. The results for insulin Si, Sg and
AIR were derived using the MINMOD Millennium software (417).
4.2.3. Biochemical analyses
Plasma glucose was measured at each centre by standard methods in Studies I-III and
by hexokinase method (Thermo Clinical Labsystems, Vantaa, Finland) in Study IV. The
serum insulin concentration was measured in a central laboratory by a
radioimmunoassay method (Pharmacia, Uppsala, Sweden) in Studies I-III and by the
chemiluminescence sandwich method (ACS, Bayer A/S, Tarrytown, NY, USA) in
Study IV. Very low density lipoprotein (VLDL), low density lipoprotein (LDL), and
HDL were separated by ultracentrifugation (Beckman Optima L-90K, Beckman
Coulter, Inc., Fullerton, CA, USA), and the concentrations of total and lipoprotein
cholesterol and total TG were analysed by enzymatic methods (Roche Diagnostics,
Mannheim, Germany) with Kone Pro Clinical Chemistry Analyser (Thermo Clinical
Labsystems, Konelab, Espoo, Finland) (Study IV). Serum total cholesterol, HDL-
cholesterol and TG were determined using an enzymatic CHOD-PAP method
(Monotest, Boehringer Mannheim GmbH, Mannheim, Germany) in Studies I-III. The
Friedewald formula (418) was used to calculate the concentration of LDL-cholesterol. A
commercial radioimmunoassay kit was used for the analysis of serum leptin
concentration (Linco Research Inc., St Louis, MO, USA) in Study IV.
   HOMA-IR was calculated in Studies I-III using the following formula: fasting plasma
glucose (mmol/l) x fasting serum insulin (mU/l)/22.5 (419). Homeostasis model
assessment for insulin secretion (HOMA-IS) was calculated in Studies I-III as 20 x
fasting serum insulin (mU/l)/(fasting plasma glucose [mmol/l] – 3.5) (419).
4.2.4. Adipose tissue biopsy (Study IV)
AT samples were drawn by syringe from abdominal SAT under local anesthesia
(lidocaine 10 mg/ml, without adrenaline), after an overnight fast, to collect 0,5-5 g of
AT. AT samples for the mRNA expression studies were washed twice with phosphate
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buffered saline (PBS, Invitrogen, Carlsbad, California, USA) and stored in RNAlater
(Ambion, Austin, TX, USA) for 24 h at 4°C. RNAlater was removed and tissues were
stored at -80°C until used for RNA extraction.
   Part of the AT sample was taken for the cell size measurement. These samples were
immediately placed in PBS and the isolation procedure was started within 30 min.
Adipocytes were isolated by the modification of Ohisalo et al. (420) of the method of
Rodbell (421) in the presence of collagenase (0.5 mg/ml) with constant shaking in water
bath at 37°C, and median adipose cell diameter was estimated by direct microscopy
(Olympus CH-2, Olympus, Tokyo, Japan) of isolated cells.
4.2.5. Genetics and transcriptomics
4.2.5.1. DNA extraction and genotyping (Studies I-III)
In study I, DNA was available from 490 individuals (161 men and 329 women). Their
mean BMI was 31.3 ± 4.6 kg/m2 and age 55.3 ± 7.1 years. In studies II and III, DNA
was available from 507 individuals (166 men and 341 women). Their mean BMI was
31.2 ± 4.5 kg/m2 and age 55.3 ± 7.1 years.
   Genomic DNA in Studies I-III was prepared from peripheral blood leucocytes by the
Puregene® DNA Purification Kit (Gentra Systems, Inc. Minneapolis, USA), which is
based on alcohol and salt precipitation. Variants in B2AR, B3AR, UCP1, UCP2, UCP3
(rs1800849), and LEPR genes were genotyped by PCR-RFLP methods, which are
presented in Table 14. Variants rs653529, rs15763, rs1726745, rs3781907 and
rs11235972 of UCP2 were genotyped by using the custom Golden Gate genotyping
reagents and consumables (Illumina Inc, San Diego, CA, USA). Due to technical
problems, only 501 (rs1726745) or 502 (rs653529, rs15763, rs3781907, rs11235972)
subjects could be genotyped by Illumina.
4.2.5.2. RNA extraction (Study IV)
Total RNA from AT was extracted by using the TRIzol reagent (1 ml/100 mg tissue)
(Invitrogen, Carlsbad, CA, USA) followed by further purification with RNeasy Mini Kit
columns (Qiagen, Valencia, CA, USA) according to the instructions provided by the
manufacturers. The RNA concentration and the A260/A280 ratio was measured using
NanoDrop spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA), the
acceptable ratio being 1.9-2.1. Integrity of the RNA was assessed using agarose gel
electrophoresis.
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4.2.5.3. Probe preparation for microarray (Study IV)
RNA samples from ten subjects from both the WR and control groups were chosen for
microarray analyses based on their success in the intervention (weight loss 5% in the
WR group and weight unchanged in the control group) and the purity of the tissue
(avoidance of blood contamination) and RNA. One microarray chip for each tissue
sample taken at both baseline and at the 33 weeks’ timepoint from the same individual
was used for hybridization. Due to the technical problems with one microarray chip, the
microarray data from one subject had to be excluded. Thus, the final number of subjects
in the WR group was nine.
   Synthesis of biotin labelled complementary RNA (cRNA), hybridization to DNA
microarrays (Affymetrix HG-U133 Plus 2.0 GeneChip) and detection of hybridised
cRNA were performed as recommended by the manufacturer (Affymetrix Inc., Santa
Clara, CA, USA). Briefly, 2 µg of total RNA was used to generate double-stranded
cDNA by reverse transcription using the One-cycle cDNA Synthesis Kit. Labelled
cRNA was prepared from the double-stranded cDNA by in vitro transcription using the
IVT Kit. Biotinylated cRNA was fragmented and added to the hybridization cocktail.
Two hundred µl of this cocktail was used for hybridization of HG-U133 Plus 2.0 array
at 45°C for 16 hours in a hybridization oven at 60 rpm, followed by washings using the
GeneChip Fluidics Station 400. The arrays were stained with streptavidin-phycoerythrin
(Molecular Probes, Eugene, OR, USA), incubated with biotinylated anti-streptavidin
IgG (Vector Laboratories, Burlingame, CA, USA) and stained again with streptavidin-
phycoerythrin.
4.2.5.4. Quantitative real-time PCR (Study IV)
Quantitative real-time PCR (QPCR) was used to confirm the microarray gene
expression results. QPCR analyses were performed with TaqMan chemistry based
assays according to the instructions provided by the manufacturer in the ABI Prism
7500 analyser (Applied Biosystems, Carlsbad, CA, USA). The analysis for the relative
quantity of a specific gene before and after the intervention in 27 subjects of the WR
group and in 18 subjects of the control group was analysed in triplets. A standard curve
with the points of 0.025, 0.075, 0.3, 0.9, 1.8 ng/µl of cDNA, respectively, and calibrator
at a concentration of 0.3 ng/µl were used on every plate. The relative quantity was
analysed using ABI Prism 7500 SDS software. Quantities on each plate were first
corrected by the calibrator on the plate. The ratio of the amount per plate to the
corresponding values of endogenous control was then calculated. The endogenous
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control was chosen using Human Endogenous Control Kit (Applied Biosystems). With
respect to the 11 possible candidates, cyclophilin A1 was the best choice for human AT.
4.2.6. Statistical analyses
4.2.6.1. Statistical analyses of the clinical data
The data were analysed using the SPSS/WIN program versions 11.0, 11.5, and 14.0
(SPSS, Chigago, IL, USA). The normality of distributions of study variables was tested
with the Kolmogorov-Smirnov test with Lilliefors’ correction, and appropriate
transformation was used when necessary. For variables with a skewed distribution,
Kruskal-Wallis or Mann-Whitney test was used to compare means among groups.
Univariate analysis of variance was used to compare the effect of the gene variants on
continuous variables (Studies I-III), or to test the difference in the baseline
characteristics and in the changes among the groups (Study IV). Adjustment for age,
gender and baseline BMI/weight was done, when appropriate. In addition, serum lipid
concentrations were adjusted for the use of cholesterol lowering medication (Study III).
Paired samples T-test was used for comparing the baseline and endpoint measurements
within the study group (Study IV). Chi square test was used in the comparison of
categorical variables (Studies I-III). Correlation analyses were done using Pearson’s
method (Study IV). Partial correlation analysis with adjustment for baseline weight and
gender was used when appropriate (Study IV). The relative changes in parameters were
calculated as follows: [(parameter – parameterbaseline)/ parameterbaseline] x 100% (Studies
I-III). Longitudinal changes were examined by general linear model (GLM) for repeated
measures. Homogeneity of variances was tested using Levene’s test. Logistic regression
(Studies I-II) or Cox regression (Study III) analysis was performed to evaluate if the
gene variants predict the development of T2DM. Adjustment was made for the study
group, baseline weight, weight change (from baseline to 3-year measurement or to the
last measurement) and baseline fasting plasma glucose.
   Haplotype frequencies in Study II were estimated by using the EH programme.
Linkage disequilibrium (LD) statistics were calculated by using the expectation
maximization algorithm (2LD programme) (Study II) or by Haploview software (422)
(Study III). Haplotype analysis (including haplotype frequencies) in Study III was done
by THESIAS 3.1 (http://ecgene.net/genecanvas), which is based on the stochastic-EM
algorithm (423). Haplotype analyses of the quantitative variables were adjusted for age,
gender and BMI, when appropriate. The survival analysis for haplotypes was adjusted
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for the study group, baseline weight, weight change and baseline fasting plasma
glucose.
   A p-value <0.05 was considered statistically significant. Correction for multiple
hypothesis testing in Study III was performed with the false discovery rate (FDR) using
Q-value 1.0 software. 0 was estimated with bootstrap method (424) using 	 range from
0 to 0.9 by 0.05. Due to the distribution of p-values, the 	 was set to 0 for correcting the
results of Cox regression. In the text, q stands for FDR, and is reported for each p<0.05
and should be interpreted as the minimum FDR that is incurred when calling that test
significant. Data are given as means ± SD, unless otherwise indicated.
4.2.6.2. Array data extraction and analysis (Study IV)
The arrays were scanned using HP GeneArray Scanner 3000 (Affymetrix Inc.). Primary
data extraction was performed with Affymetrix GeneChip Operating Software. The
software produces a one-cell intensity file that contains probe-level intensities for each
chip. The detection calls were calculated using the Affymetrix detection algorithm
(Affymetrix, Statistical algorithms description document, 2002). Microarray data
analysis was performed with dChip (www.dchip.org) software. All chips were
normalised by using Invariant Set Normalization (425). Model based expression indexes
(MBEI) (426) were calculated to summarise expression levels. A perfect match/mis-
match difference model was used in the MBEI calculation, and outlier detection and
correction was applied. After preprocessing steps, only genes that were called ‘Present’
in more than 50 percent of the replicates in at least one of the two time points were
selected for further analysis. Differentially expressed genes were identified by using
paired t-test with p<0.01 producing slightly different FDR values for the WR and
control group. Differential expression of genes was examined within the groups. The set
of differentially expressed genes was clustered with dChip's hierarchical clustering
function. Before clustering, redundant probe sets were removed. Correlation was used
as distance metric and the centroid linkage method was applied. Finally, the
differentially expressed genes were grouped by their Gene Ontology (GO) annotations
(version update 3/2007).
4.2.7. Approvals of the Ethics Committees
The study procedures were approved by the Ethics Committee of the National Public
Health Institute in Helsinki, Finland (Studies I-III), and the Ethics Committee of the
District Hospital Region of Northern Savo and Kuopio University Hospital (Study IV).
All participants gave their written informed consent.
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5. RESULTS
5.1. Association studies (Studies I-III)
5.1.1. Genotype frequencies
Genotype and minor allele frequencies of the variants in UCP1, UCP2, UCP3, B2AR,
B3AR, and LEPR genes studied are presented in Table 15, together with the minor allele
frequencies in the reference population CEU (Utah residents with ancestry from
Northern and Western Europe) of the HapMap database (116). All the frequencies were
consistent with the Hardy-Weinberg equilibrium, and did not differ between the study
groups. With respect to B2AR and B3AR, we analysed combinations of genotypes; their
frequencies are shown in Table 16. The three variants in LEPR were in strong LD
(Table 17), as well as the variants in the UCP2-UCP3 gene cluster (Study III: Table 1).
Table 15. Genotype and allele frequencies of the variants studied in DPS.
Genotype frequencies
 (%) a
Gene/ variant Rs number
0 1 2
Minor allele
frequency
Minor allele
frequency (n)
in ref. population b
B2AR
Gln27Glu rs1042714 37 47 16 0.40 0.47 (120)
B3AR
Trp64Arg rs4994 86 13 1 0.08 0.21  (184)
UCP1
A(-3826)G rs1800661 60 35 4 0.22 0.08 (116)
UCP2
G(-866)A rs659366 36 47 17 0.40 0.33 (120)
Ala55Val rs660339 30 46 24 0.47 0.37 (120)
3’UTR Del/Ins - 50 41 9 0.30 -
UCP3
C(-55)T rs1800849 38 49 13 0.38 0.19 (120)
GA rs11235972 39 48 13 0.37 0.18 (120)
AG rs3781907 44 46 10 0.33 0.28 (120)
GA rs1726745 36 47 17 0.40 0.48 (100)
GA rs15763 62 33 5 0.22 0.27 (116)
AG rs653529 35 47 18 0.42 0.37 (120)
LEPR
Lys109Arg rs1137100 41 46 13 0.36 0.34 (120)
Gln223Arg rs1137101 19 47 34 0.57 0.55 (120)
3’UTR Del/Ins - 70 28 2 0.16 -
a 0, homogyzous for the major allele; 1, heterozygous; 2, homozygous for the minor allele
b Reference population CEU (Utah residents with ancestry from Northern and Western Europe),
representing one of the populations studied in the International HapMap project. n= number of alleles
studied.
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Table 16.Distribution of genotypes defined by the Gln27Glu variant of the B2AR gene and the
Trp64Arg variant of the B3AR gene.
Trp64Arg / B3ARn (%)
Trp64Trp Trp64Arg Arg64Arg Total
Gln27Glu / B2AR
Gln27Gln 155 (31.6) 22 (4.5) 2 (0.4) 179 (36.5)
Gln27Glu 196 (40.0) 33 (6.7) 2 (0.4) 231 (47.1)
Glu27Glu  69  (14.1) 10 (2.0) 1 (0.2) 80 (16.3)
Total 420 (85.7) 65 (13.3) 5 (1.0) 490
The grey area represents the protective genotype combination for T2DM.
n= number of subjects
Table 17. Pairwise linkage disequilibrium between the variants in the LEPR gene is shown as D'
and r2 values.
D'
variant Lys109Arg Gln223Arg 3’UTR Del/Ins
Lys109Arg - 0.98 0.99
Gln223Arg 0.40 - 0.79r2
3’UTR Del/Ins 0.11 0.16 -
   The rs-numbering of genetic variants became common during this work. However, in
order to prevent confusion with the original studies where rs-numbering was not used
(Studies I-II), rs-numbering is used only in Study III in this work. Furthermore, it
should be noted that deletion-insertion polymorphisms do not have rs-numbers.
   We were able to analyse haplotypes for UCP2, UCP3 and LEPR genes, because
several variants were studied in these genes. For LEPR, six haplotypes were observed
(Study II: Table 1) with the four most common haplotypes accounting for 98% of all
observed haplotypes. The most common haplotype (frequency 0.36) included the
Arg109, Arg223, and 3’UTR Del alleles of LEPR.
   For combined UCP2 and UCP3 gene cluster, three haploblocks were formed based on
solid spine of LD; block 1 (DelIns and rs660339 of the UCP2 gene), block 2 (rs659366,
rs653529, rs15763 and rs1726745 of the UCP2 and UCP3 genes), and block 3
(rs3781907, rs11235972 and rs1800849 of the UCP3 gene) (Study III: Figure 1, Table
4). Haplotype analysis was performed separately for blocks 1, 2 and 3. Only the
haplotypes with frequency 0.05 were included in the analysis; thus, block 1 consisted 3
haplotypes (DelC, InsT, DelT), block 2 consisted 4 haplotypes (GAGA, GAGG,
AGAG, AGGG) and block 3 consisted 3 different haplotypes (AGC, GAT, AAT).
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5.1.2. Associations with anthropometric measurements
Body weight differed in longitudinal analysis according to genotypes of the UCP1 A(-
3826)G and LEPR 3’UTR Del/Ins variants. The G(-3826)G homozygotes of the UCP1
and the 3’UTR Del/Del homozygotes of the LEPR had the highest weight during the 3-
year follow-up (p=0.029 and 0.020, respectively) (Study I: Figure 1). When the study
groups were analysed separately, the trend was significant in the intervention group
(p=0.046) and nonsignificant in the control group (Figure 6). No significant associations
were seen when the absolute (kg) or relative (%) body weight changes were studied
among the different genotypes (Study II: Table 3).
Figure 6. Changes in weight (kg) during the 3-year follow-up according to the 3’UTR Del/Ins
variant of the LEPR gene. Data are mean + SEM. Black figures, intervention group; white
figures, control group; circles, Del/Del genotype; triangles, Ins allele.
   For the UCP2 and UCP3 genes, four variants in the haploblock 2 associated with
indices of abdominal obesity: WC, waist-to-hip ratio (WHR) and waist-to-height ratio
(WHtR). Rs659366, rs653529, rs15763 and rs1726745 associated with WHR at
baseline (p=0.048, 0.009, 0.018 and 0.031, respectively), as subjects with rs659366-AA,
rs653529-GG, rs15763-AA and rs1726745-GG genotypes had the lowest WHR (Study
III: Table 2). Similar, although less consistent, associations were seen between these
variants and WC and WHtR. WC was associated with rs659366, rs653529 and
rs1726745, whereas WHtR was associated with rs653529, rs15763 and rs1726745
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(Study III: Table 2). Also the DelIns variation in UCP2 associated with WHR, with
subjects with the DelDel genotype having the highest WHR at baseline (p=0.017).
   Longitudinal analysis of WHR showed that subjects with rs653529-GG, rs15763-AA
and rs1726745-GG genotypes had the lowest WHR throughout the years 0-3 (p=0.025,
0.039 and 0.035, respectively) (Study III: Figure 2). Longitudinal analyses of WC and
WHtR showed similar results, WC associating with rs15763 (p=0.030) and WHtR
associating with rs15763 and rs1726745 (p=0.009 and 0.040, respectively).
5.1.3. Associations with glucose and insulin metabolism
For the UCP2 gene, fasting and 2-h plasma glucose levels differed according to
genotypes of rs660339 (p=0.006 and 0.025, respectively) and rs659366 (p=0.007 and
0.025, respectively). Specifically, the rs660339-CC and rs659366-AA homozygotes had
the highest fasting glucose concentrations and the rs660339-CC and rs659366-GG
homozygotes had the highest 2-h plasma glucose concentrations. In addition, rs653529
associated with 2-h plasma glucose level, AA homozygotes having the highest value
(p=0.028). However, none of the associations with glucose was dependent on the allele
dosage.
   With respect to the B2AR gene, there were differences in fasting and 2-h serum insulin
levels among the genotypes (p=0.018 and 0.009, respectively). The Gln27Glu
heterozygotes had the highest values, and the Glu27Glu homozygotes had the lowest
values; thus, the associations were not dependent on the allele dosage.
   Insulin secretion was studied by HOMA-IS. No differences at baseline or at 3-year
were seen among the genotypes. However, the 3-year change in HOMA-IS (unadjusted)
was associated similarly with three UCP2 variants (DelIns, rs660339, rs659366), the
intergenic region variant rs653529 and UCP3 variant rs15763, showing increased
values for wild-type subjects, intermediate for heterozygous and decreased values for
homozygous subjects (p=0.004, 0.016, 0.037, 0.018 and 0.016, respectively) (Figure 7).
When adjusted by age, gender and baseline BMI, the results remained significant for
DelIns and  rs660339, whereas they were no longer significant for rs659366, rs653529
and rs15763 (p=0.047, 0.029, 0.095, 0.098 and 0.168, respectively).
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Figure 7. Three-year change in HOMA-IS (%, mean ± SEM) according to the variants of the
UCP2 and UCP3 genes, analysed by Kruskal-Wallis test. Number of the subjects are shown in
the corresponding bars.
5.1.4. Associations with serum total and lipoprotein lipids
Rs1726745, rs3781907, rs11235972 and rs1800849 of the UCP3 gene associated with
serum total cholesterol and LDL-cholesterol levels. Subjects with rs1726745-GG,
rs3781907-GG, rs11235972-AA and rs1800849-TT genotypes had both the highest
serum total cholesterol (p=0.022, 0.005, 0.032 and 0.050, respectively), and serum
LDL-cholesterol concentrations (p=0.005, 0.004, 0.045 and 0.071, respectively).
Moreover, the total cholesterol-to-HDL-cholesterol ratio was highest for the subjects
with rs3781907-GG genotype (p=0.045) (Study III: Table 3).
   Longitudinal changes in serum cholesterol levels associated with rs3781907 of the
UCP3 gene, with AA homozygotes having the lowest total cholesterol (p=0.020) and
LDL-cholesterol concentrations (p=0.010) throughout the years 0-3 (Study III: Figure
3). The HDL-cholesterol level was lowest in the subjects with rs3781907-GG genotype
in the intervention group (p=0.041). Furthermore, the total cholesterol-to-HDL-
cholesterol ratio was highest in those subjects with the rs3781907-GG genotype in the
entire DPS (p=0.015).
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5.1.5. Conversion to T2DM
During the 3-year follow-up, 73 individuals (22 in the intervention group and 51 in the
control group) developed diabetes (98). During the extended follow-up time of 7 years
(4 years of intervention and 3 years of post-intervention follow-up) 185 individuals (75
in the intervention group and 110 in the control group) developed T2DM (111).
   The conversion to T2DM during the 3-year follow-up differed between the three
genotypes of the Gln223Arg in LEPR gene (Figure 8, Table 18) [OR=2.01 (95% CI
1.03-3.93)]. In addition, when the study groups were analysed separately, an association
was found for the 3’UTR Del/Ins in the UCP2 gene in the intervention group [OR=5.37
(95% CI 1.06-27.21)], and Lys109Arg in the LEPR gene in the control group [OR=2.38
(95% CI 1.18-4.81)] (Figure 8). Furthermore, a risk genotype combination was found in
the two variants of the B2AR and B3AR genes [OR 1.91 (95% CI 1.09-3.33)] in the
entire DPS, Glu27+Trp64Trp (for genotype frequencies see Table 16) being the
protective combination (Table 18).
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Figure 8. Three-year incidence of T2DM by group according to the Lys109Arg (A), Gln223Arg
(B) and 3’UTR Del/Ins (C) variants in LEPR [% (number of subjects who developed T2DM/
total number of subjects)]. Numbers in the bars represent the genotype frequencies. P-values
indicate the logistic regression analysis; P= NS, unless otherwise shown in the figure.
   When the follow-up time was extended to a median of 7 years (Table 18), subjects
with the rs3781907-G allele of the UCP3 gene were at risk for T2DM when compared
to subjects with AA genotype, with HR of 1.48 (95% CI 1.09-2.00) (p=0.011). When the
study groups were analysed separately, a similar HR was seen in control group [HR
1.58 (95% CI 1.06-2.33), p=0.024], whereas no risk was seen in intervention group.
The percentage of subjects with AA genotype converting to T2DM was 32.6%, whereas
it was 38.2% and 47.9% for the subjects with AG and GG genotypes, respectively
(p=0.039) (Study III: Table 3).
   Subjects in the intervention group with the UCP2 InsIns genotype were at a higher
risk compared to subjects with Del allele, with HR 2.53 (95% CI 1.11-5.73) (p=0.027).
This risk was not seen in the control group or in the entire DPS (Table 18).
   All three variants in the LEPR gene (Lys109Arg, Gln223Arg and 3’UTR Del/Ins)
associated with T2DM conversion in the control group with HR (95% CI) of 1.53 (1.04-
2.24), 1.92 (1.21-3.05) and 1.57 (1.06-2.34), respectively. With respect to the 3’UTR
Del/Ins, the association was seen in the entire DPS as well [HR 1.41 (1.03-1.92)], with
subjects with the Ins allele being at higher risk (Table 18).
355 141 11 176  77   6               179  64 5
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Table 18. Conversion to T2DM during the 3-year (OR) and 7-year (HR) follow-up by group
according to the statistically significant variants in UCP2, UCP3, B2AR, B3AR, and LEPR.
Odds ratio (OR)
Hazard ratio (HR)
Gene/
variant
Risk
genotype/
Subjects (n)
with the risk
genotypea
Intervention
group
Pb Control
group
Pb Entire
DPS
PC
B2AR+B3AR d combinatione
216
225
2.34
1.16
0.112
0.536
1.73
1.11
0.102
0.610
1.91
1.13
0.023
0.408
UCP2 Ins/Ins
3’UTR Del/Ins 42
45
5.37
2.53
0.042
0.027
1.77
0.82
0.269
0.560
2.35
1.12
0.052
0.670
UCP3 G allele
rs3781907 265
281
1.19
1.26
0.749
0.344
1.75
1.58
0.125
0.024
1.54
1.48
0.148
0.011
LEPR
Lys109Arg Lys109Lys
194
206
0.88
0.92
0.804
0.735
2.38
1.53
0.016
0.029
1.69
1.26
0.069
0.124
Gln223Arg Gln223Gln
90
97
1.55
0.83
0.468
0.571
2.33
1.92
0.047
0.006
2.01
1.39
0.042
0.080
3’UTR Del/Ins Ins allele
144
152
0.96
1.27
0.941
0.353
1.63
1.57
0.192
0.026
1.32
1.41
0.379
0.031
a Upper line, number of subjects in logistic regression analysis (3-year follow-up); lower line, number of
subjects in Cox regression analysis (7-year follow-up)
b Adjusted for baseline body weight, weight change, and baseline FPG
c Adjusted for baseline body weight, weight change, baseline FPG, and study group
d Adjustment made without baseline FPG
e Glu27+Trp64Trp is the protective combination, whereas other combinations are at risk
5.1.6. Haplotype analysis
Haplotype analysis was performed for LEPR gene (only the survival analysis) and
UCP2-UCP3 gene cluster, including nine variants. For UCP2-UCP3, haploblocks 1, 2
and 3 were analysed separately. Only those haplotypes with a frequency 0.05 were
included.
   No haplotypic associations for the studied baseline variables or 0-3 year change in
variables were found in block 1 of UCP2-UCP3. However, in block 2, the haplotype
AGAG had lower WHR at baseline when compared to the reference haplotype GAGA
(p=0.050) (Study III: Table 4). In block 3, the haplotype GAT had higher serum total
cholesterol (p=0.006) and LDL-cholesterol (p=0.024) at baseline when compared to the
reference haplotype AGC. Moreover, the haplotype AAT showed a greater decrease (0-3
years) in LDL-cholesterol level compared to the reference haplotype AGC (p=0.037).
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   The risk of T2DM was estimated by haplotypic survival analysis. None of the studied
haplotypes in the UCP2-UCP3 gene cluster exhibited any association with conversion
from IGT to T2DM. However, with respect to the LEPR gene, two risk haplotypes for
T2DM were found (Table 19), thus confirming the original results in Study II.
   All the main findings from the association studies (both individual gene variations and
haplotypic analyses) in DPS are summarized in Table 20.
Table 19. Conversion to T2DM (Hazard Risk Ratio, HRR) during the 7-year follow-up of the
entire study population according to the haplotypes in the LEPR gene.
Marker Freq. (%) Unadjusted model Adjusted model a
Lys109Arg Gln223Arg Del/Ins HRR (95% CI) p HRR (95% CI) p
Arg Arg Del 36 1 (reference) 1 (reference)
Lys Gln Del 28 NS NS
Lys Arg Del 20 1.45 (1.11-1.89) 0.006 1.35 (1.04-1.77) 0.027
Lys Gln Ins 14 1.42 (1.03-1.94) 0.030 1.62 (1.17-2.24) 0.004
a Adjusted by baseline weight, weight change, fasting plasma glucose and study group
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5.2. Gene expression studies (Study IV)
5.2.1. Clinical characteristics
Subjects in the WR group (n=28) and control group (n=18) did not differ in any of the
clinical variables at baseline (Study IV: Table 1). The 33–week intervention resulted,
however, in a significant reduction of body weight (p<0.001), BMI (p<0.001), WC
(p<0.001), lean body mass (p<0.01), FPG (p<0.001) and serum leptin concentration
(p<0.01) in the WR group, whereas no changes were seen in control group, showing a
significant difference between the groups (Study IV: Table 2). The slight improvement
of SI in the WR group associated with weight change (r=-0.44, p=0.026).
   Dietary fat intake decreased as intended in the WR group (p<0.05), whereas the fiber
content of the diet clearly decreased in the control group (p<0.01) (Study IV: Table 3).
   For the microarray analyses we wanted to include ten subjects from both WR and
control groups. In order to select those subjects most suitable for the microarray
analyses, the WR group was divided into those who lost  5% of their body weight
(n=11, Group 1) and those who lost < 5% (n=17, Group 2). We chose the ten subjects
with most reduced body weight, but due to some technical problems with one
microarray chip, the microarray data from one subject had to be excluded. Thus, 9 (4
males/5 females) subjects from the Group 1 were included in the microarray analyses.
They had lost more weight than the rest of the WR group (7.8 ± 2.9% vs. 3.3 ± 3.3%,
p=0.002). They also had increased SI and decreased fasting serum insulin and 2-hour
glucose concentrations along with improvements in measures of body adiposity when
compared to those selected for microarray analysis from the control group (n=10; 4
males/6 females) (Study IV: Table 4).
5.2.2. Gene expression in adipose tissue
The expression of 105 genes (FDR=13%) in the WR group changed during the
intervention (Study IV: Table 5). The expression of 82 % (86/105) of genes was down-
regulated in the WR group. Overall, the changes were modest, with fold changes
ranging from 0.67 to 1.68. When GO clusters for biological processes were assessed for
enrichment of genes into each cluster with p<0.001, seven clusters were found.  These
clusters were associated with the function of the ECM and cell death. The expression of
only 62 genes (82% of which were up-regulated) changed in the control group
(FDR=13%) and no clusters were formed. None of the genes were the same as those
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detected in the WR group. To verify the results of the microarray analysis, seven genes
showing either up- or down-regulation in the microarray analysis were confirmed by
QPCR analysis (Study IV: Figure 2, Table 6).
   One of the genes that showed the most pronounced change during the intervention
was the TNMD gene. The expression level of the TNMD in AT in women before and
after the intervention was about twice as high as in men in both study groups (p=0.014-
0.005 for gender difference within the group). This is in an agreement with the fact that
the TNMD is located in X-chromosome. Interestingly, the expression of the TNMD gene
in AT correlated significantly with fasting serum insulin, SI, body fat mass and lean
body mass, both before and after the intervention (Study IV: Figure 3).
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6. DISCUSSION
6.1. Methodological considerations
6.1.1. Subjects
The study subjects in DPS were overweight with IGT, and thus at high risk of
developing T2DM. Seventy-five percent of the cohort also had the MetS at the onset of
the study (427). The advantages of this population are i) homogenous, carefully selected
and phenotyped subjects, ii) the prospective study design with extensive longitudinal
follow-up data on key variables, iii) confirmation of new T2DM diagnosis in two
subsequent OGTTs, and iv) Finnish population with only few founders (428). On the
other hand, one drawback for genetic analyses in DPS is the limited power due to the
relatively small sample-size, particularly if the analyses are carried out in smaller sub-
groups. In particular, for a genetic variant with very low minor allele frequency, it is
difficult to undertake statistical testing with adequate power. However, the sample-sizes
in previous association studies rarely exceed the sample-size in DPS, as can be seen in
tables 7-12. Moreover, the thorough longitudinal data is a major advantage in DPS.
Other research groups investigating longitudinal lifestyle intervention studies in
individuals with IGT (99, 100, 104-106) have not carried out genetic association
studies, except for the DPP Study, where several genes (none of which is overlapping
with the genes in the present series of studies) have been studied in 3548 subjects (429-
435). Furthermore, since there are separate groups for lifestyle intervention and control
subjects in DPS, it is possible to analyse interactions between the group and genotypes
and this way acquire knowledge on gene-environment interactions (436-438).
Nevertheless, in this series of studies such interactions were not found.
   The study subjects in Genobin had either IGT or IFG and two additional features of
the MetS and were therefore also at high risk of converting to overt diabetes. In many
aspects, these subjects were similar to the study subjects in DPS. Also here, as in DPS,
the subjects were Finnish, middle-aged and overweight volunteers. The proportion of
women (57%) was higher than that of men, similarly to DPS (67%).
6.1.2. Selection of candidate genes
The candidate genes B2AR, B3AR, UCP1, UCP2 and UCP3 in Studies I and III relate to
EE and lipid and glucose metabolism, being therefore good choices as obesity candidate
genes. The LEPR gene examined in Study II is related to long-term weight regulation,
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satiety and eating behavior through CNS. Monogenic human obesity due to mutations in
leptin or leptin receptor genes is extremely rare. A great number of studies have been
carried out, to search for a possible common genetic variation in these candidate genes
associating to common human obesity. However, at that time this study was designed,
studies on Finnish (439-441), Italian (442), or French Caucasian (443) subjects found
no associations between common LEP gene variants and obesity; therefore we decided
to concentrate merely on LEPR gene, which had been shown to be highly polymorphic
and associate with obesity traits in several populations (374, 375, 378, 382, 384-386,
393, 394). All the candidate genes in this series of studies have been included in the
Human Obesity Gene Map (120, 444-448).
   Gene variants for each gene were selected on the basis of earlier reported association
studies by our group and by other research groups (Studies I-III) and later by using the
International HapMap database (116) and Tagger software (449) (Study III). It should
be noted that at that time that this work was started in 2002, it was common to study
only one variant, usually a missense variation, in one gene, instead of studying multiple
variants covering the genetic information of the entire gene, which has later become
virtually a requirement for genetic studies of polygenic diseases. This kind of progress
can be seen in Studies I-III where there were increasing numbers of gene variants
included in the studies.
6.1.3. Genotyping methods
Methods in genotyping have evolved with rapidity during this work. Initially, the
variants were genotyped with laborious PCR-RFLP methods with many hands-on steps,
whereas the last variants in the UCP3 gene were genotyped with Illumina’s high-
throughput oligo ligation method. When there are many manual steps, the sources of
error are numerous when compared to automated techniques. However, with the
traditional methods, all the minor allele homozygous samples in addition to ~10% of all
samples were routinely confirmed by a second analysis to guarantee that the results
were uniform. Control samples were included in the analysis as well. The amount of
digestion enzymes was optimized so that no partial digestion occurred. Furthermore, as
the genotype frequencies are compared to the reference population CEU, it is possible to
see that differences occur either using RFLP or Illumina method.
6.1.4. Haplotype analyses
At present, the haplotypic associations have not been studied as extensively as the
individual variants, and furthermore, SNP selection rarely matches from one study
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design to another. Even if the SNP selection would match, different LD statistics can
produce different haploblocks. Therefore it is challenging to draw comparisons between
the studies and certain ‘risk haplotypes’.
6.1.5. Statistical analyses
During the present series of studies, the statistical methodology changed so that T2DM
conversion was first studied by logistic regression with 3 years’ follow-up, and later on
by survival analysis (Cox regression) with 7 years’ follow-up. Hence, the possible
genetic risk factors were finally reanalysed such that both methods were used for all
gene variants. As expected, the results differed slightly from each other both due to the
length of the follow-up time and the different statistical analysis method. Nonetheless,
we regard the survival analysis as being more reliable, because it has a longer follow-up
time and is capable of dealing with the drop-outs, thus increasing the number of
individuals included in the analysis.
   The progress of the statistical procedures can also be seen with the use of FDR. As the
number of genetic association studies increased, the number of type I errors, i.e. false
positive findings, undoubtedly increased as well, so that the publication criteria became
more stringent, demanding more accurate statistical methods. Since the use of
Bonferroni correction might be too conservative for many purposes, thus increasing the
amount of type II errors, i.e. false negative findings, we ended up using FDR to correct
for multiple testing in the Study III. Results with significant p-values and high q-values
must be interpreted with caution, since they might represent false positive findings.
FDR is widely used in microarray studies with large data sets, also in Study IV.
6.1.6. Microarray studies
From the results of GO clustering in Study IV, it can be seen that most of the expression
alterations in SAT were noted in genes of ECM and cell death. Surprisingly, no GO
clusters directly referring to insulin signaling, lipid/ carbohydrate metabolism or
immune responses were seen, although an evident amelioration in insulin sensitivity due
to weight reduction was observed in the WR subgroup 2. We do not know the reasons
for this phenomenon, but it can be speculated that the changes in gene expression might
have occurred during the 12-week intensive weight reduction period, after which a new
state of balance had been attained. More frequent AT sampling, which was not carried
out in this study due to ethical reasons, might had revealed this possibility. Additionally,
the changes in gene expression are most probably modest, due to moderate results of the
intervention, and thus, might not be detected with this kind of robust microarray
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technology covering all the genes in the human genome. However, the intervention
resembles the clinical practice and thus, gives new information on the changes of gene
expression during every day clinical practice instead of those under more artificial
experimental settings.
   Furthermore, this was also a question of data handling, for which no well-established
rules existed, and a wide variety of different methods have been used in the field. If we
had chosen less stringent statistical criteria when analysing the huge amount of
microarray data in this study, we would have ended up with >300 genes with >10
clusters involving different aspects of the immune response or its regulation. The
statistical boundaries must be clearly defined in order to determine the reliable results
inside such a massive dataset. In the present study, we applied stringent statistical
criteria (FDR 13%, p<0.01) in order to deal with interindividual variation, which is
always present in human studies, no matter how homogeneous the study population.
Today, the methodology for the statistical analyses of transcriptomic data is becoming
more standardized and it is rather well established which procedures should be
performed during the handling of data from the raw data until the final clustering steps.
   Moreover, our study was focused on SAT, thus, we do not know the magnitude of
gene expression alterations that have taken place in VAT, muscle, liver or pancreas, for
example. However, recent gene expression studies in peripheral blood mononuclear
cells (PBMC) in the Genobin Study have detected that the downregulation of the genes
involved in NF
B activation after weight loss is associated with the improvement of
insulin sensitivity (450). Moreover, weight reduction resulted in a decrease of the
expression of IL-1, IL-1 receptor antagonist, and TNF and an increase of expression
of IL-6 and IL-8 in PBMC (451). Further gene expression studies on PBMC and AT are
ongoing in the Genobin Study.
6.2. General discussion
When compared to traditional methods in genetic studies of polygenic diseases, such as
association studies, the novel GWAS strategy seems to be very effective and powerful.
It can be regarded as a major advance in the methodology, providing researchers with
highly significant novel candidate genes. However, the traditional candidate gene
studies will remain important for replication and there will always be a need for more
in-depth information on any novel findings. One recent GWAS examining a very large
population has discovered new insights into complex diseases of major public health
importance, such as T2DM, CAD, hypertension and type 1 diabetes among others
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(117). Six new genes for T2DM and one for obesity have been found by GWAS,
located on chromosomes 3 (IGF2BP2), 6 (CDKAL1), 8 (SLC30A8), 9 (CDKN2B), 10
(HHEX-IDE), and 16 (FTO). Additionally, three ‘old’ candidate genes locating in
chromosomes 3 (PPAR), 10 (TCF7L2), and 11 (KCNJ11) were also confirmed by
GWAS. None of the candidate genes studied in this series of studies associated with
T2DM risk or adiposity in GWAS, which is not surprising due to the totally different
study settings.
6.2.1. Association studies on B2AR, B3AR and UCP1 genes
In Study I, the combination of Gln27Gln variant in the B2AR gene and the Arg64 allele
in the B3AR gene was associated with an increased incidence of T2DM compared with
the other genotypes. Since 46% of the study subjects possessed this high-risk genetic
constellation (either Gln27Gln genotype or Arg64 allele or both of them), we conclude
that this is a very common genetic factor predisposing to diabetes among the IGT
population. This kind of gene-gene interaction in the prevalence of T2DM has been
previously reported in a case-control association study (188), where 38% of 237 non-
diabetic individuals and 45% of 219 diabetic individuals possessed such a genotype
combination. Individuals homozygous for the low-risk alleles (Glu27 and Trp64) had a
lower prevalence of diabetes (OR=0.58) than individuals with the other genotype
combinations, similarly to the findings of our study (OR=0.52).
   Both of the risk genotypes (Gln27Gln genotype and Arg64 allele) individually
contributed a trend towards increased incidence of diabetes, although not statistically
significant. The Arg64 variant of the B3AR has been suggested to be associated with an
earlier onset of T2DM (232, 233, 250, 253), IR (249), decreased AIR and Sg (235).
Perfetti et al. (228) have shown that human pancreas is a major site for the expression of
the B3AR gene and that transfection of the cells with the Arg64 variant of the human
B3AR is associated with a decrease in glucose-dependent insulin secretion, and in the
ability to secrete insulin in response to the activation of the B3AR.
   The situation with the B2AR gene, seems to depend on the population being studied,
i.e. both Gln27 (188, 219) and Glu27 (185) alleles have been associated with T2DM
incidence. The Swedish study (188) also showed an association between higher fasting
insulin and non-esterified fatty acid (NEFA) concentrations and the Gln27 allele. It is
not known, however, whether altered lipolysis and higher NEFA concentrations are
genetically determined or result from the obesity common in subjects with T2DM (188).
In our study, the fasting insulin concentration was highest for the heterozygous
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individuals and lowest for the Glu27Glu homozygotes, i.e. it was independent of gene
allele dosage.
   The T2DM risk in Study I was studied with 3 years’ follow-up. However, when the
follow-up time was later extended to 7 years, the risk genotype combination no longer
existed, and neither of the genes associated with T2DM incidence individually. This
certainly reduces the importance of the original findings in Study I.
   In Study I, the promoter region variant A(-3826)G in the UCP1 gene associated with
anthropometric parameters. We used repeated measures GLM to analyse body weight
among the genotypes during the 3-year follow-up. This analysis is more powerful than
cross-sectional analyses, since it takes into account the periodic and random deviation.
This longitudinal analysis suggested that the individuals homozygous for GG have the
highest body weight, thus confirming the results from previous studies (166, 266, 283,
290). Esterbauer et al. (286) have shown that the sequence variations in the UCP1 gene
account for 19.3% of the variance in its expression. The lowest expression was seen in
obese G(-3826)G homozygous individuals and the highest expression detected in obese
individuals with the AA genotype. They also demonstrated that the A(-3826)G variant is
not a functional mutation but a marker for a frequent mutation resulting in reduced
mRNA expression in AT (286).
6.2.2. Association studies on UCP2 and UCP3 genes
As far as we are aware, Study III is the first study exploring the variants rs653529,
rs15763, rs1726745, rs3781907 and rs11235972 in the UCP3 gene. Interestingly,
subjects with rs3781907-G allele experienced a higher risk for T2DM and
dyslipidaemia compared to subjects homozygous for the common allele. However,
results with significant p-values and high q-values must be interpreted with caution,
since they might be false positive findings. In the case of the rs3781907-G association
with T2DM, FDR was 0.100, thus representing a finding of borderline significance.
Conversion to T2DM and the serum levels of total cholesterol, LDL-cholesterol and
total cholesterol-to-HDL-cholesterol ratio increased gene dose-dependently according to
rs3781907 genotypes. The UCP3 promoter variant rs1800849, which is located in the
same haploblock and is in LD with rs3781907, has been previously shown to associate
with increased (324) or decreased (343) risk of T2DM, increased skeletal muscle UCP3
mRNA expression (341), higher total, LDL- (343) and HDL-cholesterol concentrations
(353), higher (342) or lower BMI (346, 350, 353), higher WHR (345, 348) and higher
fat mass and lean mass (349). In this study, rs1800849 associated with higher total
cholesterol and LDL-cholesterol at baseline, both independently as well as a member of
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haploblock 3, in line with earlier studies (343). Interestingly, all the variants in
haploblock 3 associated with total and LDL-cholesterol at the baseline, although the
most consistent association with various lipid concentrations at baseline and
longitudinally was seen for rs3781907. FDR was low for these associations, which
further provides support for our findings. However, as no previous studies on this
variant exist, confirmation of the present results will be needed in other populations.
   Although none of the single variants in Study III associated with weight or BMI,
variants in haploblock 2 associated with several indices of abdominal obesity at baseline
(rs659366, rs653529, rs15763, rs1726745) and longitudinally (rs653529, rs15763,
rs1726745). Although WC and BMI are strongly correlated (452), WC, WHR and
WHtR are all more accurate predictors of obesity-related cardiovascular risk than BMI
(453), and together with serum lipid measurements, they offer a simple clinical marker
of excess visceral fat (452). In this study, the genetic variation in UCP2-UCP3 gene
cluster seems to associate with both serum lipids (haploblock 3) and also with indices of
abdominal obesity (haploblock 2). Our results should, however, be confirmed by others.
   With respect to the functional UCP2 promoter variant G(-866)A (rs659366), previous
studies have found an association with reduced obesity prevalence (306), reduced risk
of coronary heart disease (328), reduced (322), but also increased (305) risk of T2DM,
lower insulin secretion (307, 321), reduced insulin sensitivity (317), decreased (318) but
also increased (306) UCP2 mRNA level in AT, higher oxidative stress and CHD risk
(309) and increased TG, total cholesterol and LDL-cholesterol levels (316). In our
study, the subjects with the rs659366-A allele had lower WC and WHR at baseline,
compared to subjects with the G allele, both individually as well as a member of
haploblock 2. Also the insulin secretion, measured by HOMA-IS, seemed to decrease
most in the subjects with the rs659366-A allele during the follow-up, although no
differences were detected in this allele at the baseline. These findings are in line with
previous findings on rs659366 (306, 307, 321). FDR was low for the associations with
indices of abdominal obesity providing some support for the significance of this finding,
but high for the associations with HOMA-IS, which naturally weakens its strength.
Furthermore, adjustment by age, gender and BMI abolished the statistical significance
of the HOMA-IS association.
   UCP2 has been said to act as an adiposity angel and diabetes devil (293), whereas
increased expression of UCP3 has been suggested to associate with successful weight
loss (329). The SNPs locating in the promoter area of the UCP2 and UCP3 genes are
known to be associated with gene expression levels of the corresponding genes.
Specifically, rs659366-A in UCP2 and rs1800849-T in UCP3 have been shown to
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increase their gene expression, and thus these alleles could be protective against obesity.
In our study, the rs659366-A allele associated with lower WHR and WC at baseline,
which is in line with the studies of Esterbauer et al. (306). However, no association
between rs1800849 and obesity was seen in this study. Furthermore, the promoter area
variants were not associated with the risk of T2DM. This could be due to the relatively
small study population, but also the genetic ‘makeup’ and environmental factors vary
from one population to another.
6.2.3. Association studies on LEPR gene
In Study II we found that three LEPR gene variants associated with body weight or the
conversion to T2DM. Different genotypic combinations did not give any additional
information, thus, the three variants were analysed individually in the statistical
analyses.
   The main finding of Study II is that the benefits of a lifestyle intervention on i) the
risk of T2DM and ii) changes in body weight can be modified by variants in the LEPR
gene. Subjects possessing either the Lys109Lys or Gln223Gln genotype converted more
often from IGT to overt diabetes in the control group, whereas the changes in the
intervention group were nonsignificant, and also the interaction term between the study
group and the genotype was nonsignificant. An increased risk for Gln223Gln was seen
in the entire DPS as well, whereas it was nonsignificant for Lys109Lys. Thus, we can
conclude that the exonic variation in the LEPR gene is a modulating factor when
changing ones lifestyle, suggesting that IGT individuals with Lys109Lys or Gln223Gln
genotype are more amenable to benefit from lifestyle intervention than the other
genotypes, in order to prevent T2DM.
   When the follow-up time was later extended to 7 years, the results remained
somewhat similar. In addition to the risk genotypes Lys109Lys and Gln223Gln found
earlier, subjects with the 3’UTR Ins allele also had an increased risk of T2DM. This was
seen in the entire DPS, and in the control group. This strengthens our previous findings
about the LEPR gene. The haplotypic survival analysis, which was also done later,
further reinforced our findings on the individual variants. In this analysis, two risk
haplotypes for T2DM were found (see Results, Table 19). In contradiction to our
findings, one previous study claimed the 3’UTR Ins allele associated with reduced risk
of T2DM (375). However, that study was rather small, examining only 122 men
included.
   In the anthropometric measurements, no differences with respect to different LEPR
genotypes were seen at baseline or in absolute changes from baseline to the 3-year
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examination. However, when body weight was analysed longitudinally, the subjects
with 3’UTR Del/Del genotype had a higher weight than the subjects with the Ins allele.
Thus, we suggest that the Del/Ins variation could be involved in body weight regulation.
The 3’UTR Del/Ins variant may affect mRNA stability and abundance in the cell (374).
The Ins allele has been associated with lower serum insulin levels in obese individuals
(374, 375, 454). None of the earlier studies has shown any association between 3’UTR
Del/Ins variant and body weight, as we demonstrated in Study II. However, none of
them included IGT subjects, instead they examined morbidly obese subjects, (374, 454)
young healthy men (376) or a population-based cohort (375). As far as we are aware,
there is only one previous association study on LEPR variants in an IGT population
(378), but it did not cover the Del/Ins variant. In our study we included only overweight
or obese subjects with IGT, and 75% of the cohort also had the MetS (427). Thus, it is
not surprising that the results from these different study settings are not directly
comparable with each other.
   The Lys109Arg and Gln223Arg variants are within the region encoding the
extracellular domain of the leptin receptor and, therefore, amino acid changes affect all
isoforms of the receptor, since they all have identical extracellular and transmembrane
domains. A meta-analysis has been conducted on the association of these variants with
BMI and WC (392). The result was negative, but it did conclude that the effect of these
variants could be population-specific, and that the alleles might influence intermediate
traits or phenotypes (392). Wauters et al. (378) also studied women with IGT and
observed associations of the Lys109Arg and Gln223Arg variants with glucose and
insulin levels. They concluded that the LEPR gene could interact with factors associated
with IGT, such as hyperinsulinaemia or IR. In a recent study, Chiu et al. (380) found
that the Arg223 allele is associated with IR, explaining 6-7% of the variability in insulin
sensitivity. That study was conducted in 67 healthy Caucasian subjects, and it is
consistent with other studies on young and healthy populations (381, 385, 396) but
inconsistent with studies on postmenopausal women (378, 384), IGT (378) or
overfeeding (394). They speculated that this variant could contribute to the initiation of
the events leading to IR in a subset of subjects.
   All the associations found in Studies I-III are summarized and compared to findings
made in previous studies in Table 21.
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Table 21. Comparison of the main findings in Studies I-III with previous studies.
Comparison of the associated trait with
other association studies
The risk allelea
Gene/
variant
Rs number Similar results Contradictory
results
No previous
data available
This
study
Other
studies
B2AR
Gln27Glu rs1042714 T2DM T2DM Gln Glu
B3AR
Trp64Arg rs4994 T2DM Arg Arg
UCP1
A(-3826)G rs1800661 Obesity G G
UCP2
G(-866)A rs659366 Central obesity Insulin secretion G A
Ala55Val rs660339 Insulin secretion Ala Val
3’UTR
Del/Ins - Central obesity Central obesity - -
UCP3
C(-55)T rs1800849
Total and LDL
cholesterol T T
GA rs11235972
Total and LDL
cholesterol A -
AG rs3781907
Total, HDL, and
LDL cholesterol
T2DM G -
GA rs1726745
Total and LDL
cholesterol
Central obesity - -
GA rs15763
Central obesity
Insulin secretion G -
AG rs653529
Central obesity
Insulin secretion A -
LEPR
Lys109Arg rs1137100 T2DM Lys -
Gln223Arg rs1137101 T2DM Gln -
3’UTR
Del/Ins - Obesity T2DM - Del
a The risk allele is shown here if most of the findings are consistent. If the findings are inconsistent, or if
no previous data exists, the risk allele is marked as -.
6.2.4. Gene expression in adipose tissue
The objective of Study IV was to improve our understanding of the role of interaction
between nutrition and gene expression in subjects with features of MetS. Weight
reduction -sensitive candidate genes were searched by using microarray technology,
which was applied on SAT samples before and after the weight reduction intervention.
   The gene expression results in Study IV are well in line with previous microarray
studies on human SAT (407, 408, 455), in the respect that the alterations in gene
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expression induced by caloric restriction were modest; no fold-changes >1.68 or <0.67
were observed, and the amount of regulated genes was rather limited. This was expected
due to a mild, long-term (33 weeks) dietary intervention, during which many
compensatory effects may have occurred. On the other hand, a new perspective was
achieved with this kind of moderate, easily applicable diet with high compliance,
compared to other studies where more dramatic and sometimes experimental
interventions with hypoenergetic diets lasting for ten weeks (407, 455) or very low
calorie diet (VLCD) lasting for 28 days (408) have been used.
   It was shown in Study IV that gene expression in ECM and cell death GO clusters was
downregulated. AT has an abundant ECM, with every adipocyte supported by a
basement membrane, composed of collagens and other ECM proteins (456). The ECM
is a post-natally developed mesenchyme which provides scaffolding and structural
support for cells and organs. It is capable of exchanging information with cells and
thereby modulates a whole host of processes including development, cell migration,
attachment, differentiation, and repair (457). Due to the uncontrolled and chronic
injurious stimuli as occurs in MetS and T2DM, there is chronic activation of these
above processes resulting in fibrosis, structural derangement, tissue or organ
dysfunction, and ultimate failure as a result of loss of structure and function (457).
Recent studies have shown that the ECM is involved in inflammation (410, 458),
angiogenesis (459, 460) and in the development of cardiovascular dysfunction (457,
461). Excessive synthesis of ECM components in SAT of obese subjects has also been
shown to contribute to interstitial fibrosis and tissue deterioration (458). Long-term
energy restriction in mice resulted in suppression of the genes associated with ECM
(410), whereas an increased formation of ECM constituents was seen in WAT of rats,
which were exposed to early-life under-nutrition and subsequently developed visceral
obesity (462). Our results are in line with these studies in rodents.
   In addition to ECM constituents, also genes associated with cell death were
downregulated. Approximately 10% of fat cells are renewed annually at all adult ages
and levels of BMI (30). Neither adipocyte death nor generation rate is altered in early
onset obesity, pointing to a tight regulation of fat cell number during adulthood (30).
However, the production rate of fat cells in obese individuals is higher compared to lean
individuals (30). In mice it has been shown that adipocyte death is an early and
progressive event in diet-induced obesity, suggesting that there is a homeostatic
remodeling program that promotes AT expansion in response to energy surfeit (463).
Taking into account these findings, it seems logical that weight reduction resulted in
downregulation of genes involved in cell death in our study.
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   One of the most downregulated genes in this study was the tenomodulin gene with
fold change of 0.67 in the WR group (1.06 in the control group). Tenomodulin, a type II
transmembrane glycoprotein, is predominantly expressed in tendons, ligaments, and the
eye, and is believed to regulate tenocyte proliferation and to be involved in collagen
fibril maturation (464). Tendons and ligaments connect the elements of the
musculoskeletal system and are composed of densely packed collagen-rich connective
tissue. The cellular content of tendons is dominated by tenocytes, which surround the
collagen fibrils and create cell-cell and cell-ECM interactions (464). Tenomodulin,
similarly to its homolog, chondromodulin, is a putative angiogenesis inhibitor (465),
and it should be remembered that abnormal angiogenesis is a common complication in
T2DM (466). Subsequently, the genetic studies have shown that this gene associates
with obesity and conversion from IGT to T2DM (161), low-grade inflammation (162)
and serum lipids (467) in DPS, suggesting this gene may be linked to T2DM through
effects on systemic immune mediators.
   In addition to the WR group, Study IV provides gene expression data on a control
group, also including subjects with features of MetS, but not undergoing dietary
intervention. The list of genes with altered expression in the control group included far
fewer genes than the WR group, and none of them were overlapping. Moreover, the
majority of the genes were up-regulated instead of clearly observed down-regulation in
the WR group. Thus, it can be concluded that gene expression changes are occurring
also without any lifestyle intervention, possibly due to normal seasonal or daily
variation. Thus, the results of the intervention group need to be interpreted in the light
of this data. In addition, when interpreting the results, one should bear in mind the huge
interindividual variation in gene expression, which is an enormous challenge if one is
trying to find clear cut gene clusters among free living individuals.
6.3. Concluding remarks
Obesity and T2DM are consequences of complex interactions among multiple genetic
variants and environmental risk factors. As the common-disease-common-variant
hypothesis states the genetic predisposition is a result of multiple, relatively common
genetic variants with small or modest effects. It has been estimated that ~20 genes are
needed to explain 50% of the burden of a disease in the population if the predisposing
genotypes are common (25%), even though the individual risk ratios are relatively
small (RR=1.2-1.5) (468).
91
   Identification of the genetic elements of obesity and T2DM is one of the most
important areas of research because discovery of the risk genes would certainly
facilitate understanding of the disease, its complications, and its treatment, cure, and
prevention. However, there are many obstacles on the way to this goal. Association
studies very often end up with inconsistent results due to many confounding factors, of
which publication bias is one factor. Positive studies more likely find their way into the
literature than negative studies, and therefore the proportion of positive findings, both
true-positives and false-positives, is amplified. On the other hand, false-negative
findings are also common due to the fact that study designs are often underpowered to
detect small differences between groups, which may also have been the case with this
series of studies. Inconsistency also derives from differences in the ascertainment
scheme and study design, ethnic background, phenotyping and statistical analysis. Even
meta-analyses can produce different conclusions. Nonetheless, it is obvious that a
balanced, healthy diet, and maintenance of an ideal body weight is beneficial, no matter
which genotypic profile the individual has, although the genetic studies could reveal
genotypes with high predisposition to obesity and T2DM. However, it would certainly
be cost-effective, if the genetic ‘fingerprint’ could be utilized in directing the high-risk
individuals to either a lifestyle (diet and/or physical exercise) or a medical intervention,
depending on which effort has been proven to yield the best outcome for this particular
genotype-phenotype combination. At the present, this is not the case, yet.
   The novel methodology of GWAS represents a totally different basis for studying the
genetics of common diseases and complex traits. Research groups are combining their
resources, and the high speed of technical advances is also bringing down the huge costs
of this technology. Thus, it is now possible to have genome-wide information on both
genetic variation at the level of DNA and gene expression patterns at the level of
mRNA in a relatively wide range of tissues. When these techniques are combined with
appropriate data extraction procedures one can predict that major advances will be made
in this research field. Nevertheless, the level of proteomics should not be forgotten,
since it is the posttranslationally modified proteome that truly defines the phenotype.
Viewed in this more complex and realistic way, the link between genotype and
phenotype seems potentially rather remote, especially in the case of complex traits
weakly linked to multiple alleles (469). Nonetheless, as all the ‘omics’ technologies
have now become a reality, and data mining tools are available, it is reasonable to
assume that some ‘light at the end of the tunnel’ should soon be seen.
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7. SUMMARY
Study I:
The combination of the Gln27Gln genotype in the B2AR gene and the Arg64 allele in
the B3AR gene was associated with an increased T2DM incidence in subjects with IGT.
However, no risk genotype combinations were seen when the follow-up time was
extended. The G(-3826)G genotype in the UCP1 gene associated with greater weight
during the follow-up.
Study II:
Two variants in the LEPR gene were associated with T2DM incidence in subjects with
IGT, with Lys109Lys and Gln223Gln acting as risk genotypes. These results were
further confirmed in the extended follow-up time and haplotype analysis, where in
addition to Lys109Lys and Gln223Gln, also the 3’UTR Ins allele associated with
increased T2DM incidence. The 3’UTR Del/Del genotype associated with greater
weight during the follow-up.
Study III:
Four variants (rs3781907, rs1726745, rs11235972 and rs1800849) in the UCP3 gene
associated with total and LDL-cholesterol levels. The rs3781907 variant associated also
with a higher risk of converting to T2DM in subjects with IGT. Variants rs659366,
rs653529, rs15763 and rs1726745 in the UCP2-UCP3 gene cluster associated with
measures of abdominal obesity. A risk haplotype for WHR and for serum total and
LDL-cholesterol was also found.
Study IV:
Long-term moderate weight reduction in subjects with features of MetS resulted in
downregulation of gene expression in AT. Specifically, the expression of genes
involved in ECM and cell death was reduced. In general, the changes in gene expression
were modest. One of the genes in which the most remarkable changes occurred in was
tenomodulin, which is an interesting novel candidate gene which should be investigated
in detail in future studies.
93
8. REFERENCES
1. Laakso M, Uusitupa M. Tyypin 2 diabeteksen ehkäisy. Duodecim 2007: 123 (12):
1439-1447.
2. Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. J Clin
Endocrinol Metab 2004: 89 (6): 2595-2600.
3. Vidal H. Gene expression in visceral and subcutaneous adipose tissues. Ann Med
2001: 33 (8): 547-555.
4. Shen W, Wang Z, Punyanita M et al. Adipose tissue quantification by imaging
methods: a proposed classification. Obes Res 2003: 11 (1): 5-16.
5. Pouliot MC, Despres JP, Lemieux S et al. Waist circumference and abdominal
sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose
tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol
1994: 73 (7): 460-468.
6. Zhu S, Wang Z, Heshka S, Heo M, Faith MS, Heymsfield SB. Waist circumference
and obesity-associated risk factors among whites in the third National Health and
Nutrition Examination Survey: clinical action thresholds. Am J Clin Nutr 2002: 76 (4):
743-749.
7. Balkau B, Deanfield JE, Despres JP et al. International Day for the Evaluation of
Abdominal Obesity (IDEA): a study of waist circumference, cardiovascular disease, and
diabetes mellitus in 168,000 primary care patients in 63 countries. Circulation 2007:
116 (17): 1942-1951.
8. Suomen lihavuustutkijat ry:n asettama työryhmä. Adult obesity. Duodecim 2002: 118
(10): 1075-1088.
9. Alberti KG, Zimmet P, Shaw J. International Diabetes Federation: a consensus on
Type 2 diabetes prevention. Diabet Med 2007: 24 (5): 451-463.
10. Anonymous Obesity: preventing and managing the global epidemic. Report of a
WHO consultation. World Health Organ Tech Rep Ser 2000: 894 : i-xii, 1-253.
11. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM.
Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006:
295 (13): 1549-1555.
12. Kautiainen S, Rimpelä A, Vikat A, Virtanen SM. Secular trends in overweight and
obesity among Finnish adolescents in 1977-1999. Int J Obes Relat Metab Disord 2002:
26 (4): 544-552.
13. Lahti-Koski M, Harald K, Männistö S, Laatikainen T, Jousilahti P. Fifteen-year
changes in body mass index and waist circumference in Finnish adults. Eur J
Cardiovasc Prev Rehabil 2007: 14 (3): 398-404.
14. Suomen Lastenlääkäriyhdistys ry:n asettama työryhmä. Obesity among children.
Duodecim 2005: 121 (18): 2016-2024.
15. Walley AJ, Blakemore AI, Froguel P. Genetics of obesity and the prediction of risk
for health. Hum Mol Genet 2006: 15 Spec No 2 : R124-30.
16. Stein CJ, Colditz GA. The epidemic of obesity. J Clin Endocrinol Metab 2004: 89
(6): 2522-2525.
94
17. Cummings DE, Schwartz MW. Genetics and pathophysiology of human obesity.
Annu Rev Med 2003: 54 : 453-471.
18. Maes HH, Neale MC, Eaves LJ. Genetic and environmental factors in relative body
weight and human adiposity. Behav Genet 1997: 27 (4): 325-351.
19. Sorensen TI, Holst C, Stunkard AJ. Childhood body mass index--genetic and
familial environmental influences assessed in a longitudinal adoption study. Int J Obes
Relat Metab Disord 1992: 16 (9): 705-714.
20. Ravussin E, Bouchard C. Human genomics and obesity: finding appropriate drug
targets. Eur J Pharmacol 2000: 410 (2-3): 131-145.
21. Neel JV. Diabetes mellitus: a "thrifty" genotype rendered detrimental by "progress"?
Am J Hum Genet 1962: 14 : 353-362.
22. Goossens GH. The role of adipose tissue dysfunction in the pathogenesis of obesity-
related insulin resistance. Physiol Behav 2008: 94 (2): 206-218.
23. Morrison RF, Farmer SR. Hormonal signaling and transcriptional control of
adipocyte differentiation. J Nutr 2000: 130 (12): 3116S-3121S.
24. Rosen ED, Spiegelman BM. Adipocytes as regulators of energy balance and glucose
homeostasis. Nature 2006: 444 (7121): 847-853.
25. Ronti T, Lupattelli G, Mannarino E. The endocrine function of adipose tissue: an
update. Clin Endocrinol (Oxf) 2006: 64 (4): 355-365.
26. Koutnikova H, Auwerx J. Regulation of adipocyte differentiation. Ann Med 2001:
33 (8): 556-561.
27. Frayn KN, Karpe F, Fielding BA, Macdonald IA, Coppack SW. Integrative
physiology of human adipose tissue. Int J Obes Relat Metab Disord 2003: 27 (8): 875-
888.
28. Sorisky A, Magun R, Gagnon AM. Adipose cell apoptosis: death in the energy
depot. Int J Obes Relat Metab Disord 2000: 24 Suppl 4 : S3-7.
29. Fruhbeck G, Gomez-Ambrosi J, Muruzabal FJ, Burrell MA. The adipocyte: a model
for integration of endocrine and metabolic signaling in energy metabolism regulation.
Am J Physiol Endocrinol Metab 2001: 280 (6): E827-47.
30. Spalding KL, Arner E, Westermark PO et al. Dynamics of fat cell turnover in
humans. Nature 2008: 453 (7196): 783-787.
31. Large V, Arner P. Regulation of lipolysis in humans. Pathophysiological modulation
in obesity, diabetes, and hyperlipidaemia. Diabetes Metab 1998: 24 (5): 409-418.
32. Lafontan M, Berlan M. Fat cell adrenergic receptors and the control of white and
brown fat cell function. J Lipid Res 1993: 34 (7): 1057-1091.
33. Arner P. Adrenergic receptor function in fat cells. Am J Clin Nutr 1992: 55 (1
Suppl): 228S-236S.
34. Langin D. Adipose tissue lipolysis as a metabolic pathway to define
pharmacological strategies against obesity and the metabolic syndrome. Pharmacol Res
2006: 53 (6): 482-491.
35. Arner P, Hoffstedt J. Adrenoceptor genes in human obesity. J Intern Med 1999: 245
(6): 667-672.
36. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional
cloning of the mouse obese gene and its human homologue. Nature 1994: 372 (6505):
425-432.
95
37. Kim S, Moustaid-Moussa N. Secretory, endocrine and autocrine/paracrine function
of the adipocyte. J Nutr 2000: 130 (12): 3110S-3115S.
38. de Ferranti S, Mozaffarian D. The perfect storm: obesity, adipocyte dysfunction, and
metabolic consequences. Clin Chem 2008: 54 (6): 945-955.
39. Yan QW, Yang Q, Mody N et al. The adipokine lipocalin 2 is regulated by obesity
and promotes insulin resistance. Diabetes 2007: 56 (10): 2533-2540.
40. Ahima RS, Qi Y, Singhal NS, Jackson MB, Scherer PE. Brain adipocytokine action
and metabolic regulation. Diabetes 2006: 55 Suppl 2 : S145-54.
41. Lago F, Dieguez C, Gomez-Reino J, Gualillo O. The emerging role of adipokines as
mediators of inflammation and immune responses. Cytokine Growth Factor Rev 2007:
18 (3-4): 313-325.
42. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006:
444 (7121): 881-887.
43. Fox CS, Massaro JM, Hoffmann U et al. Abdominal visceral and subcutaneous
adipose tissue compartments: association with metabolic risk factors in the Framingham
Heart Study. Circulation 2007: 116 (1): 39-48.
44. Arner P. Regional adipocity in man. J Endocrinol 1997: 155 (2): 191-192.
45. Nedergaard J, Bengtsson T, Cannon B. Unexpected evidence for active brown
adipose tissue in adult humans. Am J Physiol Endocrinol Metab 2007: 293 (2): E444-
52.
46. Virtanen KA, Lidell ME, Orava J et al. Functional brown adipose tissue in healthy
adults. N Engl J Med 2009: 360 (15): 1518-1525.
47. Cypess AM, Lehman S, Williams G et al. Identification and importance of brown
adipose tissue in adult humans. N Engl J Med 2009: 360 (15): 1509-1517.
48. van Marken Lichtenbelt WD, Vanhommerig JW, Smulders NM et al. Cold-activated
brown adipose tissue in healthy men. N Engl J Med 2009: 360 (15): 1500-1508.
49. Trayhurn P, Bing C, Wood IS. Adipose tissue and adipokines--energy regulation
from the human perspective. J Nutr 2006: 136 (7 Suppl): 1935S-1939S.
50. Allison DB, Fontaine KR, Manson JE, Stevens J, VanItallie TB. Annual deaths
attributable to obesity in the United States. JAMA 1999: 282 (16): 1530-1538.
51. Kopelman PG. Obesity as a medical problem. Nature 2000: 404 (6778): 635-643.
52. Bray GA. Medical consequences of obesity. J Clin Endocrinol Metab 2004: 89 (6):
2583-2589.
53. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005: 365
(9468): 1415-1428.
54. Karelis AD, St-Pierre DH, Conus F, Rabasa-Lhoret R, Poehlman ET. Metabolic and
body composition factors in subgroups of obesity: what do we know? J Clin Endocrinol
Metab 2004: 89 (6): 2569-2575.
55. Grundy SM, Brewer HB,Jr, Cleeman JI et al. Definition of metabolic syndrome:
Report of the National Heart, Lung, and Blood Institute/American Heart Association
conference on scientific issues related to definition. Circulation 2004: 109 (3): 433-438.
56. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus
and its complications. Part 1: diagnosis and classification of diabetes mellitus
provisional report of a WHO consultation. Diabet Med 1998: 15 (7): 539-553.
96
57. Balkau B, Charles MA, Drivsholm T et al. Frequency of the WHO metabolic
syndrome in European cohorts, and an alternative definition of an insulin resistance
syndrome. Diabetes Metab 2002: 28 (5): 364-376.
58. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in
Adults. Executive Summary of The Third Report of The National Cholesterol Education
Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood
Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001: 285 (19): 2486-2497.
59. Alberti KG, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group.
The metabolic syndrome--a new worldwide definition. Lancet 2005: 366 (9491): 1059-
1062.
60. Hanley AJ, Wagenknecht LE, D'Agostino RB,Jr, Zinman B, Haffner SM.
Identification of subjects with insulin resistance and beta-cell dysfunction using
alternative definitions of the metabolic syndrome. Diabetes 2003: 52 (11): 2740-2747.
61. Bo M, Sona A, Astengo M et al. Metabolic syndrome in older subjects: Coincidence
or clustering? Arch Gerontol Geriatr 2009: 48 (2): 146-150 .
62. Laaksonen DE, Niskanen L, Lakka HM, Lakka TA, Uusitupa M. Epidemiology and
treatment of the metabolic syndrome. Ann Med 2004: 36 (5): 332-346.
63. Laclaustra M, Corella D, Ordovas JM. Metabolic syndrome pathophysiology: the
role of adipose tissue. Nutr Metab Cardiovasc Dis 2007: 17 (2): 125-139.
64. Kotronen A, Yki-Järvinen H. Fatty liver: a novel component of the metabolic
syndrome. Arterioscler Thromb Vasc Biol 2008: 28 (1): 27-38.
65. American Diabetes Association. Diagnosis and classification of diabetes mellitus.
Diabetes Care 2007: 30 Suppl 1 : S42-7.
66. Barroso I. Genetics of Type 2 diabetes. Diabet Med 2005: 22 (5): 517-535.
67. Haffner SM. Insulin resistance, inflammation, and the prediabetic state. Am J
Cardiol 2003: 92 (4A): 18J-26J.
68. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes:
estimates for the year 2000 and projections for 2030. Diabetes Care 2004: 27 (5): 1047-
1053.
69. Diamond J. The double puzzle of diabetes. Nature 2003: 423 (6940): 599-602.
70. Roglic G, Unwin N, Bennett PH et al. The burden of mortality attributable to
diabetes: realistic estimates for the year 2000. Diabetes Care 2005: 28 (9): 2130-2135.
71. Kahn SE. Clinical review 135: The importance of beta-cell failure in the
development and progression of type 2 diabetes. J Clin Endocrinol Metab 2001: 86 (9):
4047-4058.
72. Weyer C, Bogardus C, Pratley RE. Metabolic characteristics of individuals with
impaired fasting glucose and/or impaired glucose tolerance. Diabetes 1999: 48 (11):
2197-2203.
73. Bergman RN, Ader M, Huecking K, Van Citters G. Accurate assessment of beta-
cell function: the hyperbolic correction. Diabetes 2002: 51 Suppl 1 : S212-20.
74. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction
to the pathophysiology of Type 2 diabetes. Diabetologia 2003: 46 (1): 3-19.
75. Gerich JE. The genetic basis of type 2 diabetes mellitus: impaired insulin secretion
versus impaired insulin sensitivity. Endocr Rev 1998: 19 (4): 491-503.
97
76. Chen M, Bergman RN, Pacini G, Porte D,Jr. Pathogenesis of age-related glucose
intolerance in man: insulin resistance and decreased beta-cell function. J Clin
Endocrinol Metab 1985: 60 (1): 13-20.
77. Prigeon RL, Kahn SE, Porte D,Jr. Changes in insulin sensitivity, glucose
effectiveness, and B-cell function in regularly exercising subjects. Metabolism 1995: 44
(10): 1259-1263.
78. Kahn SE, Larson VG, Beard JC et al. Effect of exercise on insulin action, glucose
tolerance, and insulin secretion in aging. Am J Physiol 1990: 258 (6 Pt 1): E937-43.
79. Chen M, Halter JB, Porte D,Jr. The role of dietary carbohydrate in the decreased
glucose tolerance of the elderly. J Am Geriatr Soc 1987: 35 (5): 417-424.
80. Kahn SE, Beard JC, Schwartz MW et al. Increased beta-cell secretory capacity as
mechanism for islet adaptation to nicotinic acid-induced insulin resistance. Diabetes
1989: 38 (5): 562-568.
81. Beard JC, Ward WK, Halter JB, Wallum BJ, Porte D,Jr. Relationship of islet
function to insulin action in human obesity. J Clin Endocrinol Metab 1987: 65 (1): 59-
64.
82. Rader DJ. Effect of insulin resistance, dyslipidemia, and intra-abdominal adiposity
on the development of cardiovascular disease and diabetes mellitus. Am J Med 2007:
120 (3 Suppl 1): S12-8.
83. Pouliot MC, Despres JP, Nadeau A et al. Visceral obesity in men. Associations with
glucose tolerance, plasma insulin, and lipoprotein levels. Diabetes 1992: 41 (7): 826-
834.
84. Peiris AN, Sothmann MS, Hennes MI et al. Relative contribution of obesity and
body fat distribution to alterations in glucose insulin homeostasis: predictive values of
selected indices in premenopausal women. Am J Clin Nutr 1989: 49 (5): 758-764.
85. Abate N, Garg A, Peshock RM, Stray-Gundersen J, Grundy SM. Relationships of
generalized and regional adiposity to insulin sensitivity in men. J Clin Invest 1995: 96
(1): 88-98.
86. Rhodes CJ. Type 2 diabetes-a matter of beta-cell life and death? Science 2005: 307
(5708): 380-384.
87. Maedler K. Beta cells in type 2 diabetes - a crucial contribution to pathogenesis.
Diabetes Obes Metab 2008: 10 (5): 408-420.
88. Mathis D, Vence L, Benoist C. beta-Cell death during progression to diabetes.
Nature 2001: 414 (6865): 792-798.
89. Deng S, Vatamaniuk M, Huang X et al. Structural and functional abnormalities in
the islets isolated from type 2 diabetic subjects. Diabetes 2004: 53 (3): 624-632.
90. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell
deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003:
52 (1): 102-110.
91. Eizirik DL, Cardozo AK, Cnop M. The role for endoplasmic reticulum stress in
diabetes mellitus. Endocr Rev 2008: 29 (1): 42-61.
92. Green K, Brand MD, Murphy MP. Prevention of mitochondrial oxidative damage as
a therapeutic strategy in diabetes. Diabetes 2004: 53 Suppl 1 : S110-8.
93. Guillausseau PJ, Meas T, Virally M, Laloi-Michelin M, Medeau V, Kevorkian JP.
Abnormalities in insulin secretion in type 2 diabetes mellitus. Diabetes Metab 2008: 34
Suppl 2 : S43-8.
98
94. Adler A. Obesity and target organ damage: diabetes. Int J Obes Relat Metab Disord
2002: 26 Suppl 4 : S11-4.
95. Golay A, Ybarra J. Link between obesity and type 2 diabetes. Best Pract Res Clin
Endocrinol Metab 2005: 19 (4): 649-663.
96. Felber JP, Golay A. Pathways from obesity to diabetes. Int J Obes Relat Metab
Disord 2002: 26 Suppl 2 : S39-45.
97. Hales CN, Walker JB, Garland PB, Randle PJ. Fasting Plasma Concentrations of
Insulin, Non-Esterified Fatty Acids, Glycerol, and Glucose in the Early Detection of
Diabetes Mellitus. Lancet 1965: 1 (7376): 65-67.
98. Tuomilehto J, Lindström J, Eriksson JG et al. Prevention of type 2 diabetes mellitus
by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med
2001: 344 (18): 1343-1350.
99. Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of type
2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002: 346 (6): 393-
403.
100. Pan XR, Li GW, Hu YH et al. Effects of diet and exercise in preventing NIDDM in
people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes
Care 1997: 20 (4): 537-544.
101. Hajer GR, van Haeften TW, Visseren FL. Adipose tissue dysfunction in obesity,
diabetes, and vascular diseases. Eur Heart J 2008: 29 (24): 2959-2971.
102. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin
resistance and type 2 diabetes. Nature 2006: 444 (7121): 840-846.
103. Vidal J. Updated review on the benefits of weight loss. Int J Obes Relat Metab
Disord 2002: 26 Suppl 4 : S25-8.
104. Eriksson KF, Lindgärde F. Prevention of type 2 (non-insulin-dependent) diabetes
mellitus by diet and physical exercise. The 6-year Malmö feasibility study. Diabetologia
1991: 34 (12): 891-898.
105. Kosaka K, Noda M, Kuzuya T. Prevention of type 2 diabetes by lifestyle
intervention: a Japanese trial in IGT males. Diabetes Res Clin Pract 2005: 67 (2): 152-
162.
106. Ramachandran A, Snehalatha C, Mary S et al. The Indian Diabetes Prevention
Programme shows that lifestyle modification and metformin prevent type 2 diabetes in
Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 2006: 49
(2): 289-297.
107. Eriksson KF, Lindgärde F. No excess 12-year mortality in men with impaired
glucose tolerance who participated in the Malmö Preventive Trial with diet and
exercise. Diabetologia 1998: 41 (9): 1010-1016.
108. Li G, Zhang P, Wang J et al. The long-term effect of lifestyle interventions to
prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up
study. Lancet 2008: 371 (9626): 1783-1789.
109. Eriksson J, Lindström J, Valle T et al. Prevention of Type II diabetes in subjects
with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study
design and 1-year interim report on the feasibility of the lifestyle intervention
programme. Diabetologia 1999: 42 (7): 793-801.
99
110. Uusitupa M, Lindi V, Louheranta A et al. Long-term improvement in insulin
sensitivity by changing lifestyles of people with impaired glucose tolerance: 4-year
results from the Finnish Diabetes Prevention Study. Diabetes 2003: 52 (10): 2532-2538.
111. Lindström J, Ilanne-Parikka P, Peltonen M et al. Sustained reduction in the
incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes
Prevention Study. Lancet 2006: 368 (9548): 1673-1679.
112. Froguel P, Boutin P. Genetics of pathways regulating body weight in the
development of obesity in humans. Exp Biol Med (Maywood) 2001: 226 (11): 991-996.
113. Bell CG, Walley AJ, Froguel P. The genetics of human obesity. Nat Rev Genet
2005: 6 (3): 221-234.
114. Hirschhorn JN, Daly MJ. Genome-wide association studies for common diseases
and complex traits. Nat Rev Genet 2005: 6 (2): 95-108.
115. Saunders CL, Chiodini BD, Sham P et al. Meta-Analysis of Genome-wide Linkage
Studies in BMI and Obesity. Obesity (Silver Spring) 2007: 15 (9): 2263-2275.
116. International HapMap Consortium. A haplotype map of the human genome. Nature
2005: 437 (7063): 1299-1320.
117. Wellcome Trust Case Control Consortium. Genome-wide association study of
14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007: 447
(7145): 661-678.
118. Frayling TM. Genome-wide association studies provide new insights into type 2
diabetes aetiology. Nat Rev Genet 2007: 8 (9): 657-662.
119. O'Rahilly S, Farooqi IS, Yeo GS, Challis BG. Minireview: human obesity-lessons
from monogenic disorders. Endocrinology 2003: 144 (9): 3757-3764.
120. Rankinen T, Zuberi A, Chagnon YC et al. The human obesity gene map: the 2005
update. Obesity (Silver Spring) 2006: 14 (4): 529-644.
121. Scuteri A, Sanna S, Chen WM et al. Genome-Wide Association Scan Shows
Genetic Variants in the FTO Gene Are Associated with Obesity-Related Traits. PLoS
Genet 2007: 3 (7): e115.
122. Frayling TM, Timpson NJ, Weedon MN et al. A common variant in the FTO gene
is associated with body mass index and predisposes to childhood and adult obesity.
Science 2007: 316 (5826): 889-894.
123. Dina C, Meyre D, Gallina S et al. Variation in FTO contributes to childhood
obesity and severe adult obesity. Nat Genet 2007: 39 (6): 724-726.
124. Lappalainen TJ, Tolppanen AM, Kolehmainen M et al. The Common Variant in
the FTO Gene Did Not Modify the Effect of Lifestyle Changes on Body Weight: The
Finnish Diabetes Prevention Study. Obesity (Silver Spring) 2009: 17 (4): 832-836.
125. Yajnik CS, Janipalli CS, Bhaskar S et al. FTO gene variants are strongly associated
with type 2 diabetes in South Asian Indians. Diabetologia 2009: 52 (2): 247-252.
126. Das SK, Elbein SC. The Genetic Basis of Type 2 Diabetes. Cellscience 2006: 2
(4): 100-131.
127. Hanis CL, Boerwinkle E, Chakraborty R et al. A genome-wide search for human
non-insulin-dependent (type 2) diabetes genes reveals a major susceptibility locus on
chromosome 2. Nat Genet 1996: 13 (2): 161-166.
128. Bowden DW, Sale M, Howard TD et al. Linkage of genetic markers on human
chromosomes 20 and 12 to NIDDM in Caucasian sib pairs with a history of diabetic
nephropathy. Diabetes 1997: 46 (5): 882-886.
100
129. Hani e, Zouali H, Philippi A et al. Indication for genetic linkage of the
phosphoenolpyruvate carboxykinase (PCK1) gene region on chromosome 20q to non-
insulin-dependent diabetes mellitus. Diabetes Metab 1996: 22 (6): 451-454.
130. Zouali H, Hani EH, Philippi A et al. A susceptibility locus for early-onset non-
insulin dependent (type 2) diabetes mellitus maps to chromosome 20q, proximal to the
phosphoenolpyruvate carboxykinase gene. Hum Mol Genet 1997: 6 (9): 1401-1408.
131. Elbein SC, Hoffman MD, Teng K, Leppert MF, Hasstedt SJ. A genome-wide
search for type 2 diabetes susceptibility genes in Utah Caucasians. Diabetes 1999: 48
(5): 1175-1182.
132. Hanson RL, Ehm MG, Pettitt DJ et al. An autosomal genomic scan for loci linked
to type II diabetes mellitus and body-mass index in Pima Indians. Am J Hum Genet
1998: 63 (4): 1130-1138.
133. Busfield F, Duffy DL, Kesting JB et al. A genomewide search for type 2 diabetes-
susceptibility genes in indigenous Australians. Am J Hum Genet 2002: 70 (2): 349-357.
134. Vionnet N, Hani EH, Dupont S et al. Genomewide search for type 2 diabetes-
susceptibility genes in French whites: evidence for a novel susceptibility locus for early-
onset diabetes on chromosome 3q27-qter and independent replication of a type 2-
diabetes locus on chromosome 1q21-q24. Am J Hum Genet 2000: 67 (6): 1470-1480.
135. Francke S, Manraj M, Lacquemant C et al. A genome-wide scan for coronary heart
disease suggests in Indo-Mauritians a susceptibility locus on chromosome 16p13 and
replicates linkage with the metabolic syndrome on 3q27. Hum Mol Genet 2001: 10
(24): 2751-2765.
136. Lyssenko V, Almgren P, Anevski D et al. Genetic prediction of future type 2
diabetes. PLoS Med 2005: 2 (12): e345.
137. Stumvoll M, Haring H. The peroxisome proliferator-activated receptor-gamma2
Pro12Ala polymorphism. Diabetes 2002: 51 (8): 2341-2347.
138. Altshuler D, Hirschhorn JN, Klannemark M et al. The common PPARgamma
Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet
2000: 26 (1): 76-80.
139. Barroso I, Luan J, Middelberg RP et al. Candidate gene association study in type 2
diabetes indicates a role for genes involved in beta-cell function as well as insulin
action. PLoS Biol 2003: 1 (1): E20.
140. Gloyn AL, Weedon MN, Owen KR et al. Large-scale association studies of
variants in genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2
(KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated
with type 2 diabetes. Diabetes 2003: 52 (2): 568-572.
141. Nielsen EM, Hansen L, Carstensen B et al. The E23K variant of Kir6.2 associates
with impaired post-OGTT serum insulin response and increased risk of type 2 diabetes.
Diabetes 2003: 52 (2): 573-577.
142. Laukkanen O, Pihlajamäki J, Lindström J et al. Polymorphisms of the SUR1
(ABCC8) and Kir6.2 (KCNJ11) genes predict the conversion from impaired glucose
tolerance to type 2 diabetes. The Finnish Diabetes Prevention Study. J Clin Endocrinol
Metab 2004: 89 (12): 6286-6290.
143. Grant SF, Thorleifsson G, Reynisdottir I et al. Variant of transcription factor 7-like
2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet 2006: 38 (3): 320-323.
101
144. Sladek R, Rocheleau G, Rung J et al. A genome-wide association study identifies
novel risk loci for type 2 diabetes. Nature 2007: 445 (7130): 881-885.
145. Scott LJ, Mohlke KL, Bonnycastle LL et al. A genome-wide association study of
type 2 diabetes in Finns detects multiple susceptibility variants. Science 2007: 316
(5829): 1341-1345.
146. Diabetes Genetics Initiative of Broad Institute of Harvard and MIT, Lund
University, and Novartis Institutes of BioMedical Research, Saxena R, Voight BF et al.
Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride
levels. Science 2007: 316 (5829): 1331-1336.
147. Zeggini E, Weedon MN, Lindgren CM et al. Replication of genome-wide
association signals in UK samples reveals risk loci for type 2 diabetes. Science 2007:
316 (5829): 1336-1341.
148. Steinthorsdottir V, Thorleifsson G, Reynisdottir I et al. A variant in CDKAL1
influences insulin response and risk of type 2 diabetes. Nat Genet 2007: 39 (6): 770-
775.
149. Uusitupa M. Gene-diet interaction in relation to the prevention of obesity and type
2 diabetes: Evidence from the Finnish Diabetes Prevention Study. Nutr Metab
Cardiovasc Dis 2005: 15 (3): 225-233.
150. Lindi VI, Uusitupa MI, Lindström J et al. Association of the Pro12Ala
polymorphism in the PPAR-gamma2 gene with 3-year incidence of type 2 diabetes and
body weight change in the Finnish Diabetes Prevention Study. Diabetes 2002: 51 (8):
2581-2586.
151. Siitonen N, Lindström J, Eriksson J et al. Association between a deletion/insertion
polymorphism in the alpha2B-adrenergic receptor gene and insulin secretion and Type 2
diabetes. The Finnish Diabetes Prevention Study. Diabetologia 2004: 47 (8): 1416-
1424.
152. Kubaszek A, Pihlajamäki J, Komarovski V et al. Promoter polymorphisms of the
TNF-alpha (G-308A) and IL-6 (C-174G) genes predict the conversion from impaired
glucose tolerance to type 2 diabetes: the Finnish Diabetes Prevention Study. Diabetes
2003: 52 (7): 1872-1876.
153. Laukkanen O, Pihlajamäki J, Lindström J et al. Common polymorphisms in the
genes regulating the early insulin signalling pathway: effects on weight change and the
conversion from impaired glucose tolerance to Type 2 diabetes. The Finnish Diabetes
Prevention Study. Diabetologia 2004: 47 (5): 871-877.
154. Todorova B, Kubaszek A, Pihlajamäki J et al. The G-250A promoter
polymorphism of the hepatic lipase gene predicts the conversion from impaired glucose
tolerance to type 2 diabetes mellitus: the Finnish Diabetes Prevention Study. J Clin
Endocrinol Metab 2004: 89 (5): 2019-2023.
155. Laukkanen O, Lindström J, Eriksson J et al. Polymorphisms in the SLC2A2
(GLUT2) gene are associated with the conversion from impaired glucose tolerance to
type 2 diabetes: the Finnish Diabetes Prevention Study. Diabetes 2005: 54 (7): 2256-
2260.
156. Wang J, Kuusisto J, Vänttinen M et al. Variants of transcription factor 7-like 2
(TCF7L2) gene predict conversion to type 2 diabetes in the Finnish Diabetes Prevention
Study and are associated with impaired glucose regulation and impaired insulin
secretion. Diabetologia 2007: 50 (6): 1192-1200.
102
157. Siitonen N, Pulkkinen L, Mager U et al. Association of sequence variations in the
gene encoding adiponectin receptor 1 (ADIPOR1) with body size and insulin levels.
The Finnish Diabetes Prevention Study. Diabetologia 2006: 49 (8): 1795-1805.
158. Mager U, Lindi V, Lindström J et al. Association of the Leu72Met polymorphism
of the ghrelin gene with the risk of Type 2 diabetes in subjects with impaired glucose
tolerance in the Finnish Diabetes Prevention Study. Diabet Med 2006: 23 (6): 685-689.
159. Mager U, Kolehmainen M, Lindström J et al. Association between ghrelin gene
variations and blood pressure in subjects with impaired glucose tolerance. Am J
Hypertens 2006: 19 (9): 920-926.
160. Mager U, Degenhardt T, Pulkkinen L et al. Variations in the ghrelin receptor gene
associate with obesity and glucose metabolism in individuals with impaired glucose
tolerance. PLoS ONE 2008: 3 (8): e2941.
161. Tolppanen AM, Pulkkinen L, Kolehmainen M et al. Tenomodulin is associated
with obesity and diabetes risk: the Finnish diabetes prevention study. Obesity (Silver
Spring) 2007: 15 (5): 1082-1088.
162. Tolppanen AM, Pulkkinen L, Herder C et al. The genetic variation of the
tenomodulin gene (TNMD) is associated with serum levels of systemic immune
mediators--the Finnish Diabetes Prevention Study. Genet Med 2008: 10 (7): 536-544.
163. Lappalainen TJ, Tolppanen AM, Kolehmainen M et al. The common variant in the
FTO gene did not modify the effect of lifestyle changes on body weight: the Finnish
Diabetes Prevention Study. Obesity (Silver Spring) 2009: 17 (4): 832-836.
164. Valve R, Heikkinen S, Rissanen A, Laakso M, Uusitupa M. Synergistic effect of
polymorphisms in uncoupling protein 1 and beta3-adrenergic receptor genes on basal
metabolic rate in obese Finns. Diabetologia 1998: 41 (3): 357-361.
165. Sipiläinen R, Uusitupa M, Heikkinen S, Rissanen A, Laakso M. Polymorphism of
the beta3-adrenergic receptor gene affects basal metabolic rate in obese Finns. Diabetes
1997: 46 (1): 77-80.
166. Sivenius K, Valve R, Lindi V, Niskanen L, Laakso M, Uusitupa M. Synergistic
effect of polymorphisms in uncoupling protein 1 and beta3-adrenergic receptor genes on
long-term body weight change in Finnish type 2 diabetic and non-diabetic control
subjects. Int J Obes Relat Metab Disord 2000: 24 (4): 514-519.
167. Ji TH, Grossmann M, Ji I. G protein-coupled receptors. I. Diversity of receptor-
ligand interactions. J Biol Chem 1998: 273 (28): 17299-17302.
168. Chruscinski AJ, Rohrer DK, Schauble E, Desai KH, Bernstein D, Kobilka BK.
Targeted disruption of the beta2 adrenergic receptor gene. J Biol Chem 1999: 274 (24):
16694-16700.
169. Rohrer DK, Chruscinski A, Schauble EH, Bernstein D, Kobilka BK.
Cardiovascular and metabolic alterations in mice lacking both beta1- and beta2-
adrenergic receptors. J Biol Chem 1999: 274 (24): 16701-16708.
170. Dixon RA, Kobilka BK, Strader DJ et al. Cloning of the gene and cDNA for
mammalian beta-adrenergic receptor and homology with rhodopsin. Nature 1986: 321
(6065): 75-79.
171. Kobilka BK, Dixon RA, Frielle T et al. cDNA for the human beta 2-adrenergic
receptor: a protein with multiple membrane-spanning domains and encoded by a gene
whose chromosomal location is shared with that of the receptor for platelet-derived
growth factor. Proc Natl Acad Sci U S A 1987: 84 (1): 46-50.
103
172. Kobilka BK, Frielle T, Dohlman HG et al. Delineation of the intronless nature of
the genes for the human and hamster beta 2-adrenergic receptor and their putative
promoter regions. J Biol Chem 1987: 262 (15): 7321-7327.
173. Parola AL, Kobilka BK. The peptide product of a 5' leader cistron in the beta 2
adrenergic receptor mRNA inhibits receptor synthesis. J Biol Chem 1994: 269 (6):
4497-4505.
174. McGraw DW, Forbes SL, Kramer LA, Liggett SB. Polymorphisms of the 5' leader
cistron of the human beta2-adrenergic receptor regulate receptor expression. J Clin
Invest 1998: 102 (11): 1927-1932.
175. Rasmussen SG, Choi HJ, Rosenbaum DM et al. Crystal structure of the human
beta2 adrenergic G-protein-coupled receptor. Nature 2007: 450 (7168): 383-387.
176. Cherezov V, Rosenbaum DM, Hanson MA et al. High-resolution crystal structure
of an engineered human beta2-adrenergic G protein-coupled receptor. Science 2007:
318 (5854): 1258-1265.
177. Palczewski K, Kumasaka T, Hori T et al. Crystal structure of rhodopsin: A G
protein-coupled receptor. Science 2000: 289 (5480): 739-745.
178. Green SA, Cole G, Jacinto M, Innis M, Liggett SB. A polymorphism of the human
beta 2-adrenergic receptor within the fourth transmembrane domain alters ligand
binding and functional properties of the receptor. J Biol Chem 1993: 268 (31): 23116-
23121.
179. Green SA, Turki J, Innis M, Liggett SB. Amino-terminal polymorphisms of the
human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory
properties. Biochemistry 1994: 33 (32): 9414-9419.
180. Dishy V, Sofowora GG, Xie HG et al. The effect of common polymorphisms of
the beta2-adrenergic receptor on agonist-mediated vascular desensitization. N Engl J
Med 2001: 345 (14): 1030-1035.
181. Large V, Hellström L, Reynisdottir S et al. Human beta-2 adrenoceptor gene
polymorphisms are highly frequent in obesity and associate with altered adipocyte beta-
2 adrenoceptor function. J Clin Invest 1997: 100 (12): 3005-3013.
182. Ehrenborg E, Skogsberg J, Ruotolo G et al. The Q/E27 polymorphism in the beta2-
adrenoceptor gene is associated with increased body weight and dyslipoproteinaemia
involving triglyceride-rich lipoproteins. J Intern Med 2000: 247 (6): 651-656.
183. Mori Y, Kim-Motoyama H, Ito Y et al. The Gln27Glu beta2-adrenergic receptor
variant is associated with obesity due to subcutaneous fat accumulation in Japanese
men. Biochem Biophys Res Commun 1999: 258 (1): 138-140.
184. Hellström L, Large V, Reynisdottir S, Wahrenberg H, Arner P. The different
effects of a Gln27Glu beta 2-adrenoceptor gene polymorphism on obesity in males and
in females. J Intern Med 1999: 245 (3): 253-259.
185. Ishiyama-Shigemoto S, Yamada K, Yuan X, Ichikawa F, Nonaka K. Association
of polymorphisms in the beta2-adrenergic receptor gene with obesity,
hypertriglyceridaemia, and diabetes mellitus. Diabetologia 1999: 42 (1): 98-101.
186. Iwamoto N, Ogawa Y, Kajihara S et al. Gln27Glu beta2-adrenergic receptor
variant is associated with hypertriglyceridemia and the development of fatty liver. Clin
Chim Acta 2001: 314 (1-2): 85-91.
104
187. Rosmond R, Ukkola O, Chagnon M, Bouchard C, Björntorp P. Polymorphisms of
the beta2-adrenergic receptor gene (ADRB2) in relation to cardiovascular risk factors in
men. J Intern Med 2000: 248 (3): 239-244.
188. Carlsson M, Orho-Melander M, Hedenbro J, Groop LC. Common variants in the
beta2-(Gln27Glu) and beta3-(Trp64Arg)--adrenoceptor genes are associated with
elevated serum NEFA concentrations and type II diabetes. Diabetologia 2001: 44 (5):
629-636.
189. Meirhaeghe A, Helbecque N, Cottel D, Amouyel P. Beta2-adrenoceptor gene
polymorphism, body weight, and physical activity. Lancet 1999: 353 (9156): 896.
190. Santos JL, Perez-Bravo F, Martinez JA, Montalvo D, Albala C, Carrasco E. No
evidence for an association between genetic polymorphisms of beta(2)- and beta(3)-
adrenergic receptor genes with body mass index in Aymara natives from Chile.
Nutrition 2002: 18 (3): 255-258.
191. Kim SH, Kim DJ, Seo IA et al. Significance of beta2-adrenergic receptor gene
polymorphism in obesity and type 2 diabetes mellitus in Korean subjects. Metabolism
2002: 51 (7): 833-837.
192. Echwald SM, Sorensen TI, Tybjaerg-Hansen A, Andersen T, Pedersen O.
Gln27Glu variant of the human beta2-adrenoreceptor gene is not associated with early-
onset obesity in Danish men. Diabetes 1998: 47 (10): 1657-1658.
193. Oberkofler H, Esterbauer H, Hell E, Krempler F, Patsch W. The Gln27Glu
polymorphism in the beta2-adrenergic receptor gene is not associated with morbid
obesity in Austrian women. Int J Obes Relat Metab Disord 2000: 24 (3): 388-390.
194. Herrmann V, Buscher R, Go MM et al. Beta2-adrenergic receptor polymorphisms
at codon 16, cardiovascular phenotypes and essential hypertension in whites and
African Americans. Am J Hypertens 2000: 13 (9): 1021-1026.
195. Duarte NL, Colagiuri S, Palu T, Wang XL, Wilcken DE. Obesity, Type II diabetes
and the beta 2 adrenoceptor gene Gln27Glu polymorphism in the Tongan population.
Clin Sci (Lond) 2003: 104 (3): 211-215.
196. Terra SG, McGorray SP, Wu R et al. Association between beta-adrenergic receptor
polymorphisms and their G-protein-coupled receptors with body mass index and obesity
in women: a report from the NHLBI-sponsored WISE study. Int J Obes (Lond) 2005: 29
(7): 746-754.
197. Yamada K, Ishiyama-Shigemoto S, Ichikawa F et al. Polymorphism in the 5'-
leader cistron of the beta2-adrenergic receptor gene associated with obesity and type 2
diabetes. J Clin Endocrinol Metab 1999: 84 (5): 1754-1757.
198. Meirhaeghe A, Helbecque N, Cottel D, Amouyel P. Impact of polymorphisms of
the human beta2-adrenoceptor gene on obesity in a French population. Int J Obes Relat
Metab Disord 2000: 24 (3): 382-387.
199. Ukkola O, Rankinen T, Weisnagel SJ et al. Interactions among the alpha2-, beta2-,
and beta3-adrenergic receptor genes and obesity-related phenotypes in the Quebec
Family Study. Metabolism 2000: 49 (8): 1063-1070.
200. Ukkola O, Tremblay A, Bouchard C. Beta-2 adrenergic receptor variants are
associated with subcutaneous fat accumulation in response to long-term overfeeding. Int
J Obes Relat Metab Disord 2001: 25 (11): 1604-1608.
105
201. Meirhaeghe A, Luan J, Selberg-Franks P et al. The effect of the Gly16Arg
polymorphism of the beta(2)-adrenergic receptor gene on plasma free fatty acid levels is
modulated by physical activity. J Clin Endocrinol Metab 2001: 86 (12): 5881-5887.
202. Corbalan MS, Marti A, Forga L, Martinez-Gonzalez MA, Martinez JA. Beta(2)-
adrenergic receptor mutation and abdominal obesity risk: effect modification by gender
and HDL-cholesterol. Eur J Nutr 2002: 41 (3): 114-118.
203. Macho-Azcarate T, Marti A, Gonzalez A, Martinez JA, Ibanez J. Gln27Glu
polymorphism in the beta2 adrenergic receptor gene and lipid metabolism during
exercise in obese women. Int J Obes Relat Metab Disord 2002: 26 (11): 1434-1441.
204. Chang TJ, Tsai MH, Jiang YD et al. The Arg16Gly polymorphism of human
beta2-adrenoreceptor is associated with type 2 diabetes in Taiwanese people. Clin
Endocrinol (Oxf) 2002: 57 (5): 685-690.
205. Ukkola O, Rankinen T, Rice T et al. Interactions among the beta2- and beta3-
adrenergic receptor genes and total body fat and abdominal fat level in the HERITAGE
Family Study. Int J Obes Relat Metab Disord 2003: 27 (3): 389-393.
206. Martinez JA, Corbalan MS, Sanchez-Villegas A, Forga L, Marti A, Martinez-
Gonzalez MA. Obesity risk is associated with carbohydrate intake in women carrying
the Gln27Glu beta2-adrenoceptor polymorphism. J Nutr 2003: 133 (8): 2549-2554.
207. Gonzalez Sanchez JL, Proenza AM, Martinez Larrad MT et al. The glutamine 27
glutamic acid polymorphism of the beta2-adrenoceptor gene is associated with
abdominal obesity and greater risk of impaired glucose tolerance in men but not in
women: a population-based study in Spain. Clin Endocrinol (Oxf) 2003: 59 (4): 476-
481.
208. Garenc C, Perusse L, Chagnon YC et al. Effects of beta2-adrenergic receptor gene
variants on adiposity: the HERITAGE Family Study. Obes Res 2003: 11 (5): 612-618.
209. Pereira AC, Floriano MS, Mota GF et al. Beta2 adrenoceptor functional gene
variants, obesity, and blood pressure level interactions in the general population.
Hypertension 2003: 42 (4): 685-692.
210. Ikarashi T, Hanyu O, Maruyama S et al. Genotype Gly/Gly of the Arg16Gly
polymorphism of the beta2-adrenergic receptor is associated with elevated fasting serum
insulin concentrations, but not with acute insulin response to glucose, in type 2 diabetic
patients. Diabetes Res Clin Pract 2004: 63 (1): 11-18.
211. Ellsworth DL, Coady SA, Chen W, Srinivasan SR, Boerwinkle E, Berenson GS.
Interactive effects between polymorphisms in the beta-adrenergic receptors and
longitudinal changes in obesity. Obes Res 2005: 13 (3): 519-526.
212. Masuo K, Katsuya T, Fu Y, Rakugi H, Ogihara T, Tuck ML. Beta2- and beta3-
adrenergic receptor polymorphisms are related to the onset of weight gain and blood
pressure elevation over 5 years. Circulation 2005: 111 (25): 3429-3434.
213. Park HS, Kim Y, Lee C. Single nucleotide variants in the beta2-adrenergic and
beta3-adrenergic receptor genes explained 18.3% of adolescent obesity variation. J Hum
Genet 2005: 50 (7): 365-369.
214. Masuo K, Katsuya T, Fu Y, Rakugi H, Ogihara T, Tuck ML. Beta2-adrenoceptor
polymorphisms relate to insulin resistance and sympathetic overactivity as early
markers of metabolic disease in nonobese, normotensive individuals. Am J Hypertens
2005: 18 (7): 1009-1014.
106
215. Masuo K, Katsuya T, Kawaguchi H et al. Rebound weight gain as associated with
high plasma norepinephrine levels that are mediated through polymorphisms in the
beta2-adrenoceptor. Am J Hypertens 2005: 18 (11): 1508-1516.
216. Petrone A, Zavarella S, Iacobellis G et al. Association of beta2 adrenergic receptor
polymorphisms and related haplotypes with triglyceride and LDL-cholesterol levels.
Eur J Hum Genet 2006: 14 (1): 94-100.
217. Masuo K, Katsuya T, Kawaguchi H et al. Beta2-adrenoceptor polymorphisms
relate to obesity through blunted leptin-mediated sympathetic activation. Am J
Hypertens 2006: 19 (10): 1084-1091.
218. Kawaguchi H, Masuo K, Katsuya T et al. beta2- and beta3-Adrenoceptor
polymorphisms relate to subsequent weight gain and blood pressure elevation in obese
normotensive individuals. Hypertens Res 2006: 29 (12): 951-959.
219. Pinelli M, Giacchetti M, Acquaviva F et al. Beta2-adrenergic receptor and UCP3
variants modulate the relationship between age and type 2 diabetes mellitus. BMC Med
Genet 2006: 7 : 85.
220. Mo W, Zhang GG, Yang TL et al. The genetic polymorphisms of beta3-adrenergic
receptor (AR) Trp64Arg and beta2-AR Gln27Glu are associated with obesity in Chinese
male hypertensive patients. Clin Chem Lab Med 2007: 45 (4): 493-498.
221. Cannon B, Nedergaard J. Brown adipose tissue: function and physiological
significance. Physiol Rev 2004: 84 (1): 277-359.
222. Arner P. Genetic variance and lipolysis regulation: implications for obesity. Ann
Med 2001: 33 (8): 542-546.
223. Susulic VS, Frederich RC, Lawitts J et al. Targeted disruption of the beta 3-
adrenergic receptor gene. J Biol Chem 1995: 270 (49): 29483-29492.
224. Bachman ES, Dhillon H, Zhang CY et al. betaAR signaling required for diet-
induced thermogenesis and obesity resistance. Science 2002: 297 (5582): 843-845.
225. Jimenez M, Leger B, Canola K et al. Beta(1)/beta(2)/beta(3)-adrenoceptor
knockout mice are obese and cold-sensitive but have normal lipolytic responses to
fasting. FEBS Lett 2002: 530 (1-3): 37-40.
226. Muzzin P, Revelli JP, Kuhne F et al. An adipose tissue-specific beta-adrenergic
receptor. Molecular cloning and down-regulation in obesity. J Biol Chem 1991: 266
(35): 24053-24058.
227. Emorine LJ, Marullo S, Briend-Sutren MM et al. Molecular characterization of the
human beta 3-adrenergic receptor. Science 1989: 245 (4922): 1118-1121.
228. Perfetti R, Hui H, Chamie K et al. Pancreatic beta-cells expressing the Arg64
variant of the beta(3)-adrenergic receptor exhibit abnormal insulin secretory activity. J
Mol Endocrinol 2001: 27 (2): 133-144.
229. Wilkie TM, Chen Y, Gilbert DJ et al. Identification, chromosomal location, and
genome organization of mammalian G-protein-coupled receptors. Genomics 1993: 18
(2): 175-184.
230. Granneman JG, Lahners KN, Chaudhry A. Characterization of the human beta 3-
adrenergic receptor gene. Mol Pharmacol 1993: 44 (2): 264-270.
231. Clement K, Vaisse C, Manning BS et al. Genetic variation in the beta 3-adrenergic
receptor and an increased capacity to gain weight in patients with morbid obesity. N
Engl J Med 1995: 333 (6): 352-354.
107
232. Widen E, Lehto M, Kanninen T, Walston J, Shuldiner AR, Groop LC. Association
of a polymorphism in the beta 3-adrenergic-receptor gene with features of the insulin
resistance syndrome in Finns. N Engl J Med 1995: 333 (6): 348-351.
233. Walston J, Silver K, Bogardus C et al. Time of onset of non-insulin-dependent
diabetes mellitus and genetic variation in the beta 3-adrenergic-receptor gene. N Engl J
Med 1995: 333 (6): 343-347.
234. Hoffstedt J, Poirier O, Thorne A et al. Polymorphism of the human beta3-
adrenoceptor gene forms a well-conserved haplotype that is associated with moderate
obesity and altered receptor function. Diabetes 1999: 48 (1): 203-205.
235. Walston J, Silver K, Hilfiker H et al. Insulin response to glucose is lower in
individuals homozygous for the Arg 64 variant of the beta-3-adrenergic receptor. J Clin
Endocrinol Metab 2000: 85 (11): 4019-4022.
236. Fujisawa T, Ikegami H, Kawaguchi Y, Ogihara T. Meta-analysis of the association
of Trp64Arg polymorphism of beta 3-adrenergic receptor gene with body mass index. J
Clin Endocrinol Metab 1998: 83 (7): 2441-2444.
237. Kurokawa N, Nakai K, Kameo S, Liu ZM, Satoh H. Association of BMI with the
beta3-adrenergic receptor gene polymorphism in Japanese: meta-analysis. Obes Res
2001: 9 (12): 741-745.
238. Kurokawa N, Young EH, Oka Y et al. The ADRB3 Trp64Arg variant and BMI: a
meta-analysis of 44 833 individuals. Int J Obes (Lond) 2008: 32 (8): 1240-1249.
239. Allison DB, Heo M, Faith MS, Pietrobelli A. Meta-analysis of the association of
the Trp64Arg polymorphism in the beta3 adrenergic receptor with body mass index. Int
J Obes Relat Metab Disord 1998: 22 (6): 559-566.
240. Zhan S, Ho SC. Meta-analysis of the association of the Trp64Arg polymorphism in
the beta3 adrenergic receptor with insulin resistance. Obes Res 2005: 13 (10): 1709-
1719.
241. Gagnon J, Mauriege P, Roy S et al. The Trp64Arg mutation of the beta3 adrenergic
receptor gene has no effect on obesity phenotypes in the Quebec Family Study and
Swedish Obese Subjects cohorts. J Clin Invest 1996: 98 (9): 2086-2093.
242. Sun L, Ishibashi S, Osuga J et al. Clinical features associated with the homozygous
Trp64Arg mutation of the beta3-adrenergic receptor: no evidence for its association
with obesity in Japanese. Arterioscler Thromb Vasc Biol 1998: 18 (6): 941-946.
243. Ghosh S, Langefeld CD, Ally D et al. The W64R variant of the beta3-adrenergic
receptor is not associated with type II diabetes or obesity in a large Finnish sample.
Diabetologia 1999: 42 (2): 238-244.
244. Tchernof A, Starling RD, Walston JD et al. Obesity-related phenotypes and the
beta3-adrenoceptor gene variant in postmenopausal women. Diabetes 1999: 48 (7):
1425-1428.
245. Urhammer SA, Hansen T, Borch-Johnsen K, Pedersen O. Studies of the synergistic
effect of the Trp/Arg64 polymorphism of the beta3-adrenergic receptor gene and the -
3826 A/G variant of the uncoupling protein-1 gene on features of obesity and insulin
resistance in a population-based sample of 379 young Danish subjects. J Clin
Endocrinol Metab 2000: 85 (9): 3151-3154.
246. Kasznicki J, Blasiak J, Majsterek I, Przybylowska K, Drzewoski J. The Trp64Arg
beta3-adrenergic receptor amino-acid variant is not associated with overweight and type
108
2 diabetes mellitus in Polish population. Exp Clin Endocrinol Diabetes 2005: 113 (10):
593-597.
247. Tamaki S, Nakamura Y, Tabara Y et al. Relationship between metabolic syndrome
and Trp64arg polymorphism of the beta-adrenergic receptor gene in a general sample:
the Shigaraki study. Hypertens Res 2006: 29 (11): 891-896.
248. Nagai N, Sakane N, Moritani T. Impact of aging and beta3-adrenergic-receptor
polymorphism on thermic and sympathetic responses to a high-fat meal. J Nutr Sci
Vitaminol (Tokyo) 2006: 52 (5): 352-359.
249. Kadowaki H, Yasuda K, Iwamoto K et al. A mutation in the beta 3-adrenergic
receptor gene is associated with obesity and hyperinsulinemia in Japanese subjects.
Biochem Biophys Res Commun 1995: 215 (2): 555-560.
250. Oksanen L, Mustajoki P, Kaprio J et al. Polymorphism of the beta 3-adrenergic
receptor gene in morbid obesity. Int J Obes Relat Metab Disord 1996: 20 (12): 1055-
1061.
251. Clement K, Ruiz J, Cassard-Doulcier AM et al. Additive effect of A/G (-3826)
variant of the uncoupling protein gene and the Trp64Arg mutation of the beta 3-
adrenergic receptor gene on weight gain in morbid obesity. Int J Obes Relat Metab
Disord 1996: 20 (12): 1062-1066.
252. Sakane N, Yoshida T, Umekawa T, Kondo M, Sakai Y, Takahashi T. Beta 3-
adrenergic-receptor polymorphism: a genetic marker for visceral fat obesity and the
insulin resistance syndrome. Diabetologia 1997: 40 (2): 200-204.
253. Silver K, Mitchell BD, Walston J et al. Trp64Arg beta 3-adrenergic receptor and
obesity in Mexican Americans. Hum Genet 1997: 101 (3): 306-311.
254. Mitchell BD, Blangero J, Comuzzie AG et al. A paired sibling analysis of the beta-
3 adrenergic receptor and obesity in Mexican Americans. J Clin Invest 1998: 101 (3):
584-587.
255. Garcia-Rubi E, Starling RD, Tchernof A et al. Trp64Arg variant of the beta3-
adrenoceptor and insulin resistance in obese postmenopausal women. J Clin Endocrinol
Metab 1998: 83 (11): 4002-4005.
256. Fogelholm M, Valve R, Kukkonen-Harjula K et al. Additive effects of the
mutations in the beta3-adrenergic receptor and uncoupling protein-1 genes on weight
loss and weight maintenance in Finnish women. J Clin Endocrinol Metab 1998: 83 (12):
4246-4250.
257. Tchernof A, Starling RD, Turner A et al. Impaired capacity to lose visceral adipose
tissue during weight reduction in obese postmenopausal women with the Trp64Arg
beta3-adrenoceptor gene variant. Diabetes 2000: 49 (10): 1709-1713.
258. Dionne IJ, Turner AN, Tchernof A et al. Identification of an interactive effect of
beta3- and alpha2b-adrenoceptor gene polymorphisms on fat mass in Caucasian women.
Diabetes 2001: 50 (1): 91-95.
259. Hsueh WC, Cole SA, Shuldiner AR et al. Interactions between variants in the
beta3-adrenergic receptor and peroxisome proliferator-activated receptor-gamma2 genes
and obesity. Diabetes Care 2001: 24 (4): 672-677.
260. Kawamura T, Egusa G, Fujikawa R, Okubo M. Beta(3)-adrenergic receptor gene
variant is associated with upper body obesity only in obese Japanese-American men but
not in women. Diabetes Res Clin Pract 2001: 54 (1): 49-55.
109
261. Walston J, Andersen RE, Seibert M et al. Arg64 beta3-adrenoceptor variant and
the components of energy expenditure. Obes Res 2003: 11 (4): 509-511.
262. Arashiro R, Katsuren K, Fukuyama S, Ohta T. Effect of Trp64Arg mutation of the
beta3-adrenergic receptor gene and C161T substitution of the peroxisome proliferator
activated receptor gamma gene on obesity in Japanese children. Pediatr Int 2003: 45 (2):
135-141.
263. Shiwaku K, Nogi A, Anuurad E et al. Difficulty in losing weight by behavioral
intervention for women with Trp64Arg polymorphism of the beta3-adrenergic receptor
gene. Int J Obes Relat Metab Disord 2003: 27 (9): 1028-1036.
264. Kim OY, Cho EY, Park HY, Jang Y, Lee JH. Additive effect of the mutations in
the beta3-adrenoceptor gene and UCP3 gene promoter on body fat distribution and
glycemic control after weight reduction in overweight subjects with CAD or metabolic
syndrome. Int J Obes Relat Metab Disord 2004: 28 (3): 434-441.
265. Wang X, Cui Y, Tong X, Ye H, Li S. Effects of the Trp64Arg polymorphism in the
beta3-adrenergic receptor gene on insulin sensitivity in small for gestational age
neonates. J Clin Endocrinol Metab 2004: 89 (10): 4981-4985.
266. Ramis JM, Gonzalez-Sanchez JL, Proenza AM et al. The Arg64 allele of the beta
3-adrenoceptor gene but not the -3826G allele of the uncoupling protein 1 gene is
associated with increased leptin levels in the Spanish population. Metabolism 2004: 53
(11): 1411-1416.
267. Erhardt E, Czako M, Csernus K, Molnar D, Kosztolanyi G. The frequency of
Trp64Arg polymorphism of the beta3-adrenergic receptor gene in healthy and obese
Hungarian children and its association with cardiovascular risk factors. Eur J Clin Nutr
2005: 59 (8): 955-959.
268. Miyaki K, Sutani S, Kikuchi H et al. Increased risk of obesity resulting from the
interaction between high energy intake and the Trp64Arg polymorphism of the beta3-
adrenergic receptor gene in healthy Japanese men. J Epidemiol 2005: 15 (6): 203-210.
269. Fisler JS, Warden CH. Uncoupling proteins, dietary fat and the metabolic
syndrome. Nutr Metab (Lond) 2006: 3 : 38.
270. Dalgaard LT, Pedersen O. Uncoupling proteins: functional characteristics and role
in the pathogenesis of obesity and Type II diabetes. Diabetologia 2001: 44 (8): 946-965.
271. Lowell BB, Flier JS. Brown adipose tissue, beta 3-adrenergic receptors, and
obesity. Annu Rev Med 1997: 48 : 307-316.
272. Ricquier D, Bouillaud F. The uncoupling protein homologues: UCP1, UCP2,
UCP3, StUCP and AtUCP. Biochem J 2000: 345 Pt 2 : 161-179.
273. Nedergaard J, Golozoubova V, Matthias A, Asadi A, Jacobsson A, Cannon B.
UCP1: the only protein able to mediate adaptive non-shivering thermogenesis and
metabolic inefficiency. Biochim Biophys Acta 2001: 1504 (1): 82-106.
274. Argiles JM, Busquets S, Lopez-Soriano FJ. The role of uncoupling proteins in
pathophysiological states. Biochem Biophys Res Commun 2002: 293 (4): 1145-1152.
275. Collins S, Cao W, Daniel KW et al. Adrenoceptors, uncoupling proteins, and
energy expenditure. Exp Biol Med (Maywood) 2001: 226 (11): 982-990.
276. Yasuda K, Matsunaga T, Adachi T, Aoki N, Tsujimoto G, Tsuda K. Adrenergic
receptor polymorphisms and autonomic nervous system function in human obesity.
Trends Endocrinol Metab 2006: 17 (7): 269-275.
110
277. Pecqueur C, Couplan E, Bouillaud F, Ricquier D. Genetic and physiological
analysis of the role of uncoupling proteins in human energy homeostasis. J Mol Med
2001: 79 (1): 48-56.
278. Lowell BB, S-Susulic V, Hamann A et al. Development of obesity in transgenic
mice after genetic ablation of brown adipose tissue. Nature 1993: 366 (6457): 740-742.
279. Hamann A, Flier JS, Lowell BB. Decreased brown fat markedly enhances
susceptibility to diet-induced obesity, diabetes, and hyperlipidemia. Endocrinology
1996: 137 (1): 21-29.
280. Cinti S. The role of brown adipose tissue in human obesity. Nutr Metab Cardiovasc
Dis 2006: 16 (8): 569-574.
281. Bouillaud F, Villarroya F, Hentz E, Raimbault S, Cassard AM, Ricquier D.
Detection of brown adipose tissue uncoupling protein mRNA in adult patients by a
human genomic probe. Clin Sci (Lond) 1988: 75 (1): 21-27.
282. Cassard AM, Bouillaud F, Mattei MG et al. Human uncoupling protein gene:
structure, comparison with rat gene, and assignment to the long arm of chromosome 4. J
Cell Biochem 1990: 43 (3): 255-264.
283. Heilbronn LK, Kind KL, Pancewicz E, Morris AM, Noakes M, Clifton PM.
Association of -3826 G variant in uncoupling protein-1 with increased BMI in
overweight Australian women. Diabetologia 2000: 43 (2): 242-244.
284. Urhammer SA, Fridberg M, Sorensen TI et al. Studies of genetic variability of the
uncoupling protein 1 gene in Caucasian subjects with juvenile-onset obesity. J Clin
Endocrinol Metab 1997: 82 (12): 4069-4074.
285. Gagnon J, Lago F, Chagnon YC et al. DNA polymorphism in the uncoupling
protein 1 (UCP1) gene has no effect on obesity related phenotypes in the Swedish
Obese Subjects cohorts. Int J Obes Relat Metab Disord 1998: 22 (6): 500-505.
286. Esterbauer H, Oberkofler H, Liu YM et al. Uncoupling protein-1 mRNA
expression in obese human subjects: the role of sequence variations at the uncoupling
protein-1 gene locus. J Lipid Res 1998: 39 (4): 834-844.
287. Ukkola O, Tremblay A, Sun G, Chagnon YC, Bouchard C. Genetic variation at the
uncoupling protein 1, 2 and 3 loci and the response to long-term overfeeding. Eur J Clin
Nutr 2001: 55 (11): 1008-1015.
288. Kiec-Wilk B, Wybranska I, Malczewska-Malec M et al. Correlation of the -
3826A/G polymorphism in the promoter of the uncoupling protein 1 gene with obesity
and metabolic disorders in obese families from southern Poland. J Physiol Pharmacol
2002: 53 (3): 477-490.
289. Fukuyama K, Ohara T, Hirota Y et al. Association of the -112A>C polymorphism
of the uncoupling protein 1 gene with insulin resistance in Japanese individuals with
type 2 diabetes. Biochem Biophys Res Commun 2006: 339 (4): 1212-1216.
290. Sramkova D, Krejbichova S, Vcelak J et al. The UCP1 gene polymorphism A-
3826G in relation to DM2 and body composition in Czech population. Exp Clin
Endocrinol Diabetes 2007: 115 (5): 303-307.
291. Pecqueur C, Alves-Guerra MC, Gelly C et al. Uncoupling protein 2, in vivo
distribution, induction upon oxidative stress, and evidence for translational regulation. J
Biol Chem 2001: 276 (12): 8705-8712.
292. Saleh MC, Wheeler MB, Chan CB. Uncoupling protein-2: evidence for its function
as a metabolic regulator. Diabetologia 2002: 45 (2): 174-187.
111
293. O'Rahilly S. Uncoupling protein 2: Adiposity angel and diabetes devil? Nat Med
2001: 7 (7): 770-772.
294. Arsenijevic D, Onuma H, Pecqueur C et al. Disruption of the uncoupling protein-2
gene in mice reveals a role in immunity and reactive oxygen species production. Nat
Genet 2000: 26 (4): 435-439.
295. Chan CB, MacDonald PE, Saleh MC, Johns DC, Marban E, Wheeler MB.
Overexpression of uncoupling protein 2 inhibits glucose-stimulated insulin secretion
from rat islets. Diabetes 1999: 48 (7): 1482-1486.
296. Chan CB, De Leo D, Joseph JW et al. Increased uncoupling protein-2 levels in
beta-cells are associated with impaired glucose-stimulated insulin secretion: mechanism
of action. Diabetes 2001: 50 (6): 1302-1310.
297. Zhang CY, Baffy G, Perret P et al. Uncoupling protein-2 negatively regulates
insulin secretion and is a major link between obesity, beta cell dysfunction, and type 2
diabetes. Cell 2001: 105 (6): 745-755.
298. De Souza CT, Araujo EP, Stoppiglia LF et al. Inhibition of UCP2 expression
reverses diet-induced diabetes mellitus by effects on both insulin secretion and action.
FASEB J 2007: 21 (4): 1153-1163.
299. Krauss S, Zhang CY, Scorrano L et al. Superoxide-mediated activation of
uncoupling protein 2 causes pancreatic beta cell dysfunction. J Clin Invest 2003: 112
(12): 1831-1842.
300. Chan CB, Kashemsant N. Regulation of insulin secretion by uncoupling protein.
Biochem Soc Trans 2006: 34 (Pt 5): 802-805.
301. Langin D. Diabetes, insulin secretion, and the pancreatic beta-cell mitochondrion.
N Engl J Med 2001: 345 (24): 1772-1774.
302. Fleury C, Neverova M, Collins S et al. Uncoupling protein-2: a novel gene linked
to obesity and hyperinsulinemia. Nat Genet 1997: 15 (3): 269-272.
303. Boss O, Samec S, Paoloni-Giacobino A et al. Uncoupling protein-3: a new member
of the mitochondrial carrier family with tissue-specific expression. FEBS Lett 1997:
408 (1): 39-42.
304. Pecqueur C, Cassard-Doulcier AM, Raimbault S et al. Functional organization of
the human uncoupling protein-2 gene, and juxtaposition to the uncoupling protein-3
gene. Biochem Biophys Res Commun 1999: 255 (1): 40-46.
305. Krempler F, Esterbauer H, Weitgasser R et al. A functional polymorphism in the
promoter of UCP2 enhances obesity risk but reduces type 2 diabetes risk in obese
middle-aged humans. Diabetes 2002: 51 (11): 3331-3335.
306. Esterbauer H, Schneitler C, Oberkofler H et al. A common polymorphism in the
promoter of UCP2 is associated with decreased risk of obesity in middle-aged humans.
Nat Genet 2001: 28 (2): 178-183.
307. Sesti G, Cardellini M, Marini MA et al. A common polymorphism in the promoter
of UCP2 contributes to the variation in insulin secretion in glucose-tolerant subjects.
Diabetes 2003: 52 (5): 1280-1283.
308. Le Fur S, Le Stunff C, Dos Santos C, Bougneres P. The common -866 g/a
polymorphism in the promoter of uncoupling protein 2 is associated with increased
carbohydrate and decreased lipid oxidation in juvenile obesity. Diabetes 2004: 53 (1):
235-239.
112
309. Dhamrait SS, Stephens JW, Cooper JA et al. Cardiovascular risk in healthy men
and markers of oxidative stress in diabetic men are associated with common variation in
the gene for uncoupling protein 2. Eur Heart J 2004: 25 (6): 468-475.
310. Kubota T, Mori H, Tamori Y et al. Molecular screening of uncoupling protein 2
gene in patients with noninsulin-dependent diabetes mellitus or obesity. J Clin
Endocrinol Metab 1998: 83 (8): 2800-2804.
311. Rosmond R, Bouchard C, Björntorp P. Lack of association between the uncoupling
protein-2 Ala55Val gene polymorphism and phenotypic features of the Metabolic
Syndrome. Biochim Biophys Acta 2002: 1588 (2): 103-105.
312. Duarte NL, Colagiuri S, Palu T, Wang XL, Wilcken DE. A 45-bp
insertion/deletion polymorphism of uncoupling protein 2 in relation to obesity in
Tongans. Obes Res 2003: 11 (4): 512-517.
313. Dalgaard LT, Andersen G, Larsen LH et al. Mutational analysis of the UCP2 core
promoter and relationships of variants with obesity. Obes Res 2003: 11 (11): 1420-
1427.
314. Walder K, Norman RA, Hanson RL et al. Association between uncoupling protein
polymorphisms (UCP2-UCP3) and energy metabolism/obesity in Pima indians. Hum
Mol Genet 1998: 7 (9): 1431-1435.
315. Cassell PG, Neverova M, Janmohamed S et al. An uncoupling protein 2 gene
variant is associated with a raised body mass index but not Type II diabetes.
Diabetologia 1999: 42 (6): 688-692.
316. Reis AF, Dubois-Laforgue D, Bellanne-Chantelot C, Timsit J, Velho G. A
polymorphism in the promoter of UCP2 gene modulates lipid levels in patients with
type 2 diabetes. Mol Genet Metab 2004: 82 (4): 339-344.
317. D'Adamo M, Perego L, Cardellini M et al. The -866A/A genotype in the promoter
of the human uncoupling protein 2 gene is associated with insulin resistance and
increased risk of type 2 diabetes. Diabetes 2004: 53 (7): 1905-1910.
318. Wang H, Chu WS, Lu T, Hasstedt SJ, Kern PA, Elbein SC. Uncoupling protein-2
polymorphisms in type 2 diabetes, obesity, and insulin secretion. Am J Physiol
Endocrinol Metab 2004: 286 (1): E1-7.
319. Marti A, Corbalan MS, Forga L, Martinez-Gonzalez MA, Martinez JA. Higher
obesity risk associated with the exon-8 insertion of the UCP2 gene in a Spanish case-
control study. Nutrition 2004: 20 (6): 498-501.
320. Cho YM, Ritchie MD, Moore JH et al. Multifactor-dimensionality reduction shows
a two-locus interaction associated with Type 2 diabetes mellitus. Diabetologia 2004: 47
(3): 549-554.
321. Sasahara M, Nishi M, Kawashima H et al. Uncoupling protein 2 promoter
polymorphism -866G/A affects its expression in beta-cells and modulates clinical
profiles of Japanese type 2 diabetic patients. Diabetes 2004: 53 (2): 482-485.
322. Bulotta A, Ludovico O, Coco A et al. The common -866G/A polymorphism in the
promoter region of the UCP-2 gene is associated with reduced risk of type 2 diabetes in
Caucasians from Italy. J Clin Endocrinol Metab 2005: 90 (2): 1176-1180.
323. Kovacs P, Ma L, Hanson RL et al. Genetic variation in UCP2 (uncoupling protein-
2) is associated with energy metabolism in Pima Indians. Diabetologia 2005: 48 (11):
2292-2295.
113
324. Gable DR, Stephens JW, Cooper JA, Miller GJ, Humphries SE. Variation in the
UCP2-UCP3 gene cluster predicts the development of type 2 diabetes in healthy
middle-aged men. Diabetes 2006: 55 (5): 1504-1511.
325. Cha MH, Kim IC, Kim KS, Kang BK, Choi SM, Yoon Y. Association of UCP2
and UCP3 gene polymorphisms with serum high-density lipoprotein cholesterol among
Korean women. Metabolism 2007: 56 (6): 806-813.
326. Yoon Y, Park BL, Cha MH et al. Effects of genetic polymorphisms of UCP2 and
UCP3 on very low calorie diet-induced body fat reduction in Korean female subjects.
Biochem Biophys Res Commun 2007: 359 (3): 451-456.
327. Rance KA, Johnstone AM, Murison S, Duncan JS, Wood SG, Speakman JR.
Plasma leptin levels are related to body composition, sex, insulin levels and the A55V
polymorphism of the UCP2 gene. Int J Obes (Lond) 2007: 31 (8): 1311-1318.
328. Cheurfa N, Dubois-Laforgue D, Ferrarezi DA et al. The common -866G>A variant
in the promoter of UCP2 is associated with decreased risk of coronary artery disease in
type 2 diabetic men. Diabetes 2008: 57 (4): 1063-1068.
329. Bezaire V, Seifert EL, Harper ME. Uncoupling protein-3: clues in an ongoing
mitochondrial mystery. FASEB J 2007: 21 (2): 312-324.
330. Schrauwen P, Hesselink M. UCP2 and UCP3 in muscle controlling body
metabolism. J Exp Biol 2002: 205 (Pt 15): 2275-2285.
331. Solanes G, Vidal-Puig A, Grujic D, Flier JS, Lowell BB. The human uncoupling
protein-3 gene. Genomic structure, chromosomal localization, and genetic basis for
short and long form transcripts. J Biol Chem 1997: 272 (41): 25433-25436.
332. Tunstall RJ, Mehan KA, Hargreaves M, Spriet LL, Cameron-Smith D. Fasting
activates the gene expression of UCP3 independent of genes necessary for lipid
transport and oxidation in skeletal muscle. Biochem Biophys Res Commun 2002: 294
(2): 301-308.
333. Hesselink MK, Mensink M, Schrauwen P. Human uncoupling protein-3 and
obesity: an update. Obes Res 2003: 11 (12): 1429-1443.
334. Schrauwen P, Hesselink M. Uncoupling protein 3 and physical activity: the role of
uncoupling protein 3 in energy metabolism revisited. Proc Nutr Soc 2003: 62 (3): 635-
643.
335. Schrauwen P, Hesselink MK. Oxidative capacity, lipotoxicity, and mitochondrial
damage in type 2 diabetes. Diabetes 2004: 53 (6): 1412-1417.
336. Schrauwen P, Hesselink MK, Blaak EE et al. Uncoupling protein 3 content is
decreased in skeletal muscle of patients with type 2 diabetes. Diabetes 2001: 50 (12):
2870-2873.
337. Schrauwen P, Xia J, Bogardus C, Pratley RE, Ravussin E. Skeletal muscle
uncoupling protein 3 expression is a determinant of energy expenditure in Pima Indians.
Diabetes 1999: 48 (1): 146-149.
338. Vidal-Puig AJ, Grujic D, Zhang CY et al. Energy metabolism in uncoupling
protein 3 gene knockout mice. J Biol Chem 2000: 275 (21): 16258-16266.
339. Cline GW, Vidal-Puig AJ, Dufour S, Cadman KS, Lowell BB, Shulman GI. In
vivo effects of uncoupling protein-3 gene disruption on mitochondrial energy
metabolism. J Biol Chem 2001: 276 (23): 20240-20244.
114
340. Clapham JC, Arch JR, Chapman H et al. Mice overexpressing human uncoupling
protein-3 in skeletal muscle are hyperphagic and lean. Nature 2000: 406 (6794): 415-
418.
341. Schrauwen P, Xia J, Walder K, Snitker S, Ravussin E. A novel polymorphism in
the proximal UCP3 promoter region: effect on skeletal muscle UCP3 mRNA expression
and obesity in male non-diabetic Pima Indians. Int J Obes Relat Metab Disord 1999: 23
(12): 1242-1245.
342. Otabe S, Clement K, Dina C et al. A genetic variation in the 5' flanking region of
the UCP3 gene is associated with body mass index in humans in interaction with
physical activity. Diabetologia 2000: 43 (2): 245-249.
343. Meirhaeghe A, Amouyel P, Helbecque N et al. An uncoupling protein 3 gene
polymorphism associated with a lower risk of developing Type II diabetes and with
atherogenic lipid profile in a French cohort. Diabetologia 2000: 43 (11): 1424-1428.
344. Dalgaard LT, Sorensen TI, Drivsholm T et al. A prevalent polymorphism in the
promoter of the UCP3 gene and its relationship to body mass index and long term body
weight change in the Danish population. J Clin Endocrinol Metab 2001: 86 (3): 1398-
1402.
345. Cassell PG, Saker PJ, Huxtable SJ et al. Evidence that single nucleotide
polymorphism in the uncoupling protein 3 (UCP3) gene influences fat distribution in
women of European and Asian origin. Diabetologia 2000: 43 (12): 1558-1564.
346. Halsall DJ, Luan J, Saker P et al. Uncoupling protein 3 genetic variants in human
obesity: the c-55t promoter polymorphism is negatively correlated with body mass
index in a UK Caucasian population. Int J Obes Relat Metab Disord 2001: 25 (4): 472-
477.
347. Lanouette CM, Giacobino JP, Perusse L et al. Association between uncoupling
protein 3 gene and obesity-related phenotypes in the Quebec Family Study. Mol Med
2001: 7 (7): 433-441.
348. Herrmann SM, Wang JG, Staessen JA et al. Uncoupling protein 1 and 3
polymorphisms are associated with waist-to-hip ratio. J Mol Med 2003: 81 (5): 327-
332.
349. Damcott CM, Feingold E, Moffett SP et al. Genetic variation in uncoupling protein
3 is associated with dietary intake and body composition in females. Metabolism 2004:
53 (4): 458-464.
350. Liu YJ, Liu PY, Long J et al. Linkage and association analyses of the UCP3 gene
with obesity phenotypes in Caucasian families. Physiol Genomics 2005: 22 (2): 197-
203.
351. Cha MH, Shin HD, Kim KS, Lee BH, Yoon Y. The effects of uncoupling protein 3
haplotypes on obesity phenotypes and very low-energy diet-induced changes among
overweight Korean female subjects. Metabolism 2006: 55 (5): 578-586.
352. de Luis DA, Aller R, Izaola O, Gonzalez Sagrado M, Conde R, Perez Castrillon
JL. Lack of association of -55CT polymorphism of UCP3 gene with fat distribution in
obese patients. Ann Nutr Metab 2007: 51 (4): 374-378.
353. Hamada T, Kotani K, Fujiwara S et al. The common -55 C/T polymorphism in the
promoter region of the uncoupling protein 3 gene reduces prevalence of obesity and
elevates serum high-density lipoprotein cholesterol levels in the general Japanese
population. Metabolism 2008: 57 (3): 410-415.
115
354. Ingalls AM, Dickie MM, Snell GD. Obese, a new mutation in the house mouse. J
Hered 1950: 41 (12): 317-318.
355. Montague CT, Farooqi IS, Whitehead JP et al. Congenital leptin deficiency is
associated with severe early-onset obesity in humans. Nature 1997: 387 (6636): 903-
908.
356. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals.
Nature 1998: 395 (6704): 763-770.
357. Farooqi IS, Matarese G, Lord GM et al. Beneficial effects of leptin on obesity, T
cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human
congenital leptin deficiency. J Clin Invest 2002: 110 (8): 1093-1103.
358. Gibson WT, Farooqi IS, Moreau M et al. Congenital leptin deficiency due to
homozygosity for the Delta133G mutation: report of another case and evaluation of
response to four years of leptin therapy. J Clin Endocrinol Metab 2004: 89 (10): 4821-
4826.
359. Farooqi IS, Jebb SA, Langmack G et al. Effects of recombinant leptin therapy in a
child with congenital leptin deficiency. N Engl J Med 1999: 341 (12): 879-884.
360. Licinio J, Caglayan S, Ozata M et al. Phenotypic effects of leptin replacement on
morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptin-deficient
adults. Proc Natl Acad Sci U S A 2004: 101 (13): 4531-4536.
361. Tartaglia LA, Dembski M, Weng X et al. Identification and expression cloning of a
leptin receptor, OB-R. Cell 1995: 83 (7): 1263-1271.
362. Lee GH, Proenca R, Montez JM et al. Abnormal splicing of the leptin receptor in
diabetic mice. Nature 1996: 379 (6566): 632-635.
363. Leibel RL, Chung WK, Chua SC,Jr. The molecular genetics of rodent single gene
obesities. J Biol Chem 1997: 272 (51): 31937-31940.
364. Iida M, Murakami T, Ishida K, Mizuno A, Kuwajima M, Shima K. Substitution at
codon 269 (glutamine proline) of the leptin receptor (OB-R) cDNA is the only
mutation found in the Zucker fatty (fa/fa) rat. Biochem Biophys Res Commun 1996:
224 (2): 597-604.
365. Chung WK, Power-Kehoe L, Chua M, Leibel RL. Mapping of the OB receptor to
1p in a region of nonconserved gene order from mouse and rat to human. Genome Res
1996: 6 (5): 431-438.
366. Chung WK, Power-Kehoe L, Chua M, Lee R, Leibel RL. Genomic structure of the
human OB receptor and identification of two novel intronic microsatellites. Genome
Res 1996: 6 (12): 1192-1199.
367. Fruhbeck G. Intracellular signalling pathways activated by leptin. Biochem J 2006:
393 (Pt 1): 7-20.
368. Margetic S, Gazzola C, Pegg GG, Hill RA. Leptin: a review of its peripheral
actions and interactions. Int J Obes Relat Metab Disord 2002: 26 (11): 1407-1433.
369. Gullicksen PS, Della-Fera MA, Baile CA. Leptin-induced adipose apoptosis:
Implications for body weight regulation. Apoptosis 2003: 8 (4): 327-335.
370. Crowley VE. Overview of human obesity and central mechanisms regulating
energy homeostasis. Ann Clin Biochem 2008: 45 (Pt 3): 245-255.
371. Harvey J, Ashford ML. Leptin in the CNS: much more than a satiety signal.
Neuropharmacology 2003: 44 (7): 845-854.
116
372. Seufert J. Leptin effects on pancreatic beta-cell gene expression and function.
Diabetes 2004: 53 Suppl 1 : S152-8.
373. Farooqi IS, Wangensteen T, Collins S et al. Clinical and molecular genetic
spectrum of congenital deficiency of the leptin receptor. N Engl J Med 2007: 356 (3):
237-247.
374. Oksanen L, Kaprio J, Mustajoki P, Kontula K. A common pentanucleotide
polymorphism of the 3'-untranslated part of the leptin receptor gene generates a putative
stem-loop motif in the mRNA and is associated with serum insulin levels in obese
individuals. Int J Obes Relat Metab Disord 1998: 22 (7): 634-640.
375. Lakka HM, Oksanen L, Tuomainen TP, Kontula K, Salonen JT. The common
pentanucleotide polymorphism of the 3'-untranslated region of the leptin receptor gene
is associated with serum insulin levels and the risk of type 2 diabetes in non-diabetic
men: a prospective case-control study. J Intern Med 2000: 248 (1): 77-83.
376. Nishikai K, Hirose H, Ishii T, Hayashi M, Saito I, Saruta T. Effects of leptin
receptor gene 3'-untranslated region polymorphism on metabolic profiles in young
Japanese men. J Atheroscler Thromb 2004: 11 (2): 73-78.
377. Lakka TA, Rankinen T, Weisnagel SJ et al. Leptin and Leptin Receptor Gene
Polymorphisms and Changes in Glucose Homeostasis in Response to Regular Exercise
in Nondiabetic Individuals: The HERITAGE Family Study. Diabetes 2004: 53 (6):
1603-1608.
378. Wauters M, Mertens I, Rankinen T, Chagnon M, Bouchard C, Van Gaal L. Leptin
receptor gene polymorphisms are associated with insulin in obese women with impaired
glucose tolerance. J Clin Endocrinol Metab 2001: 86 (7): 3227-3232.
379. Takahashi-Yasuno A, Masuzaki H, Miyawaki T et al. Association of Ob-R gene
polymorphism and insulin resistance in Japanese men. Metabolism 2004: 53 (5): 650-
654.
380. Chiu KC, Chu A, Chuang LM, Saad MF. Association of leptin receptor
polymorphism with insulin resistance. Eur J Endocrinol 2004: 150 (5): 725-729.
381. Stefan N, Vozarova B, Del Parigi A et al. The Gln223Arg polymorphism of the
leptin receptor in Pima Indians: influence on energy expenditure, physical activity and
lipid metabolism. Int J Obes Relat Metab Disord 2002: 26 (12): 1629-1632.
382. Chagnon YC, Wilmore JH, Borecki IB et al. Associations between the leptin
receptor gene and adiposity in middle-aged Caucasian males from the HERITAGE
family study. J Clin Endocrinol Metab 2000: 85 (1): 29-34.
383. Mattevi VS, Zembrzuski VM, Hutz MH. Association analysis of genes involved in
the leptin-signaling pathway with obesity in Brazil. Int J Obes Relat Metab Disord
2002: 26 (9): 1179-1185.
384. Wauters M, Mertens I, Chagnon M et al. Polymorphisms in the leptin receptor
gene, body composition and fat distribution in overweight and obese women. Int J Obes
Relat Metab Disord 2001: 25 (5): 714-720.
385. Yiannakouris N, Yannakoulia M, Melistas L, Chan JL, Klimis-Zacas D, Mantzoros
CS. The Q223R polymorphism of the leptin receptor gene is significantly associated
with obesity and predicts a small percentage of body weight and body composition
variability. J Clin Endocrinol Metab 2001: 86 (9): 4434-4439.
117
386. Quinton ND, Lee AJ, Ross RJ, Eastell R, Blakemore AI. A single nucleotide
polymorphism (SNP) in the leptin receptor is associated with BMI, fat mass and leptin
levels in postmenopausal Caucasian women. Hum Genet 2001: 108 (3): 233-236.
387. Gotoda T, Manning BS, Goldstone AP et al. Leptin receptor gene variation and
obesity: lack of association in a white British male population. Hum Mol Genet 1997: 6
(6): 869-876.
388. Thompson DB, Ravussin E, Bennett PH, Bogardus C. Structure and sequence
variation at the human leptin receptor gene in lean and obese Pima Indians. Hum Mol
Genet 1997: 6 (5): 675-679.
389. Echwald SM, Sorensen TD, Sorensen TI et al. Amino acid variants in the human
leptin receptor: lack of association to juvenile onset obesity. Biochem Biophys Res
Commun 1997: 233 (1): 248-252.
390. Matsuoka N, Ogawa Y, Hosoda K et al. Human leptin receptor gene in obese
Japanese subjects: evidence against either obesity-causing mutations or association of
sequence variants with obesity. Diabetologia 1997: 40 (10): 1204-1210.
391. Mars M, van Rossum CT, de Graaf C, Hoebee B, De Groot LC, Kok FJ. Leptin
responsiveness to energy restriction: genetic variation in the leptin receptor gene. Obes
Res 2004: 12 (3): 442-444.
392. Heo M, Leibel RL, Fontaine KR et al. A meta-analytic investigation of linkage and
association of common leptin receptor (LEPR) polymorphisms with body mass index
and waist circumference. Int J Obes Relat Metab Disord 2002: 26 (5): 640-646.
393. Heo M, Leibel RL, Boyer BB et al. Pooling analysis of genetic data: the
association of leptin receptor (LEPR) polymorphisms with variables related to human
adiposity. Genetics 2001: 159 (3): 1163-1178.
394. Ukkola O, Tremblay A, Despres JP, Chagnon YC, Campfield LA, Bouchard C.
Leptin receptor Gln223Arg variant is associated with a cluster of metabolic
abnormalities in response to long-term overfeeding. J Intern Med 2000: 248 (5): 435-
439.
395. Wauters M, Considine RV, Chagnon M et al. Leptin levels, leptin receptor gene
polymorphisms, and energy metabolism in women. Obes Res 2002: 10 (5): 394-400.
396. van Rossum CT, Hoebee B, van Baak MA, Mars M, Saris WH, Seidell JC. Genetic
variation in the leptin receptor gene, leptin, and weight gain in young Dutch adults.
Obes Res 2003: 11 (3): 377-386.
397. Liu YJ, Rocha-Sanchez SM, Liu PY et al. Tests of linkage and/or association of
the LEPR gene polymorphisms with obesity phenotypes in Caucasian nuclear families.
Physiol Genomics 2004: 17 (2): 101-106.
398. Zacharova J, Chiasson JL, Laakso M. Leptin receptor gene variation predicts
weight change in subjects with impaired glucose tolerance. Obes Res 2005: 13 (3): 501-
506.
399. Park KS, Shin HD, Park BL et al. Polymorphisms in the leptin receptor (LEPR)--
putative association with obesity and T2DM. J Hum Genet 2006: 51 (2): 85-91.
400. Lockhart DJ, Winzeler EA. Genomics, gene expression and DNA arrays. Nature
2000: 405 (6788): 827-836.
401. Nadler ST, Attie AD. Please pass the chips: genomic insights into obesity and
diabetes. J Nutr 2001: 131 (8): 2078-2081.
118
402. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW,Jr.
Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest
2003: 112 (12): 1796-1808.
403. Lee YH, Nair S, Rousseau E et al. Microarray profiling of isolated abdominal
subcutaneous adipocytes from obese vs non-obese Pima Indians: increased expression
of inflammation-related genes. Diabetologia 2005: 48 (9): 1776-1783.
404. Gomez-Ambrosi J, Catalan V, Diez-Caballero A et al. Gene expression profile of
omental adipose tissue in human obesity. FASEB J 2004: 18 (1): 215-217.
405. Nadler ST, Stoehr JP, Schueler KL, Tanimoto G, Yandell BS, Attie AD. The
expression of adipogenic genes is decreased in obesity and diabetes mellitus. Proc Natl
Acad Sci U S A 2000: 97 (21): 11371-11376.
406. Moraes RC, Blondet A, Birkenkamp-Demtroeder K et al. Study of the alteration of
gene expression in adipose tissue of diet-induced obese mice by microarray and reverse
transcription-polymerase chain reaction analyses. Endocrinology 2003: 144 (11): 4773-
4782.
407. Dahlman I, Linder K, Arvidsson Nordstrom E et al. Changes in adipose tissue gene
expression with energy-restricted diets in obese women. Am J Clin Nutr 2005: 81 (6):
1275-1285.
408. Clement K, Viguerie N, Poitou C et al. Weight loss regulates inflammation-related
genes in white adipose tissue of obese subjects. FASEB J 2004: 18 (14): 1657-1669.
409. Higami Y, Pugh TD, Page GP, Allison DB, Prolla TA, Weindruch R. Adipose
tissue energy metabolism: altered gene expression profile of mice subjected to long-
term caloric restriction. FASEB J 2004: 18 (2): 415-417.
410. Higami Y, Barger JL, Page GP et al. Energy restriction lowers the expression of
genes linked to inflammation, the cytoskeleton, the extracellular matrix, and
angiogenesis in mouse adipose tissue. J Nutr 2006: 136 (2): 343-352.
411. Han ES, Hickey M. Microarray evaluation of dietary restriction. J Nutr 2005: 135
(6): 1343-1346.
412. Capeau J, Magre J, Lascols O et al. Diseases of adipose tissue: genetic and
acquired lipodystrophies. Biochem Soc Trans 2005: 33 (Pt 5): 1073-1077.
413. Uusitupa M, Louheranta A, Lindström J et al. The Finnish Diabetes Prevention
Study. Br J Nutr 2000: 83 Suppl 1 : S137-42.
414. Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and management of the
metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood
Institute scientific statement. Curr Opin Cardiol 2006: 21 (1): 1-6.
415. Lindström J, Louheranta A, Mannelin M et al. The Finnish Diabetes Prevention
Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity.
Diabetes Care 2003: 26 (12): 3230-3236.
416. Kolehmainen M, Salopuro T, Schwab US et al. Weight reduction modulates
expression of genes involved in extracellular matrix and cell death: the GENOBIN
study. Int J Obes (Lond) 2008: 32 (2): 292-303.
417. Boston RC, Stefanovski D, Moate PJ, Sumner AE, Watanabe RM, Bergman RN.
MINMOD Millennium: a computer program to calculate glucose effectiveness and
insulin sensitivity from the frequently sampled intravenous glucose tolerance test.
Diabetes Technol Ther 2003: 5 (6): 1003-1015.
119
418. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-
density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.
Clin Chem 1972: 18 (6): 499-502.
419. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC.
Homeostasis model assessment: insulin resistance and beta-cell function from fasting
plasma glucose and insulin concentrations in man. Diabetologia 1985: 28 (7): 412-419.
420. Ohisalo JJ, Kaartinen JM, Ranta S et al. Weight loss normalizes the inhibitory
effect of N6-(phenylisopropyl)adenosine on lipolysis in fat cells of massively obese
human subjects. Clin Sci (Lond) 1992: 83 (5): 589-592.
421. Rodbell M. Metabolism of isolated fat cells. I. Effects of hormones on glucose
metabolism and lipolysis. J Biol Chem 1964: 239 : 375-380.
422. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD
and haplotype maps. Bioinformatics 2005: 21 (2): 263-265.
423. Tregouet DA, Escolano S, Tiret L, Mallet A, Golmard JL. A new algorithm for
haplotype-based association analysis: the Stochastic-EM algorithm. Ann Hum Genet
2004: 68 (Pt 2): 165-177.
424. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl
Acad Sci U S A 2003: 100 (16): 9440-9445.
425. Li C, Hung Wong W. Model-based analysis of oligonucleotide arrays: model
validation, design issues and standard error application. Genome Biol 2001: 2 (8):
RESEARCH0032.
426. Li C, Hung Wong W. Model-based analysis of oligonucleotide arrays: Expression
index computation and outlier detection. Proc Natl Acad Sci 2001: 98 : 31-36.
427. Ilanne-Parikka P, Eriksson JG, Lindström J et al. Prevalence of the Metabolic
Syndrome and Its Components: Findings from a Finnish general population sample and
the Diabetes Prevention Study cohort. Diabetes Care 2004: 27 (9): 2135-2140.
428. Norio R. Finnish Disease Heritage II: population prehistory and genetic roots of
Finns. Hum Genet 2003: 112 (5-6): 457-469.
429. Florez JC, Jablonski KA, McAteer J et al. Testing of diabetes-associated WFS1
polymorphisms in the Diabetes Prevention Program. Diabetologia 2008: 51 (3): 451-
457.
430. Florez JC, Jablonski KA, Sun MW et al. Effects of the type 2 diabetes-associated
PPARG P12A polymorphism on progression to diabetes and response to troglitazone. J
Clin Endocrinol Metab 2007: 92 (4): 1502-1509.
431. Franks PW, Jablonski KA, Delahanty L et al. The Pro12Ala variant at the
peroxisome proliferator-activated receptor gamma gene and change in obesity-related
traits in the Diabetes Prevention Program. Diabetologia 2007: 50 (12): 2451-2460.
432. Franks PW, Jablonski KA, Delahanty LM et al. Assessing gene-treatment
interactions at the FTO and INSIG2 loci on obesity-related traits in the Diabetes
Prevention Program. Diabetologia 2008: 51 (12): 2214-2223.
433. Moore AF, Jablonski KA, Mason CC et al. The association of ENPP1 K121Q with
diabetes incidence is abolished by lifestyle modification in the diabetes prevention
program. J Clin Endocrinol Metab 2009: 94 (2): 449-455.
434. Moore AF, Jablonski KA, McAteer JB et al. Extension of type 2 diabetes genome-
wide association scan results in the diabetes prevention program. Diabetes 2008: 57 (9):
2503-2510.
120
435. Florez JC, Jablonski KA, Bayley N et al. TCF7L2 polymorphisms and progression
to diabetes in the Diabetes Prevention Program. N Engl J Med 2006: 355 (3): 241-250.
436. Kilpeläinen TO, Lakka TA, Laaksonen DE et al. Physical activity modifies the
effect of SNPs in the SLC2A2 (GLUT2) and ABCC8 (SUR1) genes on the risk of
developing type 2 diabetes. Physiol Genomics 2007: 31 (2): 264-272.
437. Kilpeläinen TO, Lakka TA, Laaksonen DE et al. SNPs in PPARG associate with
type 2 diabetes and interact with physical activity. Med Sci Sports Exerc 2008: 40 (1):
25-33.
438. Kilpeläinen TO, Lakka TA, Laaksonen DE et al. Interaction of single nucleotide
polymorphisms in ADRB2, ADRB3, TNF, IL6, IGF1R, LIPC, LEPR, and GHRL with
physical activity on the risk of type 2 diabetes mellitus and changes in characteristics of
the metabolic syndrome: The Finnish Diabetes Prevention Study. Metabolism 2008: 57
(3): 428-436.
439. Karvonen MK, Pesonen U, Heinonen P et al. Identification of new sequence
variants in the leptin gene. J Clin Endocrinol Metab 1998: 83 (9): 3239-3242.
440. Oksanen L, Kainulainen K, Heiman M, Mustajoki P, Kauppinen-Mäkelin R,
Kontula K. Novel polymorphism of the human ob gene promoter in lean and morbidly
obese subjects. Int J Obes Relat Metab Disord 1997: 21 (6): 489-494.
441. Oksanen L, Ohman M, Heiman M et al. Markers for the gene ob and serum leptin
levels in human morbid obesity. Hum Genet 1997: 99 (5): 559-564.
442. Lucantoni R, Ponti E, Berselli ME et al. The A19G polymorphism in the 5'
untranslated region of the human obese gene does not affect leptin levels in severely
obese patients. J Clin Endocrinol Metab 2000: 85 (10): 3589-3591.
443. Mammes O, Betoulle D, Aubert R et al. Novel polymorphisms in the 5' region of
the LEP gene: association with leptin levels and response to low-calorie diet in human
obesity. Diabetes 1998: 47 (3): 487-489.
444. Perusse L, Rankinen T, Zuberi A et al. The human obesity gene map: the 2004
update. Obes Res 2005: 13 (3): 381-490.
445. Snyder EE, Walts B, Perusse L et al. The human obesity gene map: the 2003
update. Obes Res 2004: 12 (3): 369-439.
446. Chagnon YC, Rankinen T, Snyder EE, Weisnagel SJ, Perusse L, Bouchard C. The
human obesity gene map: the 2002 update. Obes Res 2003: 11 (3): 313-367.
447. Rankinen T, Perusse L, Weisnagel SJ, Snyder EE, Chagnon YC, Bouchard C. The
human obesity gene map: the 2001 update. Obes Res 2002: 10 (3): 196-243.
448. Perusse L, Chagnon YC, Weisnagel SJ et al. The human obesity gene map: the
2000 update. Obes Res 2001: 9 (2): 135-169.
449. de Bakker PI, Yelensky R, Pe'er I, Gabriel SB, Daly MJ, Altshuler D. Efficiency
and power in genetic association studies. Nat Genet 2005: 37 (11): 1217-1223.
450. de Mello VD, Kolehmainen M, Pulkkinen L et al. Downregulation of genes
involved in NFkappaB activation in peripheral blood mononuclear cells after weight
loss is associated with the improvement of insulin sensitivity in individuals with the
metabolic syndrome: the GENOBIN study. Diabetologia 2008: 51 (11): 2060-2067.
451. de Mello VD, Kolehmainen M, Schwab U et al. Effect of weight loss on cytokine
messenger RNA expression in peripheral blood mononuclear cells of obese subjects
with the metabolic syndrome. Metabolism 2008: 57 (2): 192-199.
121
452. Despres JP, Lemieux I, Bergeron J et al. Abdominal obesity and the metabolic
syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol
2008: 28 (6): 1039-1049.
453. Lee CM, Huxley RR, Wildman RP, Woodward M. Indices of abdominal obesity
are better discriminators of cardiovascular risk factors than BMI: a meta-analysis. J Clin
Epidemiol 2008: 61 (7): 646-653.
454. Francke S, Clement K, Dina C et al. Genetic studies of the leptin receptor gene in
morbidly obese French Caucasian families. Hum Genet 1997: 100 (5-6): 491-496.
455. Viguerie N, Vidal H, Arner P et al. Adipose tissue gene expression in obese
subjects during low-fat and high-fat hypocaloric diets. Diabetologia 2005: 48 (1): 123-
131.
456. Wang P, Mariman E, Renes J, Keijer J. The secretory function of adipocytes in the
physiology of white adipose tissue. J Cell Physiol 2008: 216 (1): 3-13.
457. Hayden MR, Sowers JR, Tyagi SC. The central role of vascular extracellular
matrix and basement membrane remodeling in metabolic syndrome and type 2 diabetes:
the matrix preloaded. Cardiovasc Diabetol 2005: 4 (1): 9.
458. Henegar C, Tordjman J, Achard V et al. Adipose tissue transcriptomic signature
highlights the pathological relevance of extracellular matrix in human obesity. Genome
Biol 2008: 9 (1): R14.
459. Scherer PE. Adipose tissue: from lipid storage compartment to endocrine organ.
Diabetes 2006: 55 (6): 1537-1545.
460. Martin A, Komada MR, Sane DC. Abnormal angiogenesis in diabetes mellitus.
Med Res Rev 2003: 23 (2): 117-145.
461. Vaziri ND, Xu ZG, Shahkarami A, Huang KT, Rodriguez-Iturbe B, Natarajan R.
Role of AT-1 receptor in regulation of vascular MCP-1, IL-6, PAI-1, MAP kinase, and
matrix expressions in obesity. Kidney Int 2005: 68 (6): 2787-2793.
462. Guan H, Arany E, van Beek JP et al. Adipose tissue gene expression profiling
reveals distinct molecular pathways that define visceral adiposity in offspring of
maternal protein-restricted rats. Am J Physiol Endocrinol Metab 2005: 288 (4): E663-
73.
463. Strissel KJ, Stancheva Z, Miyoshi H et al. Adipocyte death, adipose tissue
remodeling, and obesity complications. Diabetes 2007: 56 (12): 2910-2918.
464. Docheva D, Hunziker EB, Fassler R, Brandau O. Tenomodulin is necessary for
tenocyte proliferation and tendon maturation. Mol Cell Biol 2005: 25 (2): 699-705.
465. Shukunami C, Oshima Y, Hiraki Y. Molecular cloning of tenomodulin, a novel
chondromodulin-I related gene. Biochem Biophys Res Commun 2001: 280 (5): 1323-
1327.
466. Silvestre JS, Levy BI. Molecular basis of angiopathy in diabetes mellitus. Circ Res
2006: 98 (1): 4-6.
467. Tolppanen AM, Pulkkinen L, Kuulasmaa T et al. The genetic variation in the
tenomodulin gene is associated with serum total and LDL cholesterol in a body size-
dependent manner. Int J Obes (Lond) 2008: 32 (12): 1868-1872.
468. Yang Q, Khoury MJ, Friedman J, Little J, Flanders WD. How many genes underlie
the occurrence of common complex diseases in the population? Int J Epidemiol 2005:
34 (5): 1129-1137.
122
469. Loscalzo J. Association studies in an era of too much information: clinical analysis
of new biomarker and genetic data. Circulation 2007: 116 (17): 1866-1870.
Kuopio University Publications D. Medical Sciences 
 
 
D 432. Savonen, Kai. Heart rate response to exercise in the prediction of mortality and myocardial 
infatction: a prospective population study in men.  
2008. 165 p. Acad. Diss. 
 
D 433. Komulainen, Pirjo. The association of vascular and neuroprotective status indicators with 
cognitive functioning: population-based studies.  
2008. Acad. Diss. 
 
D 434. Hassinen, Maija. Predictors and consequences of the metabolic syndrome: population-based 
studies in aging men and women.  
2008. Acad. Diss. 
 
D 435. Saltevo, Juha. Low-grade inflammation and adiponectin in the metabolic syndrome.  
2008. 109 p. Acad. Diss. 
 
D 436. Ervasti, Mari. Evaluation of Iron Status Using Methods Based on the Features of Red Blood 
Cells and Reticulocytes.  
2008. 104 p. Acad. Diss. 
 
D 437. Muukka, Eija. Luomun tie päiväkotiin: luomuruokailun toteutettavuus ja ravitsemuksellinen 
merkitys päiväkotilapsille.  
2008. 168 p. Acad. Diss.  
 
D 438. Sörensen, Lars. Work ability and health-related quality of life in middle-aged men: the role 
of physical activity and fitness.  
2008. 83 p. Acad. Diss.  
 
D 439. Maaranen, Päivi. Dissociation in the finnish general population.  
2008. 97 p. Acad. Diss.  
 
D 440. Hyvönen, Juha. Suomen psykiatrinen hoitojärjestelmä 1990-luvulla historian jatkumon 
näkökulmasta. 2008. 279 p. Acad. Diss.  
 
D 441. Mäkinen, Heidi. Disease activity and remission in rheumatoid arthritis: comparison of 
available disease activity measures and development of a novel disease sctivity indes: the mean overall 
index for rheumatoid arthritis (MOI-RA).  
2008. 129 p. Acad. Diss.  
 
D 442. Kousa, Anne. The regional association of the hardness in well waters and the incidence of 
acute myocardial infarction in rural Finland.  
2008. 92 p. Acad. Diss.  
 
D 443. Olkku, Anu. Glucocorticoid-induced changes in osteoblastic cells: cross-talk with wnt and 
glutamate signalling pathways. 
2009. 118 p. Acad. Diss. 
 
D 444. Mattila, Riikka. Effectiveness of a multidisciplinary lifestyle intervention on hypertension, 
cardiovascular risk factors and musculoskeletal symptoms. 
2009. 92 p. Acad. Diss. 
 
D 445. Hartmann-Petersen, Susanna. Hyaluronan and CD44 in epidermis with special reference 
to growth factors and malignant transformation. 
2009. 103 p. Acad. Diss. 
 
D 446. Tolppanen, Anna-Maija. Genetic association of the tenomodulin gene (TNMD) with 
obesity- and inflammation-related phenotypes. 
2009. 111 p. Acad. Diss. 
 
 
